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Abstract
Ovarian cancer commonly relapses after remission and activating tumour-specific T 
cells with dendritic cells loaded with tumour cells is a promising approach to target 
residual microscopic tumours. SK-OV-3 cells expressing HER-2/neu and MUCl 
ovarian antigens were killed and their immunogenicity enhanced by hypochlorous 
acid (HOCl) oxidation. Treatment with 60 pM HOCl for 1 h induced necrosis in all 
the cells. Oxidised, but not live SK-OV-3 were engulfed by monocyte-derived DCs. 
Autologous T cells primed with DCs of HLA-A2^ healthy volunteers loaded with 
oxidised SK-OV-3 (HLA-A2') recognised oxidised SK-OV-3 and HLA-A2-restricted 
epitopes o f M UCl and HER-2/neu. Responses were absent with heat- or hydrochloric 
acid (HCl)-killed SK-OV-3, thus HOCl oxidation and not cell death/necrosis 
enhanced the immunogenicity o f SK-OV-3. Oxidised SK-OV-3 primed T cells did not 
respond to oxidised melanoma, or vice versa. Next, T cells of ovarian cancer patients 
in remission, whose tumours overexpressed MUCl and/or HER-2/neu, were tested 
using the same model. DCs o f HLA-A2^ and A2" patients pulsed with oxidised SK- 
OV-3 stimulated T cells specific for oxidised SK-OV-3, and HER-2/neu and MUCl 
epitopes. Oxidised SK-OV-3 loaded DCs further matured with CD40 agonistic 
antibody or monophosphoryl lipid A, primed stronger CD4^ and CD8^ responses than 
immature DCs. T cells stimulated this way also recognised autologous tumour cells 
from ascites, demonstrating that SK-OV-3 shared significant antigenic repertoire with 
tumours in patients. Finally, this DC-based vaccination was tested in vivo using the 
B16.F10 melanoma model. B16.F10 highly expressed tyrosinase-related protein 
(TRP)-2, and all the cells were necrotic after 1 h treatment with 60pM HOCl. Mice 
immunised intravenously and not intraperitoneally or subcutaneously with bone- 
marrow derived DCs loaded with oxidised B16.F10, responded to TRP-2 and oxidised
B16.F10. Oxidised and not heat- or HCl-killed B16.F10, primed specific T cells in 
vivo. DCs were required for efficient delivery for processing and presentation o f 
oxidised B16.F10 in vivo.
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Chapter 1: General Introduction
1.1. Introduction: Redefining Cancer Surveillance Theory
In the late 19‘^  century William Coley, a surgeon at the Memorial Sloan-Kettering 
Cancer Centre in New York observed that cancer patients with infectious episodes 
often had spontaneous tumour regression (Burnet, 1970). A few years later in 1909, 
Ehrlich proposed that the immune system was able to control cancer (Ehrlich, 1909). 
The modem era o f tumour immunology really began when Burnet and Thomas 
(Burnet, 1970; Thomas, 1960) introduced the term ‘cancer surveillance’ in the 1950s, 
proposing that the immune system of immunocompetent hosts continually recognised 
and eliminated tumour cells via their expression of tumour-associated antigens 
(TAAs). This hypothesis was disputed in the 1980s on the basis o f studies showing 
tumours failed to develop more rapidly in nude mice (which lack T and B cells but not 
natural killer [NK] cells) than in wild-type mice. However in the 1990s, compelling 
evidence indicated that immunodeficient mice were at greater risk for spontaneous 
tumour development o f some tumours. More recently, it has become clear that whilst 
the adaptive immune system can actively eliminate tumour cells and prevent the 
formation o f neoplasia, inflammation can also facilitate tumour progression in part by 
sculpturing the immunigenicity o f tumour as it develops. The cancer 
immunosurveillance hypothesis has therefore been refined into one termed “cancer 
immunoediting”. The 3 Es is being used to describe cancer immunoediting -  
elimination (i.e. cancer surveillance), equilibrium, and escape. During elimination, the 
immune system attempts to eradicate the cancer. If this fails, the cancer and the 
immune system achieve an equilibrium in which the immune system is able to contain 
but not eliminate the cancer. In the equilibrium phase, the cancer is under constant 
pressure from the immune system but can also undergo genetic changes that can lead 
to increased immune resistance. If this occurs, the cancer cells can become resistant
22
Chapter 1: General Introduction
and escape from immune attack even in the presence o f an intact immune system. 
Understanding the intricate balance between cancer elimination and evasion will be 
invaluable in tilting immunotherapy in favour of the host. This introduction discusses 
the concept of cancer immunoediting and summarised the recent progressed in cancer 
vaccines development. This Ph.D. project focused mainly on ovarian carcinoma and 
the major immunological aspects of this cancer are discussed in detail. A smaller 
section on melanoma is also presented. Lastly, the potential use o f hypochlorous acid 
in tumour immunotherapy is discussed.
1.2. The Immunological Control of Cancer
1.2.1 Evidence of cancer surveillance 
Three lines of evidence strongly suggest that cancer surveillance occurs in humans. 
Firstly, immunosuppressed transplant recipients usually display a higher incidence of 
viral and non-viral cancers than age-matched immunocompetent control populations. 
Assessment o f 5692 renal transplant patients from 1964 to 1982 in Scandinavia 
revealed increased incidences o f colon, lung, bladder, kidney, ureter and endocrine 
tumours (Birkeland et al., 1995). Also, 925 patients who received cadaveric renal 
transplants from 1965 to 1998 in Australia and New Zealand showed higher 
frequencies o f a variety o f non-viral cancers than the general population (Sheil, 1986). 
These observations suggested that immunosuppression intervention predisposed 
transplant patients either to de novo tumour formation or allowed the outgrowth of 
occult tumours which had previously been contained by a functioning immune 
system. Secondly, cancer patients can develop spontaneous adaptive and innate 
immune responses to the tumours that they bear (Old, 1981; Old and Chen, 1998; 
Sahin et al., 1995). Thirdly, the presence o f CD8^ lymphocytes in the tumour can
23
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indicate a better prognosis and enhanced patient survival in colon cancer (Naito et al., 
1998; Strater et a l ,  2005), oesophageal cancer (Schumacher et al., 2001; Yasunaga et 
al., 2000), cervical cancer (Piersma et al., 2007), ovarian cancer (Sato et al., 2005) 
and melanoma (Haanen et al., 2006).
Technological advancements in mouse genetics and monoclonal antibody (mAb) 
production have helped to elucidate the cellular basis of cancer surveillance. In 
particular, gene-targeted mice lacking the recombinase activating gene (RAG)-2 
(Shankaran et al., 2001) allowed the generation of mice that lack peripheral ap  T 
cells, yô T cells, B cells or NK cells with which to study the influence of host 
lymphocyte deficiency on tumour development. Studies showed that 129/SvEvRAG'^' 
and C57BL/6 RAG" ' mice receiving subcutaneous injection o f chemical carcinogen 
3’-methylcholanthrene (MCA) developed sarcomas at a faster and higher rate than 
wild-type controls (Shankaran et al., 2001; Smyth et al., 2000). Also, Helicobacter 
negative R A G '' 129/SvEv mice maintained in pathogen-free mouse facility and 
broad-spectrum antibiotics had more spontaneous epithelial tumours than the wild- 
type (Shankaran et al., 2001). T, NK and NKT cells are involved in tumour defence as 
depleting NK and NKT cells with anti-N K l.l mAh or anti-asialo-GMl in C57BL/6 
mice resulted in more tumours than wild-type (Hayakawa et al., 2003; Smyth et al., 
2000; Smyth et al., 2001). Also, mice without aP  or yô T cells were more susceptible 
to MCA-induced tumour formation than wild-type (Girardi et al., 2001).
The role o f yô T cells in anti-tumour immunity was highlighted in a recent phase I 
clinical trial where patients with metastatic hormone-refractory prostate cancer were 
treated with yÔ T cell agonist zoledronate, either alone or in combination with low-
24
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dose IL-2 to activate peripheral blood yô T cells (Dieli et al., 2007). Most o f the nine 
patients who were treated with zoledronate and IL-2 had peripheral yô T cells that 
produced IFN-y and perforin. These patients also maintained serum levels of TRAIL. 
Furthermore the numbers of these yô cells correlated positively with declining 
prostate-specific antigen levels and objective clinical outcomes that comprised three 
instances o f partial remission and five of stable disease. By contrast, most patients 
treated only with zoledronate failed to sustain either yô T cell numbers or serum 
TRAIL, and showed progressive clinical deterioration. Though a p  T cells are 
implicated in anti-tumour surveillance, a study involving a two-stage chemical 
carcinogenesis protocol o f single exposure to the mutagen 7,12- 
dimethylbenz[a]anthracene [DMBA] followed by repeated applications of the 
inflammation-inducing phorphol ester, phorbol 12-myristate 13-acetate [PMA] to 
induce malignant lesions, demonstrated that aP  T cell deficiency was associated with 
reduced tumour development and progression (Girardi et al., 2003). These novel 
tumour-promoting T cells (T-pro cells) were ap^ CD8^ CD44^ CD62' and produced 
substantial amounts o f IFN-y and TNF-a, but little perforin (Roberts et al., 2007). 
They shared intriguing similarities with uterine NK cells whereby they were not 
cytolytic and they produced cytokines associated with trophoblast growth and 
invasion of the uterine wall (Ashkar et al., 2000).
Studies showed that IFN-y protected the host against tumour growth (Dighe et al., 
1994; Kaplan et al., 1998; Shankaran et al., 2001; Street et al., 2001; Street et al., 
2002), and injection of IFN-y neutralising mAbs abolished this protection (Dighe et 
al., 1994). Moreover, 129/SvEv mice lacking IFN-y responsiveness (IFNGRl"^' or
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STATl'^' mice) had more tumours than wild-type mice (Shankaran et al., 2001). IFN- 
a /p  is also implicated in preventing cellular transformation by enhancing the p53 
tumour-suppressor gene expression in cells (Takaoka et al., 2003). In addition, 
perforin (pfp) and tumour necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) are involved in tumour cytotoxicity (Smyth et al., 2000; Smyth et al., 2003; 
Street et al., 2001; van den Broek et al., 1996). The NKG2D, an activating receptor 
expressed on all NK cells, some aP and yô T cells, and some NKT cells, is 
constitutively expressed on some tumour cell lines (Coudert and Held, 2006; 
Hayakawa et al., 2003; Pardoll, 2003; Pende et al., 2002) and might play a role in 
eliminating transformed cells. Its ligands include MHC class I chain-related proteins 
A and B (MICA/B) which are often expressed on primary carcinomas of the lungs, 
kidneys, ovary, prostate, colon (Groh et a l, 1999) and melanoma (Vetter et al., 2002), 
and UL16 binding proteins (Cosman et al., 2001; Pende et al., 2002). Conversely, the 
sustained expression o f MICA by tumours can also elicit NKG2D downregulation, 
perhaps indicating 'immunoevasion' (see section 1.2.3). In a study, it was observed 
that the constitutive R ae-1 [retinoic acid early inducible 1 ; expressed in mouse and a 
ligand for NKG2D] epsilon transgene expression in normal epithelium caused the 
downregulation o f local and systemic NKG2D expression, which in turn led to 
generalised but reversible defects in NK cell-mediated cytotoxicity and mild CD8^ T 
cell defects (Oppenheim et al., 2005). This downregulation of NKG2D correlated 
positively with increased incidence and progression of cutaneous carcinogenesis, thus 
emphasising the role of NKG2D in tumour surveillance.
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1.2.2. Equilibrium phase 
Based on the evidence o f cancer surveillance, it could be envisaged that a significant 
percentage of transformed cells are eliminated during this phase. However, some 
tumour cells might withstand the formidable pressure exerted by the cancer 
surveillance’s arsenal and emerge into clinically detectable malignant disease. Dunn 
and colleagues (Dunn et al., 2004a; Dunn et al., 2004b) suggested the existence of a 
period of tumour dormancy or equilibrium phase, whereby the immune system could 
initially inhibit the growth of heterogenous tumours that were composed of rapidly 
mutating cells but as the original tumour cells are destroyed, new variants arise that 
make them more resistant to immune attack. This equilibrium phase could persist for 
years and could allow the selection of tumour cells with reduced immunogenicity.
Studies were done to compare the immunogenicities of tumours derived from 
immunocompromised and immunocompetent mice. It was found that tumours derived 
from wild-type 129/SvEv mice grew progressively in both strain-matched wild-type 
and RAG' ' 129/SvEv mice, while 8 out of 20 tumours from RAG ' 129/SvEv mice 
were rejected in wild-type mice (Shankaran et al., 2001). Also, MCA-induced 
sarcoma from nude (Svane et al., 1996) or severe combined immunodeficiency 
[SCID] mice (Engel et al., 1997) were rejected more frequently in wild-type after 
transplantation than those derived from wild-type. Lymphomas from pfp'^' mice grew 
avidly in pfp'^' recipients but were rejected in the wild-type controls (Street et al.,
2001), suggesting that tumours growing in immunocompromised environment are 
more immunogenic than tumours developing in immunocompetent hosts.
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A clinical scenario that demonstrated the existence o f an equilibrium phase in the 
humans is the transmission of cancer from organ transplant donors to recipients. One 
study described two patients developing melanoma 1 to 2 years after receiving a 
kidney transplant each from the same donor, who was considered tumour-free having 
been treated for melanoma 16 years earlier (MacKie et al., 2003). Similar 
observations were made in recipients of allografts from those considered as healthy 
donors (Elder et al., 1997; Penn, 1991; Penn, 1995; Penn, 1996; Suranyi et al., 1998), 
suggesting that tumours had been kept in equilibrium in the donor and continuously 
administrating immunosuppressive drugs might facilitate the growth of occult cancer. 
Other clinical evidence also supports the existence of the equilibrium phase. First, the 
existence of an immune response to premalignant monoclonal gammopathy of 
undetermined significance (MGUS) cells that eventually progress to multiple 
myeloma (MM) is consistent with the equilibrium phase, with the immune system 
controlling but not eliminating MGUS cells that eventually evolve and progress to 
malignancy (Dhodapkar et al., 2003). Second, passive immunisation with 
idiotypespecific antibody in conjunction with either cytokine therapy or 
chemotherapy, can induce remission in some patients with low-grade B cell 
lymphoma; however, tumour cells are not completely eliminated and can be detected 
in the blood or bone marrow for up to 8 years following clinical remission (Davis et 
al., 1998). Studies in pediatric acute myeloid leukemia patients treated with either 
chemotherapy or chemotherapy combined with autologous bone marrow trans­
plantation also suggested a role o f the immune system in maintaining equilibrium and 
establishing long-term remission (Montagna et al., 2006). It has also been noted that 
tumors can remain dormant in patients for many years, but relapse after long periods 
(at least 10 years) of tumour remission (Callaway and Briggs, 1989; Demicheli et al..
28
Chapter 1: General Introduction
1996; Stewart et al., 1991), hence suggesting the possibility of immune control with 
subsequent escape in these cases.
1.2.3. Mechanisms of tumour evasion of immune system 
Tumour cells that survived the equilibrium phase often possess several mechanisms to 
evade the immune system (Rabinovich et al., 2007). Many human tumours lose their 
HLA class I proteins (Algarra et al., 2000; Marincola et al., 2000) or have deficient 
antigen processing and presentation pathways such as transporter associated with 
antigen processing-1 and the immuno-proteasome subunits low molecular mass 
protease [LMP] 2 and 7 (Seliger et al., 2000) to avoid immune detection. Also, 
several human lung carcinoma cell lines were unresponsive to IFN-y due to absence 
or abnormal IFN-y receptor signalling (Kaplan et al., 1998) and hence failed to 
upregulate MHC class I pathway activity when exposed to IFN-y. Tumours could 
secrete soluble factors, such as vascular endothelial growth factor [VEGF] to suppress 
DC differentiation and maturation (Dikov et al., 2001), soluble Fas ligand to induce 
lymphocyte apoptosis, or soluble MICA products to inhibit NKG2D-mediated killing 
by immune cells (Groh et al., 2002; Ryan et al., 2005). In addition, IL-10, TGF-P (Li 
et al., 2006) and prostaglandin-E [PGE2] (He and Stuart, 1999) released by tumour 
cells could inhibit immune responses of DCs and T cells. Galectin-1 (Rubinstein et 
al., 2006) and indoleamine 2,3-dioxygenase [IDO] (Uyttenhove et al., 2003) also 
inhibit T cell activation.
Immunosuppressive T cell populations in tumours, such IL-13 producing NKT cells 
(Terabe et al., 2005) and CD4^ CD25^ T regulatory cells [Tregs] (Sakaguchi et al.,
2001) have been shown to suppress anti-tumour responses. Two studies demonstrated
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that depleting CD4^ CD25^ Tregs by anti-CD25 mAh enabled mice to reject tumours 
(Onizuka et a l,  1999; Shimizu et a l,  1999). Specifically, elevated levels of CD4^ 
CD25^ Tregs were detected in patients with non-small cell lung cancer, and cancer of 
the ovary (Woo et al., 2001), breast and pancreas (Liyanage et al., 2002) and 
correlated with poor prognosis and survival (Curiel et al., 2004; Zou, 2006) [see 
sections 1.3.4 and 1.4.1 for further discussions on Tregs]. Tumour infiltrating 
lymphocytes [TILs] in melanoma (Zea et al., 1995), renal cell cancer (Cardi et al., 
1997), ovarian cancer (Lai et al., 1996) and oral cancer (Reichert et al., 1998) have 
also been found to lose their signal transducer CD3-Ç chain (CD3-Q that prevented 
their activation. In a recent study involving patients with breast cancer, it was found 
that the number of CD4^ and CDS^ T cells expressing the IL-7 receptor was reduced 
in the peripheral blood of these patients (Vudattu et al., 2007). These T cells did not 
respond to IL-7 stimulation despite expressing IL-7Ra. Further analysis showed that 
these T cells had decreased IL-2 and IFN-y production when stimulated with phorbol 
12-myristate 13-acetate (PMA)/Ionomycin, and hence suggested a defect in the IL-7 
signaling pathway.
1.2.4. Inflammation and cancer 
Clinical and epidemiologic studies have suggested a strong association between 
chronic infection, inflammation, and cancer (Coussens and Werb, 2002; 
Dobrovolskaia and Kozlov, 2005; Fox and Wang, 2007; Hussain et al., 2003). For 
example, liver cancer is associated with excessive alcohol consumption and infection 
with Hepatitis B and C virus, colon cancer is associated with inflammatory bowel 
disease, and gastric cancer can develop in individuals chronically infected with 
Helicobacter pylori. The NF-kB kinase/ NF-kB (IKK/NF-kB) signaling pathway
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provides a key molecular link between inflammation and malignant transformation. It 
is activated by many proinflammatory cytokines (Karin, 2006; Karin and Greten,
2005), and following recognition of pathogen-associated molecular patterns by pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs) and nucleotide- 
binding oligomerisation domain-like (NOD-like) receptors. Crohn’s disease which is 
associated with mutations in the N0D2 locus and enhanced IL -ip production 
(Eckmann and Karin, 2005; Hugot et a l, 2001) might predispose the individuals to 
colorectal cancer (Kurzawski et al., 2004).
Several proinflammatory cytokines can promote tumour development. Prolonged 
TNF-a production can induce NF-KB-dependent expression of anti-apoptotic and 
proliferative genes, enhance angiogenesis, and evade immune surveillance by 
conferring resistance to tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) (Elgert et a l ,  1998). IL-6, induced through TER activation or produced 
endogenously (e.g. by stromal cells), can promote cell cycle progression and 
exacerbate the effects of TNF-a. Indeed, IL-6 has been implicated in the development 
of multiple myeloma (Bommert et a l ,  2006), Kaposi’s sarcoma (Li et a l, 2001; 
Osborne et a l ,  1999) and Hodgkin’s lymphoma (Cozen et a l,  2004). IL-10 and TGF- 
p can exhibit tumour-suppressing activity under certain circumstances; mice lacking 
either IL-10 or TGF-pl are more susceptible to cancer in response to infection with 
enteric bacteria (Berg et a l ,  1996; Engle et a l,  2002; Sellon et a l, 1998). In contrast, 
they can also promote tumour development by inhibiting DC activation, suppress T 
cell responses, block the proinflammatory effects o f macrphages, NK cells, and 
neutrophils, and facilitate the induction of Tregs (Doganci et a l, 2005; Ghiringhelli et 
a l, 2005; Kortylewski et a l ,  2005; Liu et a l ,  2007; Yu et a l, 2007). IL-10, IL-6, and
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VEGF can activate STAT3 in tumour cells to endow them with enhanced survival, 
metastatic, and angiogenic properties (Yu et al., 2007). STATS can also down- 
regulate molecules necessary for anti-tumour immune responses (e.g., IL-12, IFN-y, 
and IFN-P), which are also produced following NF-kB activation. Hence STAT3 can 
block the ability of NF-kB to stimulate anti-tumour immunity (Hoentjen et ah, 2005; 
Schottelius et al., 1999) but cooperate with it to promote oncogenesis (Yu et al., 
2007). Small-molecule inhibitors targeting STAT3 directly or indirectly can block the 
signalling effects of cytokines such as IL-6 and TGF-p and reverse the abnormal 
differentiation o f DCs in cancer (Kortylewski et al., 2005; Nefedova et al., 2004).
IL-23, which belongs to the IL-12 family of proinflammatory heterodimeric 
cytokines, has been shown to promote tumour growth by upregulating 
metalloproteinase (MMP) 9, increasing angiogenesis, and decreased recruitment of 
CD8^ T cells to tumours (Langowski et al., 2006). However, in other studies, mice 
inoculated with IL-23-transduced tumour cells displayed anti-tumour properties (Lo et 
al., 2003; Ugai et al., 2003). IL-17 is an important inflammatory cytokine (Mangan et 
al., 2006) that is produced via STAT3 activation triggered by IL-23 (Cho et al., 
2006). It might be important for localising and amplifying inflammation as its 
production also leads to the induction o f many proinflammatory factors, including 
TNF-a, IL-6, and IL-Ip (Langrish et al., 2005; Park et al., 2005; Ruddy et al., 2004). 
In primary non-small cell lung carcinoma samples, IL-17 expression was frequently 
detected in TILs and was associated with increased tumour vascularity (Numasaki et 
al., 2005). Also, IL-17 might act with IL-6 to promote tumour development as the 
enhanced cervical cancer growth elicited by IL-17 was associated with increased 
expression of IL-6 and macrophage recruitment to the tumour sites (Tartour et al..
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1999). Similar to IL-23, there is also evidence of IL-17 playing a role in tumour 
surveillance in immunocompetent mice (Benchetrit et al., 2002).
1.3. Recent Progress in Developing Effective Cancer Vaccines
1.3.1. Identifying tumour-associated antigens 
Since the cloning of MAGE-1 (van der Bruggen et al., 1991), the first gene reported to 
encode a human tumour antigen recognised by T cells, molecular identification and 
characterisation o f novel tumour-associated antigens (TAAs) has rapidly evolved. 
This has been fuelled in part by the advancement of new technologies, such as using 
a) specialist software to predict epitopes of T cells on the basis of known HLA- 
binding motifs, b) biochemical methods (e.g. chromatography, mass spectrometry) to 
elute and fractionate TAA peptides from tumour cells, c) DNA microarray technology 
(e.g. representational difference analysis [RDA], differential display [DD], 
suppression subtractive hybridisation [SSH], and serial analysis o f gene expression 
[SAGE]) to compare gene expression profiles of tumour to normal tissues. In 
addition, a large collection of TAAs have been identified using antbodies by 
serological expression o f cDNA expression libraries or SEREX technology (i.e. 
screening of complementary DNA expression libraries with serum from cancer 
patients), and can be found in the database of the Institute for Cancer Research 
(http://www.licr.org/SEREX.html). TAAs recognised by T cells are summarised here.
TAAs recognised by T cells can be broadly classified according to their tissue 
distribution and HLA-allele (or MHC) restriction. MAGE-1, the first TAA to be 
identified, belongs to the cancer-testis (CT) antigens family. The CT antigens are so- 
named due to their expression in various types o f cancers (including ovarian
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carcinoma and melanoma) and restricted expression in normal spermatocytes and/ or 
spermatogonia o f testis, and occasionally in placenta. Other CT antigens include other 
MAGEs (Lucas et al., 1999; Lucas et al., 2000), the BAGE (Boel et al., 1995) and 
GAGE (Van den Eynde et al., 1995) families, NY-ESO-1 and its alternative open- 
reading frame (ORE) products (LAGE, CAMEL) (Aamoudse et al., 1999; Jager et al., 
1998; Lethé et al., 1998), SAGE (Martelange et al., 2000), SSX-2 (Ayyoub et al.,
2002) and TRAG-3 (Zhu et a l,  2003). NY-ESO-1 is also expressed in normal ovary. 
Both MHC Class I HLA- and Class II HLA-restricted epitopes of CT antigens have 
been identified (Chaux et al., 1999a; Chaux et al., 1999b; Consogno et al., 2003; 
Manici et al., 1999; Slager et a l,  2003; Tatsumi et a l, 2003; Wang et al., 2004; Zeng 
et al., 2000). CT antigens result from re-activation of genes which are normally silent 
in adult tissues but are transcriptionally activated in different tumour histotypes. They 
represent attractive targets for cancer vaccines because the very low level o f class I 
and II HLA molecules in the testis, placenta and ovary protect tissues from acting as 
targets for autoimmune reactions (Hutter and Dohr, 1998; Jassim et al., 1989).
Differentiation antigens such as CEA (Tsang et al., 1995), Ep-CAM (Nagorsen et al.,
2000), M CIR (Salazar-Onfray et al., 1997), gp-100 (Barker et al., 1995; Kawakami et 
al., 1995; Kawakami et al., 1998; Skipper et al., 1996b; Tsai et al., 1997), MART- 
1/Melan-A (Coulie et al., 1994; Kawakami et al., 1994a; Romero et al., 1997; 
Schneider et al., 1998), PS A (Corman et al., 1998; Correale et al., 1997) and 
tyrosinase (Benlalam et al., 2003; B richard et al., 1996; Kang et al., 1995; Kawakami 
et al., 1995b; Kittlesen et al., 1998; Wôlfel et al., 1994) are TAAs that are only 
expressed in normal and neoplastic cells of a defined lineage. MHC Class II HLA- 
restricted epitopes have also been found for gp-100 (Kierstead et al., 2001; Lapointe
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et a l, 2001; Li et a l ,  1998), MART-l/Melan-A (Zarour et a l,  2000), PSA (Corman et 
al., 1998) and tyrosinase (Kierstead et a l, 2001; Kobayashi et a l,  1998a; Kobayashi 
et a l, 1998b; Topalian et a l,  1994; Topalian et a l,  1996). This group of TAAs 
represents self antigens that are commonly used in current clinical vaccination trials 
with CT antigens. The third type of TAAs consists of overexpressed self antigens 
which occur in a range of different types of tumours. Some examples are Adipophilin 
(Schmidt et a l ,  2004), AIM-2 (Harada et a l,  2001), AFP (Butterfield et a l,  1999), 
ART-4 (Kawano et a l, 2000), Cyp-B (Gomi et a l, 1999), HER-2/neu (Fisk et a l, 
1995; Kawashima et a l,  1999; Okugawa et a l, 2000; Peoples et a l, 1995; Rongcun et 
a l,  1999), hTERT (Minev et a l,  2000; Vonderheide et a l,  2001), MUCl (Brossait et 
a l,  1999; Domenech et a l ,  1995), MUC2 (Bôhm et a l, 1998), PRAME (Ikeda et a l, 
1997; Kessler et a l ,  2001), SOXIO (Khong and Rosenberg, 2002b) and W Tl (Azuma 
et a l,  2002; Ohminami et a l ,  2000; Oka et a l, 2000). TAAs of the apoptotic proteins 
such as livin and surviving, (Andersen et a l,  2000; Andersen et a l ,  2001; Casati et 
a l,  2003; Schmidt et a l ,  2003; Schmitz et a l, 2000; Schmollinger et a l ,  2003) and 
tumour suppressor proteins [e.g. p53] (Azuma et a l, 2003; Umano et a l ,  2001) also 
belong to this group. These TAAs can result from the expression of novel epitopes 
from widely expressed proteins as a result of splicing aberrations, alternative ORFs or 
post-translational splicing. As they are expressed in normal tissues at a lower level, 
they are likely to make weak tumour-rejection antigens as they might trigger some 
degree of tolerance. This could be overcome by using potent vaccination protocols to 
activate and expand the remaining low-avidity T cells (see following sections).
Point mutations of normal genes can occur during neoplastic transformation and/or 
progression to give rise to unique TAAs (e.g. /7-catenin (Robbins et a l ,  1996), CDK4
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(Wôlfel et aL, 1995), caspase-8 (Mandruzzato et al., 1997), Hsp70-2 M (Gaudin et 
a l,  1999), MART-2 (Kawakami et a l,  2001), MUM-1 (Coulie et a l ,  1995), MUM-2 
(Chiari et a l, 1999), MUM-3 (Baurain et a l,  2000), Myosin (Zom and Hercend, 
1999b). In mouse models, such unique TAAs are responsible for the rejection of 
tumour transplants in mice and have been defined as tumour-specific transplantation 
antigens [TSTA] (Dudley and Roopenian, 1996). In cancer patients, response to the 
unique TAAs appears to be associated with a good prognosis (Baurain et a l ,  2000; 
Karanikas et a l,  2001; Novellino et a l, 2003). However, the major drawback is they 
are only useful in single patient-tailored anti-tumour immunotherapies. A few such 
altered antigen epitopes which are specific to tumours and are found in several 
different tumours, are generated from splicing aberrations [e.g. TRP-2/INT2 and 
TRP-2/6b] (Khong and Rosenberg, 2002a; Lupetti et a l,  1998) or common point 
mutations [e.g. N-RAS and K-RAS] (Gjertsen et a l, 1997; Linard et a l,  2002) as part 
o f the neoplastic development. In several malignancies, particularly in leukaemia, 
translocation o f chromosomes occurs to which results in fusion of distant genes. This 
gives rise to fusion proteins characteristic to each type of disease [e.g. BCR-ABL in 
chronic myelogenous leukaemia (CML) (Norbury et a l,  2000; Wagner et a l ,  2003; 
Yotnda et a l,  1998b), DEK-CAN and TEL/AMLl in acute myelogenous leukaemia 
(AML) (Ohminami et a l ,  1999; Yun et a l, 1999), ETV6/AML (Yotnda et a l,  1998a) 
and NPM/ALK in acute lymphocytic leukemia (ALL) (Passoni et a l ,  2002), and 
SYT-SSX in synovial sarcomas (Worley et a l, 2001)]. These fusion proteins can 
generate new CD8^ and CD4^ T cell epitopes spanning the fusion junction.
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1.3.2. Delivering antigens: dendritic cells as natural adjuvants 
Dendritic cells are the key regulators of all immune responses (Banchereau et ah, 
2000; Guermonprez et al., 2002; Heath and Carbone, 2001). They comprise of several 
subsets that are located in both lymphoid and non-lymphoid tissues. Three main DC 
subsets have been identified based on their cell surface markers and functional 
properties: conventional monocyte-derived DCs, plasmacytoid DCs (pDCS) and 
follicular DCs (FDCs). The monocyte-derived DCs (referred to here simply as DCs) 
are widely used in human clinical studies and are discussed below. DCs are 
responsible for inducing cellular immunity to pathogens by priming T cells into 
effector and memory cells, and activating NK and NKT cells (Fernandez et al., 1999; 
Kadowaki et al., 2001). They also induce humoural immunity by activating naïve and 
memory B cells (Caux et al., 1997; Jego et al., 2003). In addition, DCs are 
responsible for processing and presenting tumour antigens to naïve CD8^ and CD4^ T 
cells, and to activate them into CTLs and effector T helper cells, respectively, to 
combat tumour (Berzofsky et al., 2004; Gilboa, 2004; Pardoll, 1998).
Given the potent immunostimulatory capacity o f DCs, one of the major questions in 
developing effective DC vaccine protocols is the method of delivery of tumour 
antigens to the immune system via DCs. There are two general approaches, i.e. the in 
vivo route and the ex vivo route. The in vivo route involves the injection of antigen 
mixed with adjuvant into a patient. This method is relatively simple and abolishes the 
laborious task of culturing and loading DCs with tumour antigens ex vivo. An 
example is to deliver DNA encoding antigens (Garcia-Hemandez et al., 2007; 
Porgador et al., 1998) by gene gun to the resident immature DCs in the skin. Another 
example is using anti-DEC-205 antibody to target tumour antigens to DC via their
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DEC-205 receptors (Bonifaz et al., 2004; Jiang et al., 1995). For example, injecting 
mice with anti-DEC 205 antibodies coupled to tyrosinase-related protein-2 (TRP-2) 
and gp-100 led to the induction of anti-tumour responses and eradication of tumour in 
70% of the mice (Mahnke et al., 2005). Methods to simultaneously target and activate 
DCs in vivo using antigens fused to chemokines (Biragyn et al., 2001) and 
immunoglobulin G (IgG) Fc fragment (You et al., 2001) have also been described.
The alternative and more popular approach is to generate and load autologous DCs ex 
vivo (Banchereau and Palucka, 2005; Fong and Engleman, 2000; Gilboa, 2007). The 
key advantage is that DCs can be matured and differentiated ex vivo into potent 
antigen presenting cells (Kryczek et al., 2006a), and upon administration can 
efficiently migrate to draining lymph nodes and respond appropriately to local stimuli 
hence circumvent the problems encountered with in vivo vaccination. Also, the high 
endocytic capacity o f DCs can be exploited ex vivo by loading them with antigens of 
choice, whether peptides or proteins derived from TAAs, whole allogeneic or 
autologous tumour cell lysates, exosomes, necrotic or apoptotic tumour cells, tumour 
RNA or DNA. Indeed, a degree o f success has been observed in several clinical trials 
using this approach (Banchereau et a l,  2001; Hersey et al., 2004; Nestle et a l, 1998; 
Rosenberg et al., 2004; Schuler-Thumer et a l, 2002; Thumer et al., 1999). In 
addition, DCs can be genetically modified to increase their secretion of IL-12, 
granulocyte-monocyte colony stimulating factor (GM-CSF) (Nakamura et a l, 2002; 
Ojima et al., 2007; Vegh and Mazumder, 2003), anti-apoptotic proteins (Medema et 
al., 2001), or fused with tumour cells to produce fusion cells that express both DC and 
tumour markers (Avigan et al., 2004).
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1.3.3. Activating dendritic cells ex vivo 
In order to generate ex vivo a population o f antigen-loaded DCs that can stimulate 
robust and long-lasting CD8^ and CD4^ anti-tumour T cell responses in cancer 
patients upon vaccination, DCs need to be appropriately activated to become potent 
APCs. Increasing evidence showed that immature DCs can induce T cell tolerance 
and deletion, and help in the development of Tregs (Brocker, 1999; Dhodapkar et a l,  
2001; Jonuleit et al., 2000; Steinman et al., 2003). Hence, mature DCs are preferred 
as vaccines. The most widely used maturation protocol in clinical studies for human 
monocyte-derived DCs consists of TNF-a, IL-ip, IL-6, and PGE2 , collectively known 
as the monocyte-conditioned media mimic or cytokine cocktail (Jonuleit et al., 1997). 
However, a recent phase III clinical trial failed to show that vaccinating melanoma 
patients with cytokine cocktail-matured DCs provided benefit over standard 
dacarbazine chemotherapy (Schadendorf et al., 2006), raising questions whether the 
use o f PGE2 would mediate T helper (Th) 2 polarisation and promote the secretion o f 
IL-10 by DCs (Morelli and Thomson, 2003). Furthermore, another study showed that 
such cytokine cocktail-matured DCs were more effective than immature DCs in 
expanding Tregs (Banerjee et al., 2006).
An alternative maturation protocol was described by Mailliard et al and consisted of 5 
reagents: TNF-a, IL-ip, Poly EC, IFN-a, and IFN-y (Mailliard et al., 2004). Ex vivo 
study demonstrated that DCs matured with this cytokine/stimulator cocktail were 
superior in stimulating CTL responses than DCs matured with cytokine cocktail 
containing PGE2 and no Poly I:C. In addition, the DCs responded to CD40 
stimulation and produced IL-12. TLR agonists such as poly I:C are the subject of 
intensive investigation since TLR ligation and subsequent signalling can lead to
39
Chapter 1: General Introduction
potent DC maturation (Akira et a l ,  2006; Iwasaki and Medzhitov, 2004). DCs 
cultured with microbial TLR ligands or their pharmacological analogs, such as the 
TLR4 ligand lipopolysaccharide (Kisseleva et a l, 2006) and monophoshoryl lipid 
(MPL), the TLR3 ligand Poly I:C, the TLR9 ligand oligodeoxynucleotide containing 
one or more unmethylated CpG dinucleotides (CpG ODN), and the TLR7/8 ligands 
R848 and imiquimod, undergone maturation as evidenced by upregulation of their 
costimulatory molecules. In one study, immature ex vzvo-generated DCs injected into 
the skin of mice previously treated with imiquimod to induce a local inflammatory 
reaction showed that the DCs migrated to lymph and induced CTL responses (Martin- 
Fontecha et al., 2003; Nair et al., 2003). Indeed, MPL has already been approved for 
use in clinical trials (Neidhart et al., 2004; Vantomme et al., 2007). Importantly, DC 
maturation can be augmented even further by using combinations o f TLR agonists 
(Gautier et al., 2005; Napolitani et al., 2005; Warger et al., 2006).
An alternative mode o f DC maturation is ligation of CD40. Signalling through CD40 
has multiple effects on DCs, including inducing the upregulation of costimulatory 
molecules, the secretion o f cytokines (notably IL-12), and the upregulation of several 
anti-apoptotic molecules, all o f which are required by DCs to optimally activate CD8^ 
and CD4^ T cells (Grewal and Flavell, 1998; Quezada et al., 2004). It has been 
demonstrated that DCs activated with anti-CD40 antibodies or CD40 ligand enhanced 
their costimulatory molecules expression and resulted in the induction o f potent 
immune responses (French et al., 2007; Rew et al., 2005; Watanabe et al., 2003). 
Hanks et al developed a drug-inducible CD40 expression system to specifically 
augment CD40 signalling of DCs after in vivo administration (Hanks et al., 2005). It 
was shown that DCs expressing the modified CD40 molecules (made by fusing a
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membrane-localised cytoplasmic domain of CD40 to a drug-binding domain) would 
selectively undergo maturation in the draining lymph node via CD40 trimérisation 
upon injection of the appropriate drug.
1.3.4. Overcoming tolerance 
Because tumours are intrinsic, generating an effective anti-tumour response requires 
mounting an immune attack which may require breaking self tolerance. Although not 
all tumour antigens are self antigens (e.g. Epstein Barr Virus antigens in some 
lymphomas and mutated p53 in many epithelial carcinomas, as discussed in section 
1.3.1), it has become clear that inefficient tumour rejection can result not as a result of 
insufficient effector cells (Gajewski et al., 2006; Wick et al., 1997) but because of the 
immunosuppressive mechanisms exerted by the tumour itself (see section 1.2) and by 
the cells, such as Tregs, that are present in the tumour microenvironment. CD4^ 
CD25^ Tregs have emerged as important players in suppressing host anti-tumour 
responses (Terabe and Berzofsky, 2004; Wang and Wang, 2007; Zou, 2006). They act 
through heterogeneous mechanisms such as direct contact or the production of soluble 
factors such as IL-10 and TGF-p to inhibit the function of T cells (Somasundaram et 
al., 2002; Woo et al., 2002; Yang et al., 2006c), NK cells (Ghiringhelli et al., 2005), 
B cells (Lim et al., 2005) and DCs (Larmonier et al., 2007). Numerous studies have 
shown that the numbers o f CD4^ CD25^ Tregs are increased in the blood (Javia and 
Rosenberg, 2003; Liyanage et al., 2002; Somasundaram et al., 2002; W olf et al., 
2003; Woo et al., 2001), tumour and draining lymph nodes (Alvaro et al., 2005; Lee 
et al., 2005; Yang et al., 2006a; Yang et al., 2006b) o f patients with different cancers.
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Depleting Tregs in mouse models of cancer has been shown to be an effective anti­
cancer treatment (Onizuka et al., 1999; Shimizu et al., 1999). Denileukin diftitox 
(Ontak) is a recombinant fusion protein consisting o f IL-2 and diphtheria toxin that 
has been approved by the Food and Drug Agency (FDA) for treating cutaneous T cell 
leukaemia/ lymphoma (Eklund and Kuzel, 2005; Turturro, 2007). As cutaneous T cell 
leukaemia/ lymphoma is characterised by a large number of malignant CD4^ CD25^ T 
cells, Ontak works by binding the IL-2 receptor chain of CD25 on these malignant 
CD4^ CD25^ T cells to inhibit their protein translation and cause them to undergo 
apoptosis. Due to its high affinity to the IL-2 receptor, Ontak is being used in the 
clinics for inhibiting and depleting Tregs in patients with renal cell carcinoma 
(Dannull et al., 2005) and melanoma (Mahnke et al., 2007) with some degree of 
success. To further augment the Treg depletion regimen, it is important to block 
VEGF (Li et al., 2006a), prostaglandins (Mahic et al., 2006) and estrogen (Polanczyk 
et al., 2004) that are important for Treg differentiation and functions. In mouse 
models o f colon cancer and melanoma, blocking VEGF reduced the number of 
intratumoral Tregs (Li et al., 2006a). Cyclophosphamide, a standard cytotoxic 
chemotherapeutic, can also inhibit Tregs (Berd and Mastrangelo, 1987; Ghiringhelli et 
a l,  2007).
T cells in chronic viral infections and in the tumour setting are frequently impaired in 
their functions and express high level o f programmed death-1 (PDl), which is an 
inhibitory molecule induced after T cell activation (Freeman et a l,  2000). PDl 
interacts with its ligands B7-H1 [also known as PD-Ll] and B7-DC [also known as 
PD-L2] (Dong et a l ,  2002; Iwai et a l, 2002). In HIV infections, PDl expression 
correlates positively with plasma viral load and inversely with CD4^ T cell numbers
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(Day et al., 2006) and hence is used as a marker of disease progression. It was shown 
that blocking B7-H1 with specific antibodies augmented HIV-specific CD4^ and 
CD8^ T cell function ex vivo (Day et al., 2006; Petrovas et al., 2006; Trautmann et al.,
2006). In the tumour setting, B7-H1 is expressed by mouse melanoma cells and their 
in vivo growth is inhibited by administering B7-H1-specific antibody (Iwai et al.,
2002). Most human epithelial tumours and APCs express B7-H1 and B7-H4 (Kryczek 
et al., 2006b; Kryczek et al., 2006a; Tringler et al., 2005) and represent attractive 
targets for cancer immunotherapy. PDl blockade is currently being evaluated in 
humans, and it remains to be seen whether blockade of other functionally related 
coinhibitory molecules, such as B7-H3, B7-H4 (also known as B7x or B7S1), B and T 
lymphocyte attenuator (BTLA), and the recently described V-set and Ig domain- 
containing 4 [VSIG-4] (Vogt et al., 2006) will show significant anti-tumour effects in 
humans.
It is unlikely that one form of immunotherapy will successfully induce the regression 
of bulky tumours. Hence combining vaccines (DC or otherwise) with strategies to 
overcome tolerance should be considered. One promising strategy is the co­
administration o f antagonistic antibodies specific for the inhibitory signaling 
molecule, cytotoxic T lymphocyte-associated 4 (CTLA-4), that is expressed on 
activated T cells (Melero et al., 1997). In mouse models, blocking CTLA-4 antibody 
used in combination with a GM-CSF- transduced tumour cell vaccine reduced the 
number of intratumoural Treg and enhanced the rejection of poorly immunogenic 
tumours (Quezada et al., 2006). CTLA-4 blockade also released DCs from B7- 
mediated engagement with either effector T cells or Tregs, which causes the induction 
o f IDO and immune suppression due to tryptophan depletion and production of pro-
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apoptotic factors (Fallarino et al., 2003). In humans, objective tumour regression was 
observed in some melanoma patients who received both the peptide/adjuvant vaccines 
and antagonistic CTLA-4 antibody (Hodi et al., 2003; Phan et al., 2003). An ongoing 
phase III clinical trial will resolve whether CTLA4-specific antibodies as a single 
agent or administered in combination with a peptide vaccine are effective in treating 
metastatic melanoma.
1.4. Cancer of the Ovary
1.4.1. Immunobiology of ovarian carcinoma 
Ovarian cancer is the commonest female gynaecological malignancy and the 4‘^  most 
common cause o f cancer death for women in Europe and the United States (Yancik, 
1993). Nearly 90% of all ovarian cancers are epithelial ovarian carcinoma (EGG). As 
ovarian cancers are often asymptomatic in the early stage, most patients present with 
advanced disease at the time o f diagnosis. Many patients respond well to surgery and 
platinum-based chemotherapy with more than 50% of them entering remission. 
However, the majority develops recurrent chemotherapy-resistant disease. The 
median survival time is approximately 24 months and the 5-year survival rates for 
patients with stage III and IV disease are 25% and 5%, respectively. The clinical 
course of ovarian cancer is often marked by periods of relapse and remission. Patients 
in remission with minimal disease burdens are attractive candidates for evaluating 
immunotherapies.
Accumulating evidence shows that ovarian tumours are recognised and attacked by 
the immune system. Tumour-infiltrating lymphocytes (TILs) are frequently observed 
in ovarian tumours and shown to express IFN-y, IL-2 and lymphocyte-attracting
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chemokines (Zhang et a l,  2003). Such TILs are able to recognise tumour antigens 
(Fisk et a l,  1995; Peoples et a l,  1995), undergo oligoclonal expansion (Halapi et al., 
1993) and display tumour-specific cytolytic activity ex vivo (Freedman et al., 1994; 
loannides et al., 1991a; loannides et a l,  1991b). When expanded ex vivo, the T cell 
clones are able to recognise different antigenic determinants within the same patients, 
indicating the heterogeneity of the response within individuals (loannides et al., 
1991b). The presence of TILs is associated with significantly longer clinical remission 
after chemotherapy as well as improved overall survival of the patients (Zhang et al.,
2003). This strongly suggests that treatment of ovarian carcinoma, as o f other tumours 
such as melanoma, breast, prostate, renal cell, oesophageal and colorectal carcinoma 
(Marrogi et al., 1997; Naito et al., 1998; Nakano et al., 2001; Schumacher et al., 
2001; Vesalainen et al., 1994), could greatly benefit from strengthening tumour 
rejection through immunotherapy.
The immune response in the ovarian tumour microenvironment is modulated by 
interactions amongst different cell types present. Curiel et al showed that CD4^ 
CD25^ F0XP3^ Tregs accumulated in malignant ascites and tumour of patients with 
advanced stage (111 and IV) ovarian cancer and were involved in tumour evasion 
(Curiel et al., 2004). The Tregs were found in close proximity with CDS^ CD3^ T 
cells, and inhibited the latter's proliferation and production of lL-2 and IFN-y in vitro. 
They also expressed CCR4, which is the receptor for CCL22 and CCL17 chemokines, 
and were recruited into the tumours via CCL22 produced by tumour-associated 
macrophages. Blockade of CCL22 has been shown to reduce Treg trafficking in vivo 
in NOD (non-obese diabetic)/SClD mice carrying ovarian cancer xenografts (Disis et 
al., 2006). In a transgenic mouse model of intraperitoneal cancer, Tregs inhibited anti­
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tumour immunity via CTLA-4-mediated contact inhibition of immune effector T cells 
(Disis et al., 2006). Thus it should be beneficial to inhibit the function of 
intratumoural Tregs in ovarian carcinomas.
Tumour-associated macrophages are a prominent component of ovarian cancer stroma 
and contribute to tumour progression (Kryczek et al., 2006b). They were shown to 
express B7-H4 to suppress the anti-tumour T cell response, and blocking B7-H4 
restored the T cell stimulating capacity of these macrophages and resulted in tumour 
regression in vivo. IL-6 and IL-10, that were present in high levels in the tumour 
microenvironment, were found to stimulate B7-H4 expression on the macrophages. In 
contrast, GM-CSF and IL-4, which were limited in the microenvironment, inhibited 
B7-H4 expression. Hence blocking B7-H4 or depleting B7-H4 expressing tumour 
macrophages might enhance anti-ovarian cancer T cell responses. In addition, ascites 
in patients with ovarian cancer was found to contain pDCs that were capable of 
inducing CD8^ Tregs in the tumour (Wei et al., 2005). Such CD8^ Tregs expressed 
IL-10, CCR7 and CD45RO, and significantly suppressed conventional DC-mediated 
anti-tumour T cell effector functions through IL-10. Hence, ovarian tumours can 
manipulate the function and distribution of different DC subsets in the 
microenvironment to subvert anti-tumour immunity. It has also been shown that 
malignant ovarian epithelial expressed TNF-a which in turn caused a greater release 
o f chemokines CCL2 and CXCL12, IL-6, macrophage migration-inhibitory factor 
(MIF) and VEGF that were required for tumour progression and angiogenesis (Kulbe 
et al., 2007). Therefore a more complete understanding of ovarian tumour 
immunobiology is essential for developing effective immunotherapeutic strategies.
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1.4.2. Ovarian tumour-associated antigens
1.4.2.1. CT antigens: NY-ESO-1, LAGE-1, MAGEs and SSX 
Odunsi et al examined NY-ESO-1 and LAGE expressions by reverse transcription- 
PCR (RT-PCR) and immunohistochemistry in a panel of EOC tissues, and found that 
82 of 93 (88%) specimens were positive for NY-ESO-1 and 22 of 107 (21%) were 
positive for LAGE-1 (Odunsi et al., 2003). About 30% of the patients with NY-ESO- 
1 or LAGE-1 expressing tumours also developed antibodies to the antigens that were 
present for up to 3 years after initial diagnosis (Murray et ah, 2002). MAGE-1 is 
expressed in 11 o f 25 benign lesions, and 15 of 27 malignant specimens (Gillespie et 
al., 1998). MAGE-2, -3, -6 were also expressed in 5, 11 and 4 of 58 ECO, 
respectively (Yamada et al., 1995). MAGE-4 was present in 57% of the serous 
carcinomas analysed and its expression was inversely correlated to patient survival 
{P= 0.016) (Yakirevich et al., 2003). The breakpoint genes SSX-1, SSX-2, and SSX-4 
were expressed in 2.5%, 10%, and 16% of 120 EOC specimens, respectively. Two 
patients had antibodies to SSX-2 and SSX-4, while two novel HLA-DR restricted SSX- 
-^-derived T cell epitopes were also identified (Valmori et al., 2006). NY-ESO-1 
peptide has been evaluated in clinical trials (Odunsi et al., 2007) (see section 1.5.3.4).
1.4.2.2. CA125
CA 125, a large membrane glycoprotein (>1000 kDa) encoded by the M U C l6 gene, is 
expressed by epithelial cells of different organs (O'Brien, 1998). It is consistently 
elevated in ECO and is used as the gold standard for monitoring patients’ prognosis, 
disease progression and response to chemotherapy. Antibody regimes targeting 
CA125 have been developed and assessed in ovarian cancer clinical trials (see section 
1.5.3.3).
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1.4.2.3. Differentiation antigen: carcinoembryonic antigen 
Carcinoembryonic antigen (CEA) is a 180 kDa onco-fetal glycoprotein expressed in 
the normal fetal colon and adult colonic mucosa. It is over-expressed in many tumours 
including colon, pancreas, breast, lung and ovarian carcinomas. Approximately 67% 
o f ovarian tumours expressed CEA (Lagendijk et al., 1998; Multhaupt et al., 1999). It 
is also detected in the sera of ovarian cancer patients and elevated level is indicative 
o f progression of the disease (Tholander et al., 1990).
1.4.2.4. Human epidermal receptor-2/ neurological (HER-2/neu) 
HER-2/neu protein, also known as ErbB2 receptor, is a 185-kDa transmembrane 
glycoprotein with tyrosine kinase activity and extensive homology to the epidermal 
growth factor receptor (Bargmann et al., 1986; Coussen et al., 1985). It is involved in 
the proliferation, differentiation and survival of normal cells. It is frequently amplified 
and overexpressed in approximately 20% of ovarian cancers (Slamon et al., 1987) and 
in other tumours including breast (Slamon et al., 2001), pancreatic (Yamanaka et al., 
1993) and colorectal carcinomas (Maxwell-Armstrong et al., 1998). The humanised 
mAh, Trastuzumab (Herceptin), has been developed and used for treating early-stage 
breast cancer that overexpresses HER-2/neu (Mir et al., 2007; Valabrega et al., 2007). 
Data from large phase III trials showed that its use in the adjuvant setting significantly 
improved the overall survival o f the patients (Valabrega et al., 2007). Several MHC 
class I and Il-binding synthetic peptides derived from the HER-2/neu protein 
sequence (Tables 1.1 and 1.2) have been successfully tested in ovarian cancer clinical 
trials to induce immune responses against HER-2/neu^ tumours (see section 1.5.3). 
These peptides have also been useful for monitoring anti-ovarian tumour responses 
and evaluating the efficacy of ovarian cancer immunotherapies.
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Table 1.1 MHC class I-restricted epitopes of HER-2/neu
HER-2/neu
peptides
Peptide sequence HLA-presenting
allele
Reference
p63-71 TYLPTNASL A24 (Shiku et al., 2000)
p369-377 (E75) KIFGSLAFL A2, A3, A26 (Brossait et al., 1998; 
Fisk et al., 1995; 
Sotiriadou et al., 
2001)
p435-443 ILHNGAYSL A2 (Rongcun et al., 1999)
p654-662 (GP2) IISAVVGIL A2 (Brossait et al., 1998)
p665-673 VVLGVVFGI A2 (Rongcun et al., 1999)
p689-697 RLLQETELVE A2 (Rongcun et a l, 1999)
p754-762 LRENTSPK A3, A l l ,  A33 (Kawashima et a l,  
1999)
p952-961 YMIMVKCWMI A2 (Rongcun et al., 1999)
Table 1.2 MHC class Il-restricted epitopes of HER-2/neu
HER-2/neu
peptides
Peptide sequence HLA-presenting
allele
Reference
p62-76 LTYLPTNASLSFLQD DR4/15, DR51, DR53, DQ6/7 (Kobayashi et 
a/., 2000)
p369-386 KIFGSLAFLPESFDGDPA DR4/5, DR51, DR53, DQ6/7 (Kobayashi et 
a/., 2000)
p688-703 RRLLQETELVEPLTPS DR4 (Salazar et al., 
2003)
p776-788 1 GVGSPYVSRLLGI DR7, DR51 (Sotiriadou et 
a/., 2001)
p777-789 VGSPYVSRLLGIC DR4 (Tuttle et a l, 
1998)
p822-836 LLNWCMQIAKGMSYL DR1/11,DR51,DR52, DQ5/7 (Kobayashi et 
a/., 2000)
p884-899 VPIKWMALESILRRRF DR4 (Preze et al., 
2002)
p971-984 ELVSEFSRMARDPQ DR4 (Salazar et al., 
2003)
1.4.2.5. Tumour Mucin 1 (M UCl)
MUCl epithelial mucin is a highly glycosylated transmembrane type I glycoprotein 
with a molecular weight of 250 kDa. It is expressed on the apical surfaces of most 
human glandular epithelial tissues (Patton et al., 1995) and has a unique extracellular
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domain consisting mostly of 20 to 60 tandem repeats (VTNR: variable number of 
tandem repeats region which is made up by a 20-amino-acid sequence of 
PDTRPAPGSTAPPAHGVTSA). More than 80% of ovarian tumours overexpressed 
MUCl of the hypo-glycosylated form on the entire surface of the tumour cells. This 
occurs because of the premature termination of 0-glycosylation of the tumour M UCl, 
leading to an accumulation of short carbohydrate precursors such as monosaccharides 
Tn (GalNAcal-O-S/T) or disaccharide T (G aipi-3-3GalN A cal-0-S/T), and their 
sialylated forms sTn and sT, respectively (Baldus and Hanisch, 2000). This also leads 
to the exposure of the immunogenic PDTRP region of the tandem repeat that is 
hidden on normal epithelial mucins by the extensive O-glycosylation of peptide cores. 
Some cancer patients can mount a cellular and humoural response to M UCl, hence 
indicating its potential as target molecule for immunotherapy (see section 1.5.3). Both 
MHC class I and Il-restricted MUCl epitopes have been identified (Tables 1.3 and 
1.4) and tested in clinical trials.
Table 1.3 MHC class I-restricted epitopes of M UCl
M UCl
peptides
Peptide sequence Region of MUCl 
where peptide is 
derived from
HLA-
presentig
allele
References
M l.l STPPVHNV VNTR A2 (Brossart et al., 
1999)
STPPVHGV VNTR A ll (Domenech et 
1995)
M1.2 LLLLTVLTV Signal sequence A2 (Brossart et al., 
1999)
Table 1.4 MHC class Il-restricted epitope of M UCl
1 MUC-1 peptides Peptide sequence Region of M UCl 
where peptide is 
derived from
HLA-
presenting
allele
References
PGSTAPPAHGVT VNTR DR3 (Hiltbold et al., 
1998)
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1.4.2.6. Sialyl-Tn antigen and serine proteases 
Sialyl-Tn antigen (sialyla2-6Gal-NAca-Ser/Thr) is expressed in the lumen of normal 
secreting tissues such as salivary glands, gastric, intestinal and uterine mucosa, but is 
absent from most o f other tissues such as normal pancreas, ovary or breast tissues 
(Cao et al., 1996). Its expression is due to the premature sialylation of the core 
carbohydrate structure Gal-NAcal-O-Ser/Thr which stops further elongation of the 
oligosaccharide chains. It is present on the tumour MUCl mucins o f ovarian tumour 
cells. A synthetic STn-keyhole limpet hemocyanin (KLH) vaccine (Theratope®, 
Biomira) has been developed and evaluated in clinical trials involving breast and 
ovarian cancer patients with some degree of success (Sandmaier et al., 1999). On the 
other hand, several serine protease antigens, e.g. hepsin, stratum corneum 
chymotryptic enzyme, and tumour-associated differentially expressed gene product 12 
(TADG-12), TADG-14 (also called kallikrein-8 or neuropsin), TADG-15, and 
TADG-16 (testisin) are expressed in ovarian cancers but have very limited expression 
in normal ovary tissues and other normal tissues (Cannon et al., 2002). They are 
thought to play key roles in cancer invasion and metastasis, and might present new 
targets for immunotherapies.
1.4.2.7. Other emerging ovarian antigens 
The SEREX technology is being used to screen the sera of patients with advanced 
serous ovarian cancer and identified several antigens recognised only by the 
antibodies produced by the patients (Stone et a l,  2003). These antigens include p53, 
UBQLNl, H0XB6, T0P2A, putative helicase RUVBL, HEXIMl and HDCMA. It is 
found that 40% of serous ovarian cancer patients tested had serum IgG to at least one 
antigen, and 14% had antibodies to two or more of these antigens. Importantly,
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H0XB6, T0P2A and DDB5 are overexpressed in ovarian tumours relative to normal 
tissues, therefore suggesting them as potential targets for immunotherapy. In addition, 
some widely occurring TA As found in other forms of tumours are also overexpressed 
in ovarian tumours, and are summarised in Table 1.5.
Table 1.5 MHC class I-restricted epitopes of ovarian TA As
Gene Peptide sequence HLA-
presenting
allele
Reference
Adipophilin SVASTITGV A2 (Schmidt et aL, 
2004)
RSDSGQQARY A1 (Harada et al., 
2001)
ART-4 AFLRHAAL A24 (Kawano et al., 
2000)
ART-4 DYPSLSATDI A24 (Kawano et al., 
2000)
Cyp-B KFHRVIKDF A24 (Gomi et al., 1999)
Cyp-B DFMIQGGDF A24 (Gomi et al., 1999)
1 G2J0 HLSTAFARV A2 (Vissers et al., 
1999)
Htert ILAKFLHWL A2 (Vonderheida et 
a/., 1999)
MUC2 LLNQLQVNL A2 (Bohm er al., 
1998)
1.4.3. Immunotherapy o f Ovarian Cancer
1.4.3.1. Dendritic cell-based immunotherapy 
Autologous DCs pulsed with mannan-MUCl fusion protein have been evaluated in a 
phase I clinical trial to treat patients with adenocarcinoma expressing M UCl. The DC 
vaccine elicited strong T cell IFN-y Elispot responses and delayed-type 
hypersensitivity (DTH) responses at injection sites o f the patients. Two patients with 
clearly progressive disease (ovarian and renal carcinoma) at entry were stable after the 
therapy (Loveland et aL, 2006). In another phase I clinical trial, patients with
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advanced gynaecological malignancies (two patients with uterine sarcoma and six 
with ovarian carcinoma) were vaccinated with DC pulsed with KLH and autologous 
tumour antigens at 10-day or 4-week intervals. Three patients showed stable disease 
lasting 25 to 45 weeks, and five experienced tumour progression within the first 14 
weeks. KLH-tumour lysate specific response was observed in six patients (Hernando 
et al., 2002). The use of autologous DCs pulsed with HER-2/neu- or M UCl-derived 
peptides were investigated in a clinical trial involving patients with advanced breast 
and ovarian cancers. In 5 of 10 patients, peptide-specific CTLs were detected in the 
peripheral blood using both intracellular IFN-y staining and  ^^ chromium-release CTL 
assays. The major CTL response in vivo was induced with the HER-2/neu-derived 
E75 and the M UCl-derived M1.2 peptide, which lasted for more than 6 months, 
suggesting that these peptides might be immunodominant. Antigen spreading seemed 
to occur as one patient vaccinated with the MUCl-derived peptides also developed 
CE A- and MAGE-3 peptide-specific T-cell responses after several vaccinations. 
Another patient immunised with HER-2/neu peptides also exhibit MUCl-specific T 
cell response after 7 immunisations (Brossart et a i, 2000).
1.4.3.2. T cell adoptive transfer 
In one study, 28 patients with advanced ovarian cancer received two cycles o f five 
daily intraperitoneal infusions of autologous ex vivo activated peripheral blood T 
lymphocytes re-targeted with bispecific monoclonal antibody OC/TR, which is 
directed against CD3 and the folate receptor, plus recombinant IL-2. A 27% overall 
response rate and 10% complete response rate which lasted 18-26 months were seen 
(Freedman and Platsoucas, 1996). To optimise adoptive T cell transfer strategy 
further, it is important to select the appropriate lymphocyte subsets for ex vivo
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expansion, for example, TILs are preferred as they presumably contain a higher 
frequency of TAA-specific T cells than peripheral blood T cells. However, many 
CD 8  ^ TILs do not express CD28. They could be expanded by artificial APCs 
expressing the NKG2D ligand Letal and coated with OKT3/CD28 antibodies or even 
0KT3 alone (Conejo-Garcia et aL, 2004). In addition, Tregs could be present in high 
numbers in ovarian tumours (Curiel et aL, 2004; Woo et aL, 2001) and should be 
depleted prior to expansion of T cells for adoptive transfer. At present, several clinical 
trials are testing the efficacy o f targeting Treg with anti-CTLA4 mAh (Hodi et aL, 
2003; Phan et aL, 2003) or DAB389IL-2 diphtheria toxin fusion protein (ONTAK) 
directed against IL-2 receptor/ CD25 (Frankel et aL, 2003). Patients with recurrent, 
multi-drug resistant ovarian cancer have been treated in these trials. If these initial 
data are encouraging, suppression of Tregs will certainly be important as part of the 
tumour immunotherapy strategies.
1.4.3.3. Antibody therapies 
Oregovomab is an IgG Ik subclass murine mAb that binds with high affinity to 
circulating CA125 (Schultes et aL, 1999). 145 patients with stage III or IV EOC 
received intravenous oregovomab at first clinical remission (Berek et aL, 2004). 
Patients given the mAh experienced a longer period of remission (13 months) 
compared to those with placebo (10.3 months). Another strategy is vaccination with 
anti-idiotypic antibodies. The mAh Abagovomab (formally know as ACA125) that 
mimics a specific epitope of the tumour-associated antigen CA125 expressed by most 
EOC has been evaluated in clinical trials (Reinartz et aL, 1999). After treatment with 
ACA125, patients showed strong increase o f intracellular IFN-y and IL-2, and a 
delayed induction o f T helper 2-type response that promoted antibody-mediated
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immunity by B cells. In another phase I and II study of ACA125, 42 patients with 
advanced or recurrent EOC were given four injections of intramuscular alum- 
precipitated abagovomab at 2 weeks intervals (Saleh et aL, 1998). Anti-CA125 
66.7%) and CTL responses against CA 125-expressing human ovarian cancer cell 
lines were observed, and in patients the overall survival was also enhanced (19.9 
months) compared to with placebo (5.3 months).
1.4.3.4. Peptide therapies 
In a phase I clinical trial of HER-2/neu peptide vaccination in 19 patients with HER- 
2/neu over-expressing stage III or IV ovarian or breast cancer (Knutson et aL, 2001), 
patients received monthly vaccinations with three 15 amino acid HER-2/neu-derived 
peptides MHC class II ‘helper’ peptides, containing within each the HLA-A2 binding 
motifs (representing the CTL epitope) for six months. It was found that peptide- 
specific T cell immunity was induced 83% of the patients, and the T cell responses 
were long-lived and detected for more than 1 year after the final vaccination in a few 
patients. Another clinical trial was conducted by vaccinating patients with NY-ESO-1 
peptide, ESO 157 .170 which consisted o f epitopes recognised by both CD4^ T cells and 
CD8  ^ T cells. Long-lived and CD8  ^ and CD4^ T cells specific to NY-ESO-1 were 
detectable in some patients up to 12 months after immunisation (Odunsi et aL, 2007).
1.5. Cancer of the Skin
1.5.1. Immunobiology of melanoma 
The highly immunogenic cutaneous malignant melanoma is the most extensively 
investigated human malignancy in tumour immunology. It is well-recognised that 
melanoma patients might develop melanoma antigen-specific T cell responses
55
Chapter I: General Introduction
spontaneously in the absence of any external stimulation (Germeau et aL, 2005; 
Lonchay et aL, 2004). Cultured single cell suspensions derived from melanoma 
métastasés and invaded lymph nodes for 30 to 60 days in the presence of IL-2 were 
often able to produce as many as 10* -^10*  ^ T cells, with most of them exerting CTL 
activity on fresh tumour cell preparations (Yannelli et aL, 1996). Adoptive transfer of 
these T cells with high-dose IL-2 produced objective tumour responses in a higher 
proportion of the patients than with IL-2 treatment alone (Rosenberg et aL, 1988). The 
frequency of CTL precursors was higher in the TILs and in tumour-invaded lymph 
nodes than in PBMCs (Mazzocchi et aL, 1994; Romero et aL, 1998). Melanoma 
patients made tumour-free by surgery or other means mount a response to antigen(s) 
expressed by autologous melanoma that could be sustained for years (Sensi and 
Anichini, 2006). These observations prompted the exploration o f immunotherapy in 
melanoma patients. However, the overall results from melanoma clinical trials are far 
from satisfactory. Like ovarian carcinoma, immunosuppressive mechanisms are 
present at the tumour site in melanoma and need to be overcome (Lizee et aL, 2006). 
CD4^ CD25^ FOXP3^ Tregs in melanoma can actively subvert the actions of CD8 
and CD4 anti-tumour effector T cells. Human melanoma can also produce soluble 
factors, such as IL-10 and TGF-p that could inhibit DC and T cell functions. They 
also express and secrete soluble Fas ligand, TRAIL and MICA/B that can inhibit NK 
and CTL functions.
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1.5.2. Melanoma-associated tumour antigens
1.5.2.1.MART-1/Melan-A 
The melanoma differentiation antigen, MART-1/ Melan-A, is the most widely studied 
tumour antigen in melanoma. It is a type III membrane protein with a molecular mass 
of 22-24 kDa and is highly enriched in early melanosomes, suggesting that it might 
play some role in early melanogenesis (Kushimoto et al., 2001). Approximately 10- 
75% melanoma patients have T cell responses against the antigen (Dhodapkar et aL, 
2000; Griffioen et aL, 2001; Lee et aL, 1999; Pittet et aL, 1999; Scheibenbogen et aL, 
1997). Using tetramer staining, up to 0.4% of CD8^ T cells in the peripheral blood of 
melanoma patients were reactive to MART-1 (Pittet et aL, 1999). Up to 3.5% of 
melanoma draining lymph node CD8^ T cells were MART-1 specific. Upon a short­
term ex vivo expansion, this percentage increased up to 21% (Romero et aL, 1998). 
Further analyses showed that peripheral MART-1-specific T cells are mainly [about 
two-thirds] CD28+ CD45RA'’'*'’ or CD45RA''‘®'' CCR7^ representing naive T cells 
(Hamann et aL, 1999; Pittet et aL, 1999; Pittet et aL, 2002; Sallusto et aL, 1999). 
However, one-third o f melanA/M ART -1 -specific T cells are of effector memory type 
(Valmori et aL, 2002). Interestingly, about 95% of melanA/M ART -1 -specific T cells 
at the tumour site represent this effector memory subtype (Pittet et aL, 2002).
1.5.2.2. Tyrosinase-related proteins 1 and 2
Tyrosinase-related protein (TRP) 1 and 2 are multifunctional glycoproteins with 
molecular weights o f approximately 60 to 70 kDa, and are essential for the 
biosynthesis of the skin pigment melanin (Hearing and Jimenez, 1987). These 
differentiation antigens are overexpressed in melanoma and are used as targets in 
immunotherapy of melanoma. The mouse TRP-1 and TRP-2 homologs have been
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cloned and widely studied. Using intracellular cytokine and tetramer staining, 
Valmori et al demonstrated in a stage IV melanoma patient that around 5% of CD3^ 
CD8^ T cells were specific to tyrosinasc3 6 8 -3 7 6  (Valmori et aL, 2002). Most of them 
were CD45RA^ CCR7^ granzyme that was characteristic o f CTL effector cells 
(Campbell et al., 2001; Sallusto et al., 1999; Valmori et al., 2002). Consistent with 
their phenotype, these tyrosinase-specific T cells were able to recognise and lyse 
tyrosinase-expressing tumour cells (Valmori et al., 2002).
1.5.2.3. Melanoma antigen (MAGE)
The prototype of the cancer-germline genes is MAGE gene family which is composed 
of 24 genes that range across three subfamilies: MAGE-A, -B, and -C, located in three 
different regions of the X chromosome (Chômez et al., 2001; De Plaen et al., 1994; 
van der Bruggen et al., 1991). The expression of MAGE genes in tumours appears to 
be triggered by the déméthylation of their promoter, apparently as a consequence of 
the widespread déméthylation process that occurs in many tumours, including 
melanoma (De Smet et al., 1996). CTLs responsive against the MAGE family are 
very rarely found despite extensive studies (Chaux et al., 1998; Dhodapkar et al., 
2000; Gaugler et al., 1994; Griffioen et al., 2001; Scheibenbogen et al., 1997; 
Traversari et al., 1992; van der Bruggen P et al., 1994; Zom and Hercend, 1999a). 
MAGE-A 10-encoded nonapeptide2 5 4 -2 6 2  which is presented by HLA-A2.1 could be an 
exception. CTL responses to this peptide were detected after short-term ex vivo 
expansion in 8 of 12 patients with a MAGE-A 10-expressing melanoma using 
tetramers of HLA-A2/ peptide MAGE-AIO2 5 4 -2 6 2  complexes (Valmori et al., 2001). 
Interestingly, samples from 3 of 10 patients whose tumors had no detectable MAGE-
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AlO expression and 2 of 10 healthy donors were also positive for the MAGE-A 10 
tetramer (Valmori et aL, 2001).
1.5.2.4. NY-ESO-1
NY-ESO-1, another widely studied TA A, is often over-expressed in melanoma. Jager 
et al demonstrated that 10 of 27 patients with tumours expressing NY-ESO-1 
frequently elicited spontaneous CTL and antibody responses against NY-ESO-1 
protein (Jager et aL, 2000a; Jager et aL, 2000b). Most of these NY-ESO-1-reactive T 
cells were CD45RA^ CD28^, representing a memory subset of T cells (Hamann et aL, 
1999; Valmori et aL, 2000). Some melanoma patients have spontaneous responses 
against LAGE-1, an ORE product of NY-ESO-1 (Griffioen et aL, 2001).
1.5.2.5. Gp-lOO/ Pmell?
Gp-lOO or Pm ell? is the human homologue of murine silver, whose disruption of 
function produces a silver hair color in mice (Kawakami et aL, 1994b). Although 
natural T cell responses against gp-100 is infrequent, responses against 209-217-2M, 
a modified peptide and gp-1 0 0 17-25 after ex vivo expansion were observed in 
melanoma patients (Yamshchikov et aL, 2001).
Table 1.6 Main antigenic peptides used to vaccinate melanoma patients
Gene Frequency of HLA- Peptide Ref.
expression in 
metastatic
presenting
allele
sequence
melanoma
MAGE-Al 46% A2 KVLEYVIKV (Ottaviani et aL,
A3 SLFRAVITK 2005; Pascolo et 
aL, 2001) 
(Chaux et aL, 
1999a)
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MAGE-A3 74% A1
DP4
EVDPIGHLY
KLLTQHFVQENYLEY
(Gaugler et aL, 
1994) 
(Schultz et aL, 
2000)
MAGE-A4 28% A2 GVYDGREHTV (Duffour et aL, 
1999)
MAGE-AIO 47% A2 GLYDGMEHL (Huang et aL, 
1999)
MAGE-A12 62% Cw7 VRIGHLYIL (Breckpot et aL, 
2004)
MAGE-C2 59% A2 ALKDVEERV (Ma et aL, 2004)
NY-ESO-
l/LAGE-2
28% A2 SLLMWITQC [Chen et aL, 2000; 
Jager et aL, 1998; 
Valmori et aL, 
2000)
Tyrosinase >90% A2 YMDGTMSQV (Skipper et aL, 
1996a; Wolfel et 
aL, 1994)
MART-1/
Melan-A
>90% A2 EAAGIGILTV (Schneider et aL, 
1998)
Gp-100 >90% A2 ITDQVPFSV (Kawakami et 
a L ,1995) 1
*More information can be found at:
http : //www. cancerimmunity. org/peptidedatabase/Tcellepitopes. htm.
1.5.3. Immunotherapy o f Melanoma
1.5.3.1. Dendritic cell-based immunotherapy 
To provide an option to overcome HLA restriction inherent to loading DC vaccines 
with peptides, Palucka et al vaccinated 20 patients in stage IV melanoma with 
autologous monocyte-derived DCs loaded with killed allogeneic Colo829 melanoma 
cell line (Palucka et aL, 2006). The antigen-loaded DCs were activated ex vivo with 
TNF and CD40 ligand. The patients had a median overall survival o f 22.5 months. In 
2 patients who failed previous therapy, 1 experienced complete regression and 1 
partial regression lasting 18 and 23 months, respectively. 3 out o f 13 patients also 
developed MART-1 specific T cells. One patient elicited CD8^ T cell immunity 
specific to a novel peptide-derived from MART-1 antigen, suggesting that cross- 
presentation o f melanoma antigens by DC vaccine had occurred. DCs loaded with
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peptides derived from four melanoma antigens (MART-1, TRP, MAGE-3, and gp- 
100) and influenza matrix peptide (Flu-MP) have also been evaluated in the clinic 
(Banchereau et aL, 2005). 14 of 20 patients received peptide-pulsed DCs without 
KLH and 6 received KLH-loaded DCs. Melanoma-peptide-specific recall memory 
CD8^ T cells secreting IFN-y were detected in 6 of the patients. The median overall 
survival was 12 months and the median event-free survival was 4 months.
To determine the best route of administration of auotologous DCs pulsed with 
melanoma peptides (MART-1, gp-100 and TRP) in vivo, 27 patients with metastatic 
melanoma were randomly assigned to receive the DC vaccines via the intravenous 
[IV], intranodal [IN], or intradermal [ID] route in a phase I study (Bedrosian et aL, 
2003). 22 of 27 (81.5%) patients completed all four vaccinations with a few patients 
developing some toxicity including rash, fever, and injection site reaction. All routes 
of administration induced comparable increases in tetramer-staining CD8^ T cells (5 
o f 7 patients from IV route, 4 of 7 patients from IN route, and 4 of 6 patients from ID 
route). However, the IN route induced significantly higher number of CD8^ T cells 
that recognised the peptide antigen and DTH response compared with other routes (6 
of 7 IN patients versus 2 of 6 ID patients versus 0 of 6 IV patients; P =0.005), 
suggesting that IN route is the preferred route for administrating DC vaccines.
1.5.3.2. T cell adoptive transfer 
In a phase I study, Rosenberg et al reported that 18 of 35 advanced metastatic 
melanoma patients treated with autologous tumour-reactive lymphocyte cultures 
experienced an objective clinical response [>50% reduction in tumour] (Rosenberg 
and Dudley, 2004). In some patients, tumour regression was accompanied by a large
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in vivo expansion of the administered anti-tumour lymphocytes that persisted in the 
peripheral blood for many months. Another study by Morgan et al circumvented the 
requirement of expanding patients’ pre-existing anti-tumour T cells ex vivo by 
culturing patients’ PBMCs with IL-2 and anti-CD3, and transduced with a retroviral 
vector containing the gene for T cell receptor (TCR) a  and p chains reactive against 
the melanoma antigen MART-1 (Morgan et aL, 2006). All 17 patients with refractory 
disease received fludarabine and cyclo-phosphamide as part of a lympho-depleting 
regimen, followed by transduced T cells and IL-2. Transduced TCRs were shown to 
persist in the DNA of PBMCs, and 2 of 17 patients had complete responses. This is 
the first published using cells transduced with specific TcR, and may lead to further 
advances in adoptive T cell therapy.
1.5.3.3. Peptide therapies
Meijer et al vaccinated stage I to III melanoma patients with the modified HLA-A2- 
binding gp-100(209-217-2M) peptide, and detected 3 types of responses amongst the 
patients (Meijer et a l ,  2007). One group of patients responded only to the modified 
peptide used for immunisation, whereas another group of patients reacted to both the 
modified and native gp-100 peptides. In the third group of patients, circulating CD8^ 
T cells recognised HLA-A2^, gp-100 expressing melanoma cell lines and also the 
modified and native gplOO peptides. High avidity, tumour-reactive T cells were 
detected in most patients. On the other hand, most patients also had low avidity T 
cells that were only capable of lysing tumour cells if  tumour cells were first pulsed 
with the native gp-100(209-217) peptides. These results indicate that vaccination with 
a modified gp-100 peptide induced a heterogeneous group o f gp-100-specific T cells 
with a spectrum of functional avidities.
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In a phase I clinical trial, 11 end-stage melanoma patients were vaccinated 
intradermally with 3 peptides: MART-126-35 peptide E27L (ELAGIGILTV), 
tyrosinase368-376 peptide N375Q (YMDGTMSQV), and gp-10 0209-2i7 peptide T210M 
(IMQVPFSV), together with tetanus toxoid and GM-CSF (Bins et aL, 2007). 
Although all patients showed a rise in anti-tetanus IgG titres, peptide-specific CD8  ^
T-cells were induced in only 3 patients. In 2 of the 3 patients, the response was 
directed against MART-126-35 and made up of 0.2% and 3.3% of the CDS^ population; 
however, in both instances these cells did not produce IFN-y on stimulation with the 
unmodified peptide. The third patient mounted a small (0.1%) response against gp- 
100. None of the 11 patients responded clinically according to response evaluation 
criteria in solid tumors criteria. These results strongly suggested that peptide 
vaccination in itself was not potent enough as an effective melanoma immunotherapy 
in advanced-stage patients, and need to be combined with other forms of therapies to 
increase its efficacy.
1.5.3.4. Other therapies 
Ipilimumab (MDX-010), a commercially available anti-CTLA-4 antibody, has been 
evaluated in several published phase 1 and phase 11 trials producing objective clinical 
responses in approximately 15% of pre-treated patients (Attia et aL, 2005; Hodi et aL, 
2003; Phan et aL, 2003; Sanderson et aL, 2005). A higher response rate (22% in 36 
patients) was observed when ipilimumab was used in combination with high dose IL- 
2 (Maker et aL, 2005). Ticilimumab, another anti-CTLA-4 antibody, is also being 
tested in a phase 1 trial and demonstrated equivalent efficacy to ipilimumab (Ribas et 
aL, 2005). Successful anti-CTLA-4 antibody therapies are frequently associated with 
side-effects such as diarrhea, colitis and autoimmune hypophysitis with symptoms
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such as extreme fatigue, headaches and memory loss (Beck et aL, 2006; Blansfield et 
aL, 2005). While autoimmune side effects are dangerous, they are associated with 
clinical response and successful activation o f the immune system by anti-CTLA-4. 
Careful monitoring of patients undergoing anti-CTLA-4 antibody treatment is 
essential.
IFN-a has been used in the treatment of melanoma for decades, although its 
application has been limited by toxicity. The immunomodulatory effects of IFN-a 
were demonstrated in 2 recent studies. In the first study, 20 patients with stage III 
melanoma were treated with high dose IFN-a for four weeks followed by 
lymphadenectomy. 55% of the patients had objective response rate (ORR), and 15% 
had a complete response. Immunohistochemical analysis also revealed T lymphocytes 
infiltrating the tumours (Moschos et aL, 2006). A second study showed that the 
relapse-free survival in 200 patients treated with adjuvant high-dose IFN-a correlated 
with the development o f auto-antibodies and clinical autoimmunity (Gogas et aL, 
2006). Together, these two studies demonstrated the promising anti-tumour activity of 
IFN-a in melanoma.
1.6. Hypochlorous acid (HOCl) as a link between innate and adaptive immunity
1.6.1. HOCl as potent oxidising microbicidal agent 
Phagocytic cells such as neutrophils and macrophages play a key role in innate 
immunity in recognising, ingesting and destroying many pathogens. Upon 
phagocytosis, phagocytes produce a variety of reactive oxygen species (ROS), such as 
nitric oxide (NO), the superoxide anion (O2’), hydrogen peroxide (H2O2) and 
hyphochlorous acid (HOCl) that are directly toxic to bacteria. NO is produced by an
64
Chapter 1: General Introduction
inducible high expression form of NO synthase (iN0S2), whilst O2 ' is generated by a 
multicomponent, membrane associated nicotinamide adenine dinucleotide phosphate 
reduced oxidase in a process known as the respiratory burst due to transient 
consumption of oxygen (Roos et aL, 2003). Then O2 is converted by the enzyme 
superoxide dismutase to H2O2 for killing microorganisms and for conversion by 
myeloperoxidase (MPO) to microbicidal HOCl (Figure 1.1).
N A D PH  
N A D P
^  O 2  
H 2 O 2
M PO -----  HOCl
Cl
Cytoplasm Intraphagosomal or
extracellular space
Figure 1.1 MPO-H202-chloride antimicrobial system (Klebanoff, 2005).
HOCl is the major end-product of neutrophil respiratory burst (Foote et aL, 1983). In 
the acidic phagosome, HOCl predominates and reacts with excess chloride to form 
molecular chlorine (CI2) (Hazen et aL, 1996b; Hazen et aL, 1996a; Henderson et aL, 
1999). Both o f them are short-lived but highly reactive oxidising agents that can 
attack microorganisms at a variety o f chemical sites (Winterboum, 2002). Numerous 
chemical groups on the organism, e.g. sulfhydryl groups, iron-sulfur centres, sulfur- 
ether groups, heme groups, unsaturated fatty acids, can be oxidised and cause the loss 
of microbial membrane transport (Albrich et aL, 1986), an interruption of the 
membrane electron transport chain (Rakita et aL, 1990), dissipation o f adenylate 
energy reserves (Barrette, Jr. et aL, 1987), and suppression of microbial DNA
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synthesis (Rosen et aL, 1990). HOCl also reacts with nitrogen-containing compounds, 
such as taurine which is present at a high concentration in neutrophil cytoplasm 
(Learn et aL, 1990; Schuller-Levis and Park, 2003), to form derivatives such as mono- 
and dichloramines that are long-lived oxidising species hence allowing the 
prolongation of the oxidant activity.
1.6.2. HOCl enhances the immunogenicity of protein antigens 
Besides showing strong microbicidal activity, HOCl has also been shown to enhance 
the immunogenicity of protein antigens by several folds via oxidation in vivo and ex 
vivo. One possible mechanism is by tagging antigens with aldehydes. During acute 
inflammation, activated neutrophils produce HOCl that quantitatively deaminates 
serine and converting it into glycolaldéhyde (Anderson et ah, 1997; Anderson et aL, 
1999; Hazen et aL, 1996b). One study showed that mice immunised with hen egg 
lysozyme (HEL) oxidised with sodium periodate (NaI0 4 ) or with neutrophil 
glycolaldéhyde, developed enhanced T cell immune responses compared to mice 
immunised with unmodified HEL (Allison and Fearon, 2000). This observation was 
correlated with the in vitro demonstration of enhanced presentation of 
glycolaldehyde-modified antigen to T cells by macrophages and bone marrow-derived 
DCs. Oxidation by HOCl may also involve aldehyde-independent mechanisms. 
Proteins oxidised by HOCl were more readily taken up and processed by APC and led 
to enhanced activation of antigen-specific T cells in vitro (Marcinkiewicz et aL, 1991; 
Marcinkiewicz et aL, 1992). One reason might be that oxidation of protein antigens 
allow protein unfolding (e.g. by the reduction of disulphide bonds in the protein) and 
therefore enhances both processing and exposure of immunogenic peptides to specific 
T cells (Carrasco-Marin et aL, 1998). The heat-shock protein (Hsp) 70 might also
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have a role in chaperoning polypeptides that unfolded during oxidative stress to help 
them regain a functional structure or by directing them to a degradation pathway 
(Feder and Hofmann, 1999). Myeloperoxidase activity therefore acts as a link 
between the innate immune response and the induction o f adaptive immunity 
(Marcinkiewicz, 1997).
1.6.3. HOCl-oxidised proteins in pathology and breaking tolerance 
ROS are involved in various physiological responses o f vascular cells, such as 
mitosis, apoptosis, migration, hypertrophy and modifications of the extracellular 
matrix. They are also implicated in several major intracellular signal transduction 
pathways leading to changes in gene transcription and protein synthesis (Droge, 2002; 
Valko et aL, 2007). However, increasing evidence showed that ROS might play a role 
in disease processes where chronic inflammation is involved. Indeed, HOCl modified 
protein epitopes are abundantly present in inflammatory diseases such as neutrophil- 
mediated liver disease (Hanumegowda et aL, 2003), glomerulosclerosis (Malle et aL, 
1997), and atherosclerosis (Hazell et aL, 1996). For atherosclerosis, numerous studies 
support the notion that protein and lipid components o f the arterial wall undergo 
oxidative damage early in atherogenesis (Stocker and Keaney, Jr., 2004). The stable 
chlorinated product of HOCl, 3-chlorotyrosine (Hazen et aL, 1997; Hazen and 
Heinecke, 1997), is found in low-density lipids (LDLs) recovered from human 
atherosclerotic aorta. Its amount is 30-fold higher than that present in the LDL 
recovered from plasma of healthy donors, and it is also increased in the proteins of 
atherosclerotic verus normal aortic intima (Hazen and Heinecke, 1997).
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The etiology of osteoartliritis (OA) is poorly understood, however it has been 
suggested that a series of inflammatory processes may be involved in initiating and 
propagating the disease (Benito et aL, 2005). MPO, HOCl and CI2 modified proteins 
(Cl-peptides) were present in the synovial fluid of 30 patients with early OA but 
absent in healthy individuals (Steinbeck et aL, 2007). This therefore suggested their 
pathological involvement in OA. HOCl has also been implicated in the development 
of rheumatoid arthritis (Hitchon and El Gabalawy, 2004). One study demonstrated 
that HOCl-oxidised cartilage antigen collagen type II induced the development of 
arthritis in rats immunised with oxidised collagen II. The immunised rats presented 
high IgG titre specific to oxidised and non-oxidised collagen II. Also, IFN-y and IL- 
1 p mRNA expressions were detected in the lymph nodes o f rats 10 days after 
immunisation (Westman et aL, 2006). In addition, ROS had been identified in the 
synovial fluid o f 90% of patients with rheumatoid arthritis (Lunec et aL, 1981). The 
ability of HOCl-oxidised antigens to break self-tolerance and induce immunity can be 
exploited in the context of tumour immunotherapy where induction of immunity to 
self antigens is often necessary.
1.7. Introduction to this Ph.D. Project
This research project has three aims. DC-based immunotherapy is a promising 
approach to cancer treatment and has been widely investigated in clinical trials. In 
order for DCs to prime a strong and durable T cell immunity against tumours, a good 
source of immunogens such as the allogeneic ovarian carcinoma cell line SK-OV-3 
that over-expressed two important ovarian TAAs (i.e. HER-2/neu and M UCl), is 
needed. Live SK-OV-3 cells are poorly immunogenic, hence the first aim was to 
determine whether oxidation with HOCl would kill, and enhance the immunogenicity
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and the uptake of these cells by DCs. Using DCs and T cells from healthy volunteers, 
an ex vivo human cell culture system was developed to study the ability of DCs pulsed 
with oxidised SK-OV-3 to prime autologous tumour-specific T cells. The breadth of 
the response was evaluated using a panel o f ovarian and melanoma antigens, and 
compared to priming with SK-OV-3 killed with non-oxidative methods (i.e. heat or 
HCl). The second aim is to explore whether T cells from ovarian cancer patients in 
remission, that are exposed to high levels of ovarian TAAs over prolonged periods in 
vivo are tolerant or primed effectively with oxidised SK-OV-3 ex vivo, and reactive 
towards autologous tumour cells from ascites. The use of activating CD40 antibody or 
MPL (both approved for use in clinical trials) for maturing patients’ DCs and 
enhancing anti-tumour T cell responses with such DCs was also investigated. The 
third aim was to test the efficacy of DC preloaded with oxidised B16 mouse 
melanoma as cancer vaccines in vivo in a melanoma C57BL/6 mouse model. Several 
parameters that could affect the overall anti-tumour response, such as the route of 
immunisation, the need to use DCs in the vaccination protocol, and vaccination with 
DCs preloaded with oxidised B16 or non-oxidised B16 (i.e. killed with heat or HCl) 
was assessed.
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Human Studies 
2.1. Media
Dulbecco's Modified Eagle's Medium (DMEM), Roswell Park Memorial Institute 
(RPMI)-164, M l99 and AIM-V media were purchased from Invitrogen, Paisley, UK. 
Complete DMEM, RPMI and M l99 media were made by supplementing with 10% 
heat-inactivated fetal calf serum (PCS), 2 mM L-glutamine, 100 lU/ml penicillin and 
100 pg/ml streptomycin (all obtained from Cancer Research UK, Lincoln Inn’s Field, 
London, except PCS which was purchased from PAA laboratories GmbH, 
Haidmannwerg, Austria). Complete AIM-V medium was made by supplementing 
with 2 mM L-glutamine, 100 lU/ml penicillin and 100 pg/ml streptomycin.
2.2. Cells
2.2.1. Tumour cell lines
2.2.1.1. SK-OV-3
The ovarian carcinoma SK-OV-3 (HLA-A3VA28^, HER-2/neu^, M UCl^) was a kind 
gift from Dr. Mike O’Hare (Ludwig Institute o f Cancer Research, London, UK) and 
were cultured in complete DMEM at 37°C, 5% CO].
2.2.1.2. SK-BR-3 and MDA-MB-231
The breast adenocarcinoma SK-BR-3 (HER-2/neu^, MUCI^) and MDA-MB-231 
(HLA-A2^, HER-2/neu^, MUCl^) cell lines were also kind gifts from Dr Mike 
O’Hare (Ludwig Institute of Cancer Research, London, UK). They were maintained 
in complete DMEM medium at 37°C, 5% CO].
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2.2.I.3. MEL-8, MEL-11 and MEL-12 
Melanoma cell lines MEL-8 (HLA-A3^/A24^; B7^/B14\ HER-2/neu, M U C l, 
M ART-T, MAGE-1+), MEL-11 (HLA-A24VA25*; B18*; Cw5 , HER-2/neu, M UCl,
MART-1^ MAGE-1^) and MEL-12 (HLA-A2VA32^; B14VB57\ HER-2/neu, 
MUCL, MART-1^, MAGE-1^) were gifts from Dr Luciene Lopes (Department of 
Immunology and Molecular Pathology, UCL, London, UK) and maintained in 
complete DMEM at 37°C, 5% CO2 (Palmer et aL, 1999).
All the cell lines above were tested regularly for Mycoplasma contamination and 
found to be negative.
2.2.2. Ovarian cancer patient ascites samples 
This study was approved by the UCL Hospitals Ethics Committee (project 03/0241). 
Samples were collected from patients or healthy volunteers after informed consent 
had been obtained. Details of the patients used in the study are shown in Table 4.1. 
Ascites samples were collected under sterile conditions from patient 23 and 26 who 
had confirmed epithelial carcinoma o f the ovary with peritoneal involvement. Tumour 
cells, collected at diagnosis and before chemotherapy, were isolated from ascites by 
density gradient centrifugation, washed twice in Hanks’ Balanced Salt Solution 
(HBSS) and plated in complete M l99 medium [both from Invitrogen, Paisley, UK]. 
The ovarian tumour cell clumps would adhere to the culture plate surface and were re­
fed with fresh media after three days o f culture. At least 10  ^ cells from each ascites 
sample were frozen in 10% dimethyl sulphoxide (DMSO) in complete M l99 on the 
day o f collection for use as targets in IFN-y ELISPOT.
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2.2.3. Dendritic cell preparation and purification 
Immature monocyte-derived DCs were prepared from 120 ml of heparinised fresh 
whole blood collected by venesection from HLA-A2^ and non-HLA-A2^ healthy 
volunteers and ovarian cancer patients after informed consent (project approved by 
UCL Hospitals Ethics Committee project 03/0241). Peripheral blood mononuclear 
cells (PBMCs) were isolated by Ficoll/Paque (Nycomed Pharma, Oslo, Norway) 
density gradient centrifugation at 400 x g for 30 min (brake off). At least 1 x 1 0 ^  
PBMCs were cryopreserved in PCS with 10% DMSO as APCs for T cells 
restimulation and ELISPOT, while the rest were resuspended in complete RPMI 1640 
to allow adhesion to tissue flask. After 2 h of incubation at 37°C, 5% CO2 , non­
adherent cells were gently removed and frozen in PCS with 10% DMSO at -80°C as a 
source o f T cells. The adherent cells were subsequently cultured in complete AIM-V 
with 100 ng/ml recombinant human GM-CSP and 50 ng/ml IL-4 [gifts from Schering- 
Plough Research Institute, Kenilworth, NJ. After 5 days o f culture, B cells, T cells, 
and natural killer cells were removed by using mAh mouse anti-human CD 19, CD3, 
and CD2, respectively, by incubating on ice for 30 min and followed by sheep anti­
mouse IgG (Dynal Biotech, Oslo, Norway) at 4 x 10  ^beads/ml for 45 min at 4°C. The 
immature DCs were >95% pure after 7 days of culture and expressed moderate levels 
of HLA-DR, HLA-ABC, and CD40, low level of CD86, and no CD83, CD14 and 
CD19.
2.2.4. T cell isolation and purification 
Cryopreserved non-adherent fraction of PBMCs was rapidly thawed, washed twice 
with HBSS and resuspended in complete AIM-V media. The cells were then 
incubated with mAh antibodies to HLA-DR, CD 19 and CD 14 to remove activated T
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cells, B cells and monocytes, respectively. In some experiments, CD4^ T cells were 
isolated by adding depleting anti-CD8 antibody (clone UCHT-4, Sigma-Aldrich, UK) 
in addition to the antibodies mentioned above. The purified whole T cell population or 
CD4^ T cells were then added to the DC-antigen on the first day of cocultures.
2.3. Synthetic Peptides
2.3.1. HER-2/neu derived peptides 
The sequences of the HLA-A* 0201-restricted peptides, E75 (KIFGSLAFL) and GP2 
(IlSAVVGIL) (Fisk et aL, 1995; Peoples et aL, 1995), were derived from the 
extracellular domain o f HER-2/neu. They were purchased from Alpha Diagnostic 
International (San Antonio, Texas, USA) with purities greater than 84% and 79%, 
respectively, as indicated by reverse-phase high-performance liquid chromatography 
(HPLC) and mass spectrometry. The MHC class II T helper peptides derived from 
HER-2/neu -  H369 (KIFGSLAFLPESFDGDPA) and H776 (GVGSPYVSRLLGICL) 
(Disis et aL, 2002; Sotiriadou et aL, 2001) -  were synthesised by Cancer Research 
UK Protein and Peptide Chemistry laboratory (Lincoln’s Inn Fields, London). The 
H369 peptide was derived from the extracellular domain of HER-2/neu and contained 
a CTL epitope. It was presented by HLA-DR4, DR5, DR51, DR53, DQ6, and DQ7. 
The H776 peptide was derived from the intracellular domain of HLR-2/neu and was 
presented by HLA-DR51, DR7 and DR4. Both peptides were >79% pure as 
determined by HPLC and mass spectrometry.
2.3.2 MUCl derived peptides 
Sequences o f MUCl derived HLA-A*0201-restricted peptides, M l.l (STAPPVHNV) 
and M l.2 (LLLLTVLTV) (Brossart et aL, 2000; Brossart et aL, 2001), were
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purchased from Alpha Diagnostic International. The M l.l peptide was derived from 
the extracellular domain of tumour MUCl which consisted mostly of 20 to 60 tandem 
repeats (abbreviated VTNR: variable number of tandem repeats region), while M l.2 
was derived from the signal sequence of tumour MUCl. The purities were >79% as 
evaluated by reverse-phase HPLC and mass spectrometry.
2.3.3. M ART-1 derived peptides 
The sequence o f the HLA-A* 0201-restricted peptide MART-1 (EAAGIGILTV) 
(Romero et a l ,  1997) was derived from melanoma, and was purchased from Alpha 
Diagnostic International and with a purity of >79% by reverse-phase HPLC and mass 
spectrometry.
All the lyophilised peptides were dissolved in at least 50% DMSO plus HBSS to a 
stock concentration o f 1 mM, filter-sterilised with 0.2 pm filter and stored at -80°C 
until they were required.
2.4. Antibodies for Dendritic Cell Phenotyping
The following unconjugated mAbs were used; (a) CD la  (supernatant mouse mAb 
NAl/34, IgG2a) was a gift from Professor A. McMichael (John Radcliffe Hospital, 
Oxford, UK); (b) CD2 (mouse mAb RPA-2.10, IgGl; eBiosecience, San Diego, CA); 
(c) CD3 (supernatant mouse mAb UCH T l, IgGl); (d) CD 14 (supernatant mouse 
mAb HB246, IgG2b); and (e) HLA-DR (supernatant mouse mAb L243, IgG2a) were 
all gifts from Professor P.C.L. Beverley (The Edward Jenner Institute for Vaccine 
Research, Berkshire, UK); (f) CD 19 (supernatant mouse mAh BU I2, IgGl); and (g) 
CD86 (supernatant mouse mAh BU63, IgG l) were gifts from D. Hardie (Birmingham
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Medical School, Birmingham, UK); (h) CD40 (mouse mAb 5C3, IgGl; eBioscience, 
San Diego, CA); (i) CD83 (mouse mAb HB15e, IgGl; eBioscience, San Diego, CA); 
(j) HLA-ABC (mouse mAb W6/32 IgG2a; SeroTec, Kidlington, Oxford, UK); and (k) 
lgG2a isotype control (Dako A/S). The secondary antibody for flow cytometry was 
rabbit anti-mouse FITC-conjugated (Dako Cytomation, Denmark) at a 1:20 dilution of 
a 0.3 mg/ml stock to give a final concentration of 15 pg antibody/10  ^cells/ 100 pi.
The following PE-conjugated mAbs were used: (h) CD83 (Clone HBlSe, mouse 
IgG l; R&D Systems, UK); (i) CD40 (Clone 82111, mouse IgG2b; R&D Systems, 
UK); (j) CD86 (Clone 37301, mouse IgGl; R&D Systems, UK); (k) PE-conjugated 
mouse anti-HLA-DR (eBioscience, San Diego, CA); (1) CD3 (Clone UCHTl, mouse 
IgG 1 ; R&D Systems, UK) as an isotype control for DC phenotyping.
2.5. Western Blot Analysis of HER-2/neu and MUCl Expression
1 x 1 0 ^  SK-OV-3 ovarian tumour cells or 1 x 10  ^ tumour cells from ovarian cancer 
patients’ ascites were washed twice with HBSS and lysed in 20 pi of reducing sample 
buffer (2% sodium dodecyl sulfate [SDS; Sigma], 10% glycerol [BDH, UK], 2% (3- 
mercaptoethanol [Sigma], 60 mM Tris-HCl [pH 6.8; Calbiochem, San Diego, CA, 
USA], and bromophenol blue [Sigma]). The cell lysate was sonicated for 30 sec and 
boiled for 8 min. It was resolved on a 7.5% SDS-polyacrylamide gel electrophoresis 
electrophoresis at lOOV in running buffer (14.4% glycine and 3% Tris-base [both 
from Sigma] in dH20) for 1.5 h at room temperature (RT), and transferred to Hybond- 
ECL nitrocellulose membrane (Amersham Biosciences, UK) at 30V at 4°C overnight. 
After protein transfer, the membrane was incubated for 1 h at RT with blocking buffer 
(5% skimmed milk powder [Tesco, UK] in Tris buffered saline [TBS] plus 0.1%
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Tween 20 [BDH, UK]). It was then washed 4 times (5 min each with shaking) with 
washing buffer (TBS with 0.1% Tween 20), and incubated with relevant primary 
antibody solution (primary antibody in TBS containing 0.1% skimmed milk powder 
and 0.1% Tween 20) at 4°C overnight. HER-2/neu was detected by anti-HER-2/neu 
mAb (Santa Cruz Biotechnology) at a 1:100 dilution, and MUCl was detected by 
HMFG2 anti-MUCl mAb (A gift from Dr Joyce Taylor-Papadimitriou from Cancer- 
Research UK, GKT School of Medicine, London) at 1:10 dilution. The following day, 
the membrane was washed 4 times with washing buffer and incubated with 
horseradish peroxidase (HRP) conjugated swine anti-rabbit IgG [Dako] at 1:3000 
dilution for 1 h at RT. Then membrane was washed 4 times with washing buffer, and 
immunodetection of the proteins was carried out by using the ECL reagent according 
to the manufacturer’s guidelines (Amersham Pharmacia Biotech). For positive 
control, SK-BR-3 breast tumour cell line that highly expressed HER-2/neu and MUCl 
was used. MEL-8 and MEL-11 cell lines that expressed none of the proteins were 
processed as described above and used as negative controls.
2.6. Immunohistochemistry of HER-2/neu and MUCl Expression in Primary 
Ovarian Tumours
HER-2/neu immunostaining was carried out using the Dako Hercep Test Kit 
(Carpinteria, CA, USA). Paraffin sections were dewaxed, rehydrated and heated in 
Epitope Retrieval Solution in a water bath at 98°C for 40 min. After washing, primary 
polyclonal antibody was applied for 30 minutes. The staining was visualized using 
peroxidase coupled secondary antibodies and di-aminobenzidine. Sections were 
rinsed and counterstained with haematoxylin, before mounting. Controls included 
three breast cancer cell lines scoring 3+, 2+, 1+ and 0, and a positive and negative
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tissue control section. Slides were scored based on the staining pattern. 0: No staining 
at all, or very slight partial membrane staining in less than 10% of tumour cells. 1+: 
Faint barely perceptible membrane staining in more than 10% of tumour cells or the 
cells are stained in only part of their membrane. 2+: Weak to moderate complete 
membrane staining in more than 10% of tumour cells. 3+: Strong complete membrane 
staining in more than 10% of tumour cells. For MUCl immunostaining, paraffin 
sections were dewaxed, rehydrated and heated in retrieval solution (ERI) for 20 min at 
100°C. Monoclonal MUCl antibody (HMFG2) was used at a dilution of 1:10, for 20 
min. Staining was visualized as above. Immunostaining was assessed on the basis of 
intensity of staining (1+ to 3+) and distribution (membrane and cytoplasmic).
2.7. Methods for Inducing Tumour Cell Death
2.7.1. Oxidative-killing with hypochlorous acid
Different concentrations of hypochlorous acid (HOCl) solutions [5 to 60 pM] were 
prepared by diluting the stock sodium hypochlorite (NaOCl) reagent [Sigma-Aldrich] 
with HBSS and added immediately to the SK-OV-3 cells to give a final cell density of 
8 X lOVml. The tumour cell suspensions were then incubated for 1 h at 37°C, 5% C0] 
with gentle agitation every 30 min to induce oxidation-dependent tumour cell death. 
After that, tumour cells were harvested and washed twice with HBSS for further use.
2.7.2. Killing by hydrochloric acid
To induce tumour cell necrosis, 1 M hydrochloric acid (HCl) solution was prepared 
by diluting the 10 M stock HCl (Sigma-Aldrich) in isotonic sodium chloride and 
added to SK-OV-3 cells to give a final cell density of 8 x 10^/ml. The cell suspension 
was incubated for 1 min at RT and immediately neutralised with 1 M sodium
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hydroxide (NaOH, Sigma-Aldrich). The tumour cells were washed twice with HBSS 
before adding to the DCs,
2.7.3. Killing by heat 
To induce tumour cell death, SK-OV-3 cells were resuspended in complete AIM-V 
medium to a final cell density of 8 x 10^/ml, and heated at 56°C for 30 min. Then the 
tumour cells were harvested and washed twice with HBSS before use.
2.8. Measuring Cell Death with Propidium Iodide Staining
Propidium iodide (PI) staining was used on ethanol permeabilised SK-OV-3 cells 
after HOCl-treatment to measure DNA content and to differentiate between apoptosis 
and necrosis. 1 x 10  ^ tumour cells (pretreated with O-lOOpM HOCl as outlined in 
section 2.7.1) were resuspended in 1 ml of HBSS, and an equal volume o f 70% ice- 
cold ethanol was added drop wise to the cells (to a final concentration of 35% ethanol) 
and left on ice for 10 min to allow permeabilisation. Then, cells were washed twice 
with HBSS, resuspended in 250 pi of HBSS and treated with RNase (Sigma-Aldrich) 
[lOng/ml final concentration] and PI (Sigma-Aldrich) [1 mg/ml final concentration] 
for 30 min at 37°C, 5%C02. After that, they were harvested and analysed by flow 
cytometry. Apoptosis could be detected by the appearance of a sub-Go peak, 
representing partially degraded DNA. This method that measures DNA cell content 
directly has previously been validated by comparison to annexin V/ PI staining (Rad 
et ah, 2003d). It was chosen in preference because oxidation might damage the 
annexin V binding epitope on the cell surface and hence lead to false negatives. To 
quantify the percentage of dead SK-OV-3 tumour cells after HOCl-treatment, 1x10^ 
tumour cells were collected in 250 pi of HBSS and treated with RNase and PI as
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described above, and analysed by flow cytometry. Dead SK-OV-3 cells were positive 
for PI staining while live cells, being able to exclude the PI dye, were negative.
2.9. Uptake of Tumour Cells by Dendritic Cells
To determine SK-OV-3 tumour cells uptake by DCs, tumour cells were labeled with 
3’ tetra-methyl-indocarbocyanine perchlorate (Dil, Sigma-Aldrich; final concentration 
5 pM) in complete RPMI 1640 medium for 30 min at 37°C, 5%C02 before HOCl- 
oxidation (Dil staining o f tumour cells was less efficient after HOCl treatment). After 
labeling and oxidation, tumour cells were collected and washed twice with HBSS 
before adding to the DCs at 1:1 ratio. To detect double positive DCs that had 
phagocytosed tumour cells, the co-cultures were incubated at 37°C, 5%C02 for 4 or 
24 h. They were collected, blocked with staining buffer on ice for 10 min. Then cells 
were washed twice with staining buffer (HBSS, 10% filtered rabbit serum, 0.1% 
sodium azide) and incubated with mouse anti-HLA-DR for staining of DCs (30 min 
on iee). Cells were again washed twice to remove excess antibodies and ineubated 
with FITC conjugated rabbit anti-mouse IgG for 30 min on ice. Parallel co-cultures 
were set up at 4°C for 24 h to determine the level of non-specific Dil transfer to DCs. 
Flow cytometry analysis was performed on the same day.
2.10. Activation of Dendritic Cell
2.10.1. Activation with oxidisied SK-OV-3 
To investigate whether oxidised tumour cells were capable of inducing DC 
maturation, SK-OV-3 cells were treated with HOCl as described in Section 2.6.1., and 
cocultured with DCs at 1:1 ratio for 24 h at 37°C, 5%C02. After incubation, the DC- 
tumour cocultures were harvested and phenotyped as described in section 2.11.2.
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2.10.2. Activation with CD40 agonistic antibody and monophoshoryl lipid A 
DC maturation was induced using either CD40 agonistic antibodies (mouse IgGl, 
clone mAb89, Immunotech, Marseille, France), or a lipopolysaccharide A (Kisseleva 
et al., 2006a) analogue monophosphoryl lipid A (MPL: detoxified lipid A derived 
from Salmonella) [Avanti Polar Lipids, Inc., Alabaster, AL], chosen as both reagents 
have previously been approved for use in clinical trial (French et al., 2007b; Neidhart 
et al., 2004b; Tuttle et al., 1998; van Mierlo et al., 2002; Vantomme et al., 2007). DCs 
were cocultured with HOCl-oxidised SK-OV-3 to determine the optimal 
concentration of stimulus as described below, and then treated with increasing 
concentration of CD40 antibody (100 to 1000 ng/ml) or MPL (50 to 200 ng/ml) for 24 
h at 37°C/ 5%C02 complete AIM-V. As a negative control, DCs were cultured in 
complete AIM-V. For positive control, DCs were treated with LPS (100 ng/ml) 
[Sigma-Aldrich] for 24 h. After activation, DCs were phenotyped as described in 
section 2.11.3.
2.11. Phenotypic Analysis
2.11.1. HLA-A2 typing of peripheral blood mononuclear cells 
PBMCs were isolated from the whole blood o f healthy volunteers and ovarian cancer 
patients were incubated on ice for 30 min with mAh to the HLA-A2 antigen (clone 
BB7.2, mouse Ig02b; Abeam PL, Cambridge, UK). The cells were then washed 2 
times with cold staining buffer (HBSS, 10% filtered rabbit serum, 0.1% sodium azide) 
and incubated with FITC-conjugated rabbit anti-mouse IgG for a further 30 min on 
ice. After that, the cells were washed three times with staining buffer, fixed in 3.8% 
formaldehyde (Fluka) and collected the same day on a FACScan flow cytometer 
(Becton Dickinson). The data was analysed using the CellQuest software.
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2.11.2. Phenotyping dendritic cells after exposure to oxidised SK-OV-3
To investigate whether HOCl-oxidised tumour cells were capable of inducing DC 
maturation, SK-OV-3 cells were treated with HOCl as described in Section 2.6.1., and 
cocultured with DCs at 1:1 ratio for 24 h at 37°C, 5%C02. After incubation, the DC- 
tumour co-cultures were harvested and resuspended in cold staining buffer for 15 min 
incubation on ice. Relevant unconjugated mAbs for DC maturation markers (i.e. 
CD83, CD86, CD40 and DR) were added and left on ice for further 30 min. Then two 
washes were done, and the cells incubated with FITC-conjugated rabbit anti-mouse 
IgG for 30 min on ice. After that, cells were washed twice with staining buffer and 
blocked with 1% normal mouse serum in HBSS (10 min on ice). PE-conjugated 
mouse anti-HLA-DR was added to double-stain DCs and left on ice for further 30 
min. After that, the cells were washed three times, fixed in 3.8% formaldehyde and 
collected the same day on a FACScan flow cytometer.
2.11.3. Phenotyping dendritic cells after exposure to maturation stimuli 
After treatment with CD40 agonistic antibodies or MPL, DCs were harvested and 
resuspended in cold staining buffer blocked for 15 min on ice, washed, and then 
incubated with PE-conjugated HLA-DR, CD83, CD86 and CD40 antibodies for a 
further 30 min on ice. The cells were washed three times in cold HBSS, fixed in 3.8% 
formaldehyde and collected the same day on a FACScan flow cytometer.
2.12. Ex Vivo Priming of Naïve T cells with Dendritic Cells Loaded with Antigens
2.12.1. Priming T cells with immature dendritic cells 
A total of 2 X 10  ^ autologous DCs were pulsed with 2 x 10  ^ 60 pM HOCl-oxidised 
SK-OV-3 cells overnight to allow uptake. In some experiments, 2 x 10  ^60 pM HOCl-
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oxidised MEL-11 cells were used. 60 (J.M HOCl was chosen for tumour cell oxidation 
because it consistently induced >99% of necrotic SK-OV-3 tumour cell death (as 
determined by PI staining) and most efficiently upregulated CD40, CD83, and CD86 
maturation markers on DCs. In some experiments, DCs were pulsed with either HCl- 
killed or heat-killed SK-OV-3, or the DCs were pulsed with HER-2/neu (E75) or 
MUCl peptides (final concentration of 1 pM). After 24 h of incubation at 37°C, 
5%C02, a total of 2 x 10  ^ purified autologous T cells were added to the DC-antigen 
coculture and cultured in complete AIM-V medium. After 7 days, viable T cells were 
purified of necrotic debris by separation on Ficoll Lymphoprep and restimulated with 
x-ray irradiated autologous PBMCs (20 Grays) pulsed with relevant oxidised, or 
killed tumour cells, or peptides in AIM-V medium. Then T cells were re-purified by 
Ficoll Lymphoprep 4 days after restimulation and cultured in fresh AIM-V media 
without antigen for further 3 days. After that, viable T cells were harvested for IFN-y 
ELISPOT or restimulated for another week with relevant antigens (i.e. HER-2/neu 
peptide [E75], MUCl peptide [M1.2]) or media for pentamer staining.
2.12.2. Priming T cells with activated dendritic cells 
2 x 1 0 ^  autologous DCs were pulsed with 2 x 10  ^ 60 pM HOCl-oxidised SK-OV-3 
cells or MEL-11 tumour cells for 4 hours to allow uptake. After that, activating anti- 
CD40 antibody (final concentration of 500ng/ml) or MPL (final concentration of 
1 OOng/ml) was added to induce DC maturation. After 24 h, 2 x 10  ^ purified 
autologous T cells (whole T cells or CD4^ T cells) were added to the DC-antigen 
coculture and cultured in complete AIM-V medium. After 7 days, viable T cells were 
purified by separation on Ficoll Lymphoprep and restimulated with x-ray irradiated 
autologous PBMCs (20 Grays) pulsed with relevant oxidised tumour cells in AIM-V
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medium. Four days after restimulation, T cells were purified of necrotic debris with 
Ficoll Lymphoprep and cultured in fresh medium with no antigen for 3 more days. 
Then viable T cells were either harvested for IFN-y ELISPOT.
2.13. Ex Vivo Evaluation of Tumour-Specific T cell Responses
2.13.1. IFN-y enzyme-linked immunospot (ELISPOT) assay 
IFN-y ELISPOT was performed according to the manufacturer’s recommendations. 
The MultiScreen™-Immobilon™ -P Filtration Plate (Millipore, Bedford, USA) were 
coated with anti-human IFN-y capture antibody (1-DIK clone; Mabtech) at 2pg/ml in 
HBSS (lOOpl/well) overnight at 4°C. Under aseptic conditions, the plates were 
washed 3 times with HBSS and blocked with AIM-V medium containing 10% human 
AB serum for 1 h at 37°C, 5%C02. Then 2 washes with HBSS were done and the T 
responder cells were seeded in the wells at 1 x 10  ^ cells/well. Cryopreserved 
autologous PBMCs were rapidly thawed, washed, irradiated (20 Grays) and co­
cultured at 5 X 10"* cells/well with the T responder cells in the presence of relevant 
antigens (i.e. graded dose of SK-OV-3 cells or MEL-11 cells oxidised with 60 pM 
HOCl per well, HER-2/neu, M UCl, or MART-1 peptides all used at a final 
concentration of 1 pM per well). To check for specificity, T responder cells in certain 
wells were incubated with PBMCs without antigen or in AIM-V medium only to 
determine the background secretion of IFN-y. The ELISPOT plate was incubated for 
40 h at 37°C, 5%C02- After incubation, the cells were removed by washing with 
MilliQ water and PBS, and the presence of IFN-y produced by Ag-specific T cells 
was detected by the sequential addition of biotinylated mouse anti-human IFN-y (2 h 
at RT) and followed by 4 washes with PBS (Cancer Research UK, Lincoln Inn’s
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Field, London), and alkaline phosphatase-conjugated streptavidin (1 h at RT) and 
followed by 4 washes with PBS. The number of spots corresponding to the IFN-y 
producing cells was counted with an automatic plate reader (Autoimmun Diagnostica 
GmbH, Strassberg, Germany). Results were expressed as IFN-y spots per 10  ^T cells.
2.13.2. HER-2/neu pentamer staining 
T cells were stimulated with DCs preloaded with 60 pM HOCl-oxidised SK-OV-3 
cells (1 tumour cell to 1 DC) as described in Section 2.12.1. Viable T cells were 
harvested and re-stimulated for a 3"^  ^week with relevant antigens (i.e. 1 pM of HER- 
2/neu peptide [E75] or MUCl peptide [M l.2], or with media) and lL-2 (5 ng/ml). At 
the end of 3^  ^week viable T cells were obtained by Ficoll Lymphoprep, and 5 x 10  ^T 
cells per group were washed once with staining buffer (PBS with 1% filtered FCS and 
0.1% sodium azide) and stained with PE-conjugated HLA-A*0201-resticted HER- 
2/neu pentamer specific for KIFGSLAFL (abbreviated p-HER-2/neu 309-377)  
[Prolmmune, Oxford, UK] for 20 min at 37°C. Cells were then counterstained with 
CD8-F1TC (Clone LT8; Prolmmune, Oxford, UK) for 30 min on ice. After washing 
twice with PBS containing 0.1% sodium azide, the cells were fixed with 3.8% 
formaldehyde and analysed by flow cytometry by appropriately gating on CD8^ cells 
and excluding CD4^ cells. T cells that were double positive for CD8 and HER-2/neu 
pentamer were expressed as a percentage of the total number of CD8^ T cells gated.
Animal Studies
2.14. Mice
6-8 weeks old male C57BL/6 mice (H-2^ haplotype) were obtained from Charles 
River U.K. The mice were maintained in the Biological Service Unit in Windeyer
85
Chapter 2: Materials and Methods
Institute of Medical Sciences, UCL. All the experiments were carried out under U.K. 
ethical guidelines.
2.15. Cells
2.15.1. Melanoma B 16.F 10
The mouse melanoma B16, subline F 10, which overexpressed the tyrosinase-related 
protein 2 (TRP-2) was syngenic to C57BL/6 mice (Bloom et al., 1997). It was a kind 
gift from Dr. Jonathan Silk (Tumour Immunology Unit, Weatherall Institute of 
Molecular Medicine, John Radcliffe Hospital, Oxford, U.K.) and was cultured in 
complete RPMI medium at 37°C, 5% 00%.
2.15.2. Chinese hamster ovary (CHO) cells
The CHO cells were kind gifts of Dr. Yves Delneste (Centre d'lmmunologie Pierre 
Fabre, France) and maintained in complete DMEM at 37°C, 5% CO].
2.15.3. Mouse bone marrow-derived dendritic cell preparation
After removing the muscle tissues from the femurs and tibias, the ends of the bones 
were disinfected with 70% ethanol for few seconds and rinsed twice with HBSS. One 
end of the bone was cut with scissor in a dish, and the bone marrow was removed 
using 200 pi o f complete Iscove’s modified DMEM (IMDM) [i.e. supplemented with 
10% heat-inactivated FCS, 2 mM L-glutamine, 100 lU/ml penicillin, 100 pg/ml 
streptomycin, and 50 pM  p-mercaptoethanol] with a 1 ml syringe and 25 gauge 
needle. The cells were washed twice with HBSS and plated in a 6-well pate at a cell 
density of 5 x lOVml in complete IMDM containing 20 ng/ml recombinant mouse 
granulocyte/ macrophage-colony stimulating factor (rGM-CSF). On day 4 of culture.
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half of the media was in each well was gently removed and replenished with fresh 
complete IMDM containing mouse rGM-CSF. The immature DCs were >70% pure 
after 6 days of culture and were identified by high levels of CD 11c and MHC Class 11.
2.15.4. Preparation of mouse spleen cells 
Fresh spleens were obtained from naïve mice (i.e. untreated mice) or mice previously 
vaccinated with DCs preloaded with oxidised B16 or media, or HBSS alone (i.e. no 
DCs). The spleen was rinsed with HBSS and cut into small pieces. They were gently 
mashed with a sterile 2 ml syringe plunger in a 40 pm cell strainer (BD Falcon, 
Bedford, MA, USA) containing 2 ml of complete RPMI to obtain single cell 
suspension. Then the cells were washed once with HBSS and incubated with Red 
Blood Cell Lysing Buffer Hybri-Max™ (Sigma) for 5 min at RT. Following that, 
cells were washed twice with HBSS before use.
2.16. Tyrosinase-Related Protein 2 Synthetic Peptides
The MHC Class 1 H-2K*’ restricted peptides derived from tyrosinase-related protein 
(TRP)-2 (SVYDFFVWL) (Bloom et a/., 1997) were synthesised by Cancer Research 
UK’s Protein and Peptide Chemistry laboratory (Lincoln’s Inn Fields, London) and 
were > 79% pure as indicated by reverse-phase HPLC and mass spectrometry.
2.17. Western Blot Analysis of Tyrosinase-Related Protein 2 Expression
The procedures for western blotting were exactly the same as described in Section 2.5 
except with minor modifications. 1x10^ B16.F10 tumour cells were lysed in 20 pi of 
sample buffer, sonicated for 30 sec and boiled for 5 min. It was resolved on a 12.5% 
SDS-PAGE electrophoresis and transferred to Hybond-ECL nitrocellulose membrane
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at 30V at 4°C overnight. The membrane was blocked overnight at 4°C and washed 4 
times the following day. It was then incubated with anti-PEP8 (a kind gift from 
Professor Vincent J. Hearing of National Institutes of Health, Bethesda; a rabbit 
polyclonal antibody against the synthetic peptide PEP8 and recognised specifically 
TRP-2 in melanocytes (Tsukamoto et a l, 1992)) at 1:1000 dilution for 1 h at RT with 
shaking. After that, incubation with HRP conjugated swine anti-rabbit IgG [Dako] at 
1:3000 dilution for 1 h at RT was done, and TRP-2 was detected by following the 
Amersham Biosciences enhanced chemiluminescence protocol. CHO cell line that 
had no TRP-2 expression were processed as described above and used as negative 
controls.
2.18. Activation of Mouse Bone Marrow-Derived Dendritic Cells
To determine the optimal concentrations for DC activation, day 6 mouse DCs were 
treated with recombinant mouse IFN-y (100 lU/ml; Peprotech, U.K) and different 
concentrations o f LPS (100 or lOOOng/ml; Sigma-Aldrich) or MPL (100 ng/ml, 1 or 
10 pg/ml) for 24 h at 37°C, 5% CO2 . For negative control, DCs were treated with 
media only.
2.19. Phenotypic Analysis of Dendritic Cells
After treatment with CD40 agonistic antibodies, MPL or LPS, DCs were harvested 
and resuspended in cold staining buffer (HBSS, 10% rat serum, 0.1% sodium azide) 
and blocked for 15 min on ice. Then the cells were washed and incubated on ice for 
30 min with FITC-conjugated CD80 (Clone 16-lOAl, Armenian hamster Ig02), 
CD54 [Clone 3E2, Armenian hamster IgGl], CD86 (Clone GLl, rat IgG2a) or MHC 
Class II (I-A/I-E) [Clone M5/114.15.2, rat IgG2b] and double-stained with PE-
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conjugated CDl l c  (Clone N418, Armenian hamster IgGl). All the antibodies were 
purchased from BD Biosciences, Pharmingen, San Diego, CA. After that, the cells 
were washed three times in cold HBSS containing 0.1% sodium azide, fixed in 3.8% 
formaldehyde and collected the same day on a FACScan flow cytometer.
2.20. Ex Vivo Loading of Dendritic Cells
Day 6 bone marrow-derived DCs were pulsed with 60 pM HOCl-oxidised B16.F10 at 
the ratio of 1:1 or with complete IMDM media for 24 h at 37°C, 5%C02. Then the 
cocultures were harvested, washed twice and resuspended in HBSS for vaccination.
2.21. Vaccination Protocols
For the intravenous route of administration, each C57BL/6 mouse was injected using 
a BD Micro-Fine U-100 sterile 1 ml insulin syringe (Becton Drive, NJ, USA) in the 
tail vein with 50 pi o f HBSS containing DC/ tumour coculture (i.e. 1x10^ DCs plus 1 
X 10  ^ oxidisd B16). For the intraperitoneal route, each mouse was injected in the 
peritoneum with 100 pi of HBSS containing DC/tumour coculture. For the 
subcutaneous route, each mouse was injected subcutaneously on the left flank with 
100 pi of HBSS containing DC/tumour coculture. After 2 weeks of vaccination via 
the different routes, the mice were sacrificed and the spleen cells isolated for 
evaluation in the IFN-y ELISPOT.
2.22. Mouse IFN-y ELISpot
IFN-y ELISPOT was performed according to the manufacturer’s recommendations 
and performed as described in section 2.13.1. with minor modifications. The 
MultiScreen™-Immobilon™-P Filtration Plate (Millipore, Bedford, USA) were
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coated with anti-mouse IFN-y capture antibody (BD Biosciences Pharmingen, San 
Diego, CA) at 10 pg/ml in HBSS overnight at 4°C, and blocked with RPMI medium 
containing 5% FCS for 1 h at 37°C, 5%C02 the following day. Then 2 washes with 
HBSS were done and the responder cells (i.e. splenocytes from treated mice) were 
seeded in the wells at 1 x 10  ^ cells/well. Fresh spleen cells (with red cells removed) 
obtained from naïve mouse were used as APCs and were cocultured with the 
responder cells in the presence of relevant antigens (i.e. 1 x 10  ^ B16 oxidised with 60 
pM HOCl per well or final of 1 pM TRP-2 peptides per well). To check for 
specificity, responder cells in certain wells were incubated with naïve splenocytes in 
the absence of antigen to determine the background secretion of IFN-y. The ELISPOT 
plate was incubated for 20 h at 37°C, 5%C0i. IFN-y production by Ag-specific 
splenocytes was detected with biotin rat anti-mouse IFN-y (BD Biosciences 
Pharmingen, San Diego, CA) [at 1 pg/ml] and counted as described in section 2.13.1.
2.23. Statistical Analysis
Means for different experimental groups were analysed from a minimum of three 
independent experiments (i.e. cells from at least three different subjects). The analysis 
of significance was carried out using Mann-Whitney, 1-way Anova, with Dunnetfs 
post-hoc modification or paired Student /-test as detailed below.
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3.1. Introduction
Ovarian cancer commonly relapses after remission and new strategies to target 
microscopic residual diseases are required. One promising approach is to activate 
tumour-specific CTLs with DCs loaded with tumour cells. Immunisation with whole 
ovarian tumour cells that express both characterised and uncharacterised TA As may 
elicit a stronger overall CD4^ and CD8^ immune response, and will diminish the 
chance of driving the emergence of escape mutations in the tumour cells. As live 
ovarian tumour cells are poorly immunogenic, a strategy to kill the tumour cells and 
at the same time enhance their immunogenicity is required. HOCl, a potent oxidant 
which has been shown to enhance the immunogenicity o f protein antigens, is used. 
Hence, this study tests the hypothesis that allogeneic ovarian tumour cells, SK-OV-3, 
oxidised by HOCl would become potent immunogens that are efficiently taken up and 
cross-presented by DCs to stimulate autologous tumour-specific T cell responses.
3.2. Objectives
• To characterise and evaluate the suitability of allogeneic ovarian tumour cells, 
SK-OV-3, as a source of immunogens for DC-based immunotherapy of ovarian 
carcinoma.
• To develop an ex vivo human cell culture model for priming tumour-specific T 
cells with autologous DCs pulsed with HOCl-oxidised SK-OV-3 tumour cells, and 
evaluation using IFN-y ELISpot assay and pentamer staining.
• To compare the immunogenicity of HOCl-oxidised SK-OV-3 cells to SK-OV-3 
cells killed by non-oxidative methods (i.e. heat-killed and acid-killed).
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3.3. Results
3.3.1. SK-OV-3 cells express HER-2/neu and MUCl antigens
The SK-OV-3 line has been widely studied by both molecular and immunological 
techniques and was therefore chosen as a model source of antigen for these studies. 
The expression of the two epithelial tumour-associated antigens MUCl and HER- 
2/neu was confirmed by immunoblotting (Fig. 3.1 A, B). HER-2/neu (molecular 
weight approximately 185 kDa) was detected as a single band in SK-OV-3 and the 
breast cancer derived line SK-BR-3. MUCl glycoproteins were detected as multiple 
glycosylated variants o f approximately 250 kDa in both epithelial lines. Both antigens 
were absent from the melanoma tumour line MEL-11. SK-OV-3 has previously been 
shown to express HLA-A3 (zum Buschenfelde et al., 2002); the absence of HLA-A2 
was confirmed by flow cytometry (not shown).
3.3.2. HOCl induces cell death of SK-OV-3 cells via necrosis
The sensitivity o f SK-OV-3 cells to HOCl oxidation is shown in Fig. 3.2. Cell 
survival and cellular DNA content were measured by PI staining of intact and 
permeabilised cells as described in Materials and Methods. Treatment of SK-OV-3 
cells with increasing concentrations o f HOCl resulted in a dose dependent increase in 
the % of unpermeabilised cells which took up PI (gate M l, Fig. 3.2A left column, 
quantified in Fig. 3.2B). Since viable cells are impermeable to PI, the % PI positive 
cells gave a measure o f dead cells. 99% cell death or above was consistently observed 
at 60 pM HOCl or above, and this concentration was used in all further experiments. 
Extensive cell fragmentation was observed with 65 pM HOCl or higher (data not 
shown). Annexin V/PI staining did not show the presence of apoptotic cells in the 
HOCl-treated population (not shown). Lack of annexin V staining could have resulted
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from oxidative damage to the annexin V binding epitope, however. The DNA content 
of the cells was therefore measured directly (Panel A, right column). PI staining 
clearly showed the presence of the Gi and G2 peaks, but no sub-Go staining 
corresponding to fragmented DNA from cells undergoing apoptosis [c.f. effects of 
DNA cross-linking agents on tumour cells, which induce apoptosis and the 
appearance of a clear sub-Go peak (Rad et al., 2003)].
3.3.3. Activation of dendritic cells on exposure to oxidised SK-OV-3 cells 
Previous studies from our own (Rad et al., 2003) and other laboratories (Chen et al., 
2001; Sauter et al., 2000; Slingluff, Jr. et al., 2003) have suggested that necrotic cells 
may activate DC. DCs were therefore cocultured with HOCl-oxidised tumour cells (or 
LPS as a known DC activator) and the levels o f cell surface CD86, CD83, and CD40 
measured by flow cytometry (Table 3.1). Untreated cells had low levels o f CD86, no 
CD83 expression, and intermediate levels o f CD40. Increasing HOCl concentration 
significantly increased mean fluorescent intensity (MFI) for CD86 and CD40 
(P<0.05, one-way ANOVA). There was also a small but not statistically significant 
(P>0.05) increase in the expression o f CD83. However, the MFI at all concentrations 
of HOCl was significantly less than that induced in response to LPS (P<0.01, 
ANOVA with Dunnett’s modification).
3.3.4. HOCl treatment enhances uptake of SK-OV-3 by dendritic cells 
Uptake of tumour cells is a critical step in the pathway leading to both class I and 
class II MHC cross-priming. The ability of DC to phagocytose tumour cells was 
evaluated by flow cytometry, using a method developed previously (Rad et al., 2003) 
[Fig. 3.3]. Tumour cells were identified by staining with the membrane dye Dil (FL2,
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Figure 3.1 Expression of HER-2/neu and MUCl tumour antigens on SK-OV-3 cells. 
A and B) 1 X 10  ^ SK-OV-3, SK-BR-3, and MEL-11 cells were lysed in sample 
buffer, resolved on 7.5% SDS-PAGE electrophoresis, and transferred to nitrocellulose 
membranes. The expressions of HER-2/neu and MUCl were detected by anti-HER- 
2/neu and anti-MUCl monoclonal antibodies. Note that HER-2/neu appeared as a 
single band in both SK-OV-3 and SK-BR-3, while MUCl glycoproteins were 
detected as multiple glycosylated variants of approximately 250 kDa in both epithelial 
lines. Data shown are representative of three independent experiments.
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Figure 3.2 Dose dependent necrosis of SK-OV-3 cells treated with HOCl. A and B) 
SK-OV-3 tumour cells were incubated with different concentrations o f HOCl as 
shown for 1 h at 37°C. Cells were washed and stained with PI as described in 
Materials and methods either without (non-perm, A left column) or after 
permeabilisation with 70% ethanol (perm, A right column). The percentage of highly 
PI positive cells (M l gate) corresponded to percentage of dead cells was plotted 
against HOCl concentration in B. Data are representative o f 5 independent 
experiments.
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Table 3.1 HOCl-treated tumour cells induce partial dendritic cell activation
Percentage (%) of Mean Fluorescence Intensity (MFI) of
untreated DCs
HOCl 4iM) CD86 CD83 CD40
0 103.4+ 15.2 133.1 + 29.5 100.6± 14.9
30 120.4±20 136.1±15.5 111.6± 11.6
40 165.5+36 152.3+13.8 121.2+22.6*
50 181.9+21.4* 160.6+ 14.9 131.5 + 25.3**
60 162.3±20.5 162.3 + 21.2 129.6± 11.6*
LPS matured DCs 394.0±60.2** 355.4±25.8** 222.6+32.2**
SK-OV-3 tumour cells were incubated with HBSS (0 fiM) or 30 pM to 60 |iM 
HOCl for 1 h at 37°C, 5%C0] and cocultured with immature DCs at 1:1 ratio for 24 
h. Cells were harvested and double-stained for HLA-DR and one of the markers of 
DC maturation CD86, CD83 or CD40. The mean fluorescent intensity (MFI) for 
each marker was obtained. Because the absolute MFI values showed individual 
variation, all values were normalised to mean MFI values o f DC cultured in absence 
of tumour cells. Table 3.1 shows the mean ± standard error of the mean for 3 
independent experiments. Asterix indicates a significant difference from DC alone, 
calculated using 1-way Anova with Dunnett’s modification on the original 
unnormalised MFI values for each marker.
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Figure 3.3 HOCl-oxidised SK-OV-3 cells are efficiently phagocytosed by dendritic 
cells. Dil-labeled SK-OV-3 tumour cells were treated with HBSS, 25 pM HOCl, or 
60 pM HOCl for 1 h, washed and co-cultured with DCs at 1:1 ratio for 0, 4, or 24 h at 
37 or 4°C. Cocultures were harvested, stained for HLA-DR, and analysed by flow 
cytometry. A) Representative flow cytometry profile (one o f three experiments). Free 
residual tumor cells are shown in the top left quadrant, while DCs are found in the 
right hand quadrants (HLA-DR^). DCs which have taken up SK-OV-3 cells are 
positive for both HLA-DR and Dil and appeared in the upper right quadrant. B) The 
percentage of DC (DR positive cells) which have taken up Dil under different 
experimental conditions was plotted against HOCl concentrations, mean ± standard 
error o f the mean for three experiments. The asterisk shows significant difference 
from 0 pM HOCl within each group. Student’s paired t test, P<0.05.
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vertical axis) while DCs were identified by the expression of HLA-DR (FLl, 
horizontal axis). There was little or no uptake of live untreated SK-OV-3 cells even 
over a 24 h coculture. In contrast, there was rapid uptake of HOCl-treated cells, with 
maximum uptake observed at 60 pM HOCl (Fig. 3.3A, B). Uptake was inhibited at 
4°C confirming that SK-OV-3 cells were being taken up by an active process (Fig. 
3.3B). It was however noted that passive transfer of Dil to the DCs could not be 
excluded; this might be the reason why approximately 10% of DCs were Dil-positive 
when incubated with live Dil-labelled SK-OV-3 cells at 4°C for 24 h (Fig. 3.3A, 
lowest panel). Oxidised tumour cells, while still intact, became rather fragile, and 
fragmented upon prolonged incubation (note the absence of labeled cells from the 
upper left quadrant in the 4°C panels).
3.3.5. Dendritic cells pulsed with oxidised SK-OV-3 cells stimulate T cells 
specific to tumour cell and to epitopes o f HER-2/neu and MUCl 
DCs prepared from PBMCs o f HLA-A2^ healthy volunteers were cocultured with 60 
pM HOCl-oxidised SK-OV-3 cells (HLA-A2', ratio of one DC to one tumour cell) 
overnight. DCs were then cocultured with purified autologous T cells (ten T cells to 
one DC). Viable T cells were harvested after 1 week and restimulated with autologous 
PBMCs pulsed with oxidised SK-OV-3 cells for a further 4 days, and then cultured in 
the absence of antigen stimulation for 3 days as described in Materials and Methods. 
The surviving T cells were tested by IFN-y ELISPOT assay to assess tumour-specific 
T cell responses. As shown in Fig. 3.4A, T cells primed with HOCl-oxidised SK-OV- 
3 cells showed a significant (R<0.05) antigen specific recall response to the original 
immunogen (oxidised SK-OV-3 cells). A response was seen in all seven individuals 
tested, with a range o f 130-220 spots/10  ^T cells.
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T cells primed with oxidised SK-OV-3 gave significant IFN-y responses to live SK- 
OV-3 cells in the presence of exogenous PBMC (Fig. 3.4A, second bar). This result 
indicates that the T cells stimulated by the oxidised SK-OV-3 cells also recognise 
non-modified antigens, an essential requirement if the cells are to have useful anti­
tumour aetivity in vivo. In contrast, the T cells stimulated by the oxidised SK-OV-3 
cells failed to respond to oxidised melanoma cells, indicating that the response 
showed cell type specificity.
The T cells stimulated with the oxidised SK-OV-3 cells also responded to peptides 
eneoding known HLA-A2 epitopes of HER-2/neu and M UCl. Since SKOV-3 cells 
are HLA-A2", this response demonstrates that the oxidised SK-OV-3 cells had been 
taken up and eross-presented by the stimulating DC. The response to E75 HER-2/neu 
peptide was consistently better than the response to GP2 HER-2/neu peptide (three of 
three individuals, although the difference in the means did not reach significance; 
P=0.06), suggesting that a predetermined epitope hierarchy exists within the HER- 
2/neu antigen. The T cells did not respond significantly to an HLA-A2 melanoma 
peptide, confirming antigen specificity of the observed response.
T eells primed with DC in the absence o f tumour cells failed to show significant recall 
responses to any of the antigens tested (Fig. 3.4B). Furthermore, T cells primed with 
live SK-OV-3 cells (X-ray irradiated in order to prevent proliferation) gave only very 
weak responses (less than 60 spots/10^ cells; data not shown). It was important, to 
however, to determine whether the enhanced immune response seen was due 
specifically to oxidation by HOCl, or was simply a result o f cell necrosis. SK-OV-3 
necrosis was therefore induced by two other means, heat treatment (56°C, 30 min) or
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Figure 3.4 Dendritic cells loaded with HOCl-oxidised SK-OV-3 cells, but not heat- 
killed or HCl-killed SK-OV-3, stimulate T cell responses to tumour cells and to 
specific tumour antigen epitopes HER-2/neu and M UCl. T cells from HLA-A2^ 
individuals were stimulated with autologous DCs pulsed with: A) 60 pM HOCl- 
treated SK-OV-3, B) complete AIM-V media without antigen, C) Heat-killed SK-OV- 
3 cells, or D) HCl-killed SK-OV-3 cells as described in Materials and methods. 
Viable T cells were harvested after 1 week and re-stimulated with autologous PBMCs 
pulsed with the same antigen for another 4 days, and cultured in fresh medium 
without antigen for three more days. IFN-y production was measured by ELISPOT. 
The results are the means ± standard error o f the mean for at least three independent 
experiments (i.e. PBMCs from different individuals). The asterisk indicates those 
columns differing significantly (P<0.05) from the medium only control (one-way 
ANOVA with Dunnett’s modification for multiple comparisons).
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Figure 3.5 Dendritic cells preloaded with HOCl-oxidised SK-VO-3 cells cross­
primed autologous CDS^ T cells that were specific to HER-2/neu. T cells were co­
cultured with autologous DCs (ten T cells to one DC) preloaded with HOCl-oxidised 
SKOV-3 cells, HER-2/neu E75 peptide or MUCl M l.2 peptide as shown. After two 
further rounds of antigen stimulation (see details in Materials and methods) viable T 
cells were harvested and double-stained with anti-CD8 FITC and PE-conjugated 
HER-2/neu pentamer specific for HER-2/neu E75/HLA-A2. The percentage of total 
CD8^ T cells positive for pentamer is shown on the top right hand comer. Data are 
one representative out of three independent experiments.
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brief exposure to acid (1 M HCl, 60 sec). In these conditions, SK-OV-3 tumour cells 
retained cellular integrity but were >99% dead by necrosis (confirmed by trypan blue 
and PI staining, data not shown). T cells primed using DC loaded with either heat-kill 
(Fig. 3.4C) or acid killed (Fig. 3.4D) SK-OV-3 failed to prime a significant immune 
response to any antigen tested.
3.3.6. Direct versus indirect presentation of oxidised SK-OV-3 cells 
The presence of HLA-A2 restricted HER-2/neu specific cells, suggesting cross­
presentation of HLA-A2" SK-OV-3 cells by HLA-A2^ DC, was confirmed by HLA- 
A2 pentamer staining. T cells were stimulated with autologous DCs pulsed with either 
60 pM HOCl-oxidised SK-OV-3, HLA-A2 restricted HER-2/neu E75 peptide, or 
MUCl Ml . 2 peptide, and expanded as described in Materials and methods. Viable T 
cells were harvested and double-stained with anti-CD8 antibody and HER-2/neu 
pentamer specific for HER2/neu E75 peptide bound to HLA-A2. T cells primed with 
oxidised SK-OV-3 cells, as well as HER-2/neu E75 peptide contained a population of 
pentamer binding CDS positive T cells (Fig. 3.5A, top two panels) while cells primed 
with MUCl peptide showed background staining (Fig. 3.5A, bottom panel). Three 
individuals were tested in this way, with average CDS/pentamer positive percentages 
of 1.42% (primed with oxidised SK-OV-3 cells), 0.77% (primed with HER-2/neu 
E75) and 0.02% (primed with MUCl M l.2).
In order to determine whether oxidised SK-OV-3 cells stimulated IFN-y release by 
primed T cells directly (i.e. allogeneic direct interaction), or whether T cell 
stimulation depended exclusively on reprocessing by autologous antigen presenting 
cells, T cells were cultured with HOCl-oxidised SK-OV-3 cells in the presence or
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absence o f HLA-A2^ PBMCs as source of antigen presenting cells (Fig. 3.6). The 
response to HOCl-treated cells was not significantly above background in the absence 
of PBMCs. HOCl treatment therefore seems not only to enhance cross-presentation, 
but to inhibit direct allogeneic recognition. It was to be pointed out that one important 
control which was lacking was the use o f naïve T cells or PBMCs prior to antigen 
stimulation to determine the precursor frequency of ovarian-specific T cells. This 
would be useful to determine the effectiveness of T cell priming with oxidised SK- 
OV-3 and to show any increase in the number of ovarian-specific T cell precursors 
following antigen stimulation. In Fig. 3.7, T cells from an HLA-A2^ individual 
primed to the oxidised SK-OV-3 cells, responded directly (i.e. in the absence of 
exogenous PBMC) to live cells of an HLA-A2^ and MUCl and HER-2/neu 
expressing breast cancer cell line MDA-231 (an HLA-A2^ ovarian line was not 
available to us) but not to an HLA-A2^ melanoma cell line M EL-12.
3.3.7. Responses to oxidised tumour cells are cell type specific 
The role o f HOCl in enhancing tumour-specific T cell responses was tested further 
using an HLA-A2' melanoma cell line, MEL-11, which expresses the melanoma 
assoeiated antigen MART-1 (not shown) but neither HER-2/neu nor M UCl (Fig. 3.1). 
T cells primed with DC loaded with HOCl-oxidised M EL-11 cells showed strong 
responses to MEL-11 cells, as well as to an HLA-A2 restricted peptide derived from 
MART-1 (Fig. 3.8). Thus, HOCl-oxidised melanoma cells, like ovarian tumour cells, 
effectively stimulate antigen specific T cells via cross-priming. MEL-11 stimulated 
cells, however, failed to respond to oxidised SK-OV-3 cells, or any of the HER-2/neu 
or MUCl peptides.
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Figure 3.6 Cross-priming is necessary for presentation o f HOCl-oxidised SK-OV-3 
cells. T cells were primed with HOCl-oxidised SK-OV-3 cells as in Figure 3.4A and 
their IFN-y responses to HOCl-oxidised SK-OV-3 or HER-2/neu peptide, in the 
presence or absence of autologous PBMC was evaluated with ELISPOT. The results 
are the means ± standard error o f the mean for at least three independent experiments 
(i.e., PBMCs from different individuals). The asterisk indicates those columns 
differing significantly (f<0.05) from the T cell only control (one-way ANOVA with 
Dunnett’s modification for multiple comparisons).
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Figure 3.7 T cells stimulated with dendritie cells pulsed with oxidised SK-OV-3 cells 
were capable of directly recognising live HLA-A2^ eell line that overexpressed HER- 
2/neu and M UCl. T cells were primed with HOCl-oxidised SK-OV-3 cells as in 
Figure 3.4A and their IFN-y responses to live MDA-231 (HLA-A2^, MUCl^, HER- 
2/neu^) or live MEL-12 (HLA-A2^, MUCl", HER-2/neu") in the absence of 
autologous PBMC was evaluated with ELISPOT. The results are one representative 
experiment of two.
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Figure 3.8 HOCl-oxidised M EL-11 cells induce melanoma specific T cells which do 
not cross-react with SK-OV-3 cells. T cells were primed to oxidised M EL-11 cells as 
described in Figure 3.4. Their IFN-y production in response to HOCl-oxidised SK­
OV-3 or MEL-11 cells, HER-2/neu peptide, MUCl peptides, or MART-1 peptides in 
the presence of autologous PBMC was measured by ELISPOT. The results are the 
means ± standard error of the mean for at least three independent experiments (i.e., 
PBMCs from different individuals). The asterisk indicates those columns differing 
significantly (P<0.05) from the medium only control (one-way ANOVA with 
Dunnett’s modification for multiple comparisons).
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3.4. Discussion
Dendritic cells are key regulators of the immune system and are capable of initiating 
and inducing tumour-specific cytotoxic and helper T cells. Indeed, DC-based 
immunotherapy has been vigorously pursued in clinical trials with some success (see 
Chapter 1). In the case of ovarian carcinoma, DCs have been pulsed with HLA-A2 
restricted peptides coding for immunodominant epitopes o f either HER-2/neu or 
MUCl proteins (Santin et al., 2004). Though the synthesis of large quantities of 
clinical grade peptides is technically straightforward, there are several limitations of 
peptide immunogens, including the need for patients with specific HLA haplotype, 
limited anti-tumour responses, selection of escape variants, and lack o f long-lasting 
memory. An alternative is to use whole ovarian tumour cells that highly express HER- 
2/neu and M UCl, together with many as yet undefined TA As (Hernando et al., 2002). 
In this study, we developed a robust ex vivo human cell culture system of loading 
HLA-A2^ DCs from healthy volunteers with whole allogeneic SK-OV-3 tumour cells, 
and assessing their potential for generating autologous tumour-specific T cells.
The first key element of this model was that the immunogenicity of the tumour cells 
was enhanced by treatment with HOCl, a strong oxidising agent, which induced rapid 
necrosis of SK-OV-3 tumour cells. Enhancement of anti-tumour immunity thus 
extends previous observations of enhanced immune responses to protein antigens 
treated with HOCl (Allison and Fearon, 2000; Marcinkiewicz et al., 1991; 
Marcinkiewicz et al., 1992). Several studies have suggested that cell necrosis, per se, 
may enhance immunogenicity, perhaps by exposing heat shock proteins (Basu et al., 
2000; Kotera et al., 2001; Sauter et al., 2000). Importantly, therefore, enhanced 
imunogenicity to oxidised cells was seen when compared to response to SK-OV-3
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cells killed by other means, such as heat or acid treatment. Since HOCl, and the 
closely related chemical HCl, differ principally in that the former is a strong oxidising 
agent, while the latter is not, these results suggest that oxidation is an essential feature 
of the enhancement in immunogenicity observed. Preliminary studies have shown that 
other forms o f oxidation (e.g. by hydrogen peroxide) can also improve 
immunogenicity, and the precise nature of the chemical reactions responsible are 
being investigated further.
The mechanism for enhanced immunogenicity may be explained, at least in part, by 
the fact that the oxidised eells were taken up much more efficiently than live cells by 
DC, and experiments are underway to try and identify the receptor involved in DC 
uptake. However, HCl-killed or heat-killed tumour cells also showed some enhanced 
uptake in comparison with live cells (not shown), suggesting that other mechanisms, 
such as more efficient processing, may also play a role. In addition, oxidised SK-OV- 
3 tumour cells induced a partial activation of DCs by upregulating the maturation 
associated markers CD86 and CD40. DC maturation induced by oxidised SK-OV-3 
cells was sub-optimal compared to the Toll-like receptor (TLR) agonist LPS, 
however, and additional stimulation of DC (e.g. via CD40 ligation) may further 
enhance the response.
A second key aspect o f this model was the role of cross-presentation versus direct T 
cell/tumour cell interaction. The detection of responses to well-defined HLA-A2 
restricted epitopes of HER-2/neu and MUCl clearly demonstrated that oxidised SK- 
OV-3 cells (which were HLA-A2" and allogeneic to the DC and T cells) were 
efficiently cross-presented by the DC. The strong peptide-specific responses
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demonstrated that a major part of the T cell response was to “ native” cellular 
antigens, rather than to new neo-epitopes formed by chemical modification with 
HOCl. The ability o f T cells primed to oxidised tumour cells to recognise live tumour 
targets was confirmed by using an HLA-A2^ expressing breast tumour line, MDA- 
231, which shared both M UCl and HER-2/neu antigen expression with SK-OV-3 
(Fig. 3.7). Shared antigen expression was essential for recognition, since an HLA-A2 
matched melanoma tumour was not recognised.
HOCl oxidation not only promoted cross-presentation, but also seemed to block direct 
allo-recognition, since the T cell IFN-y response to oxidised cells (Fig. 3.6) showed an 
absolute requirement for antigen presenting cells. Unexpectedly, the T cells primed to 
oxidised SKOV-3 also recognised live SK-OV-3 (Fig. 3.7), even though these cells 
were taken up very poorly, and did not express HLA-A2. Direct recognition of SK­
OV-3 cells could have occurred, however, either through a shared unknown HLA 
allele between volunteer and SKOV-3 (since the volunteers were typed only for the 
presence of HLA-A2), or via the presence of promiscuous tumour derived peptides 
able to interact with many different HLA alleles. The dominance o f cross-presentation 
in this model may have important practical consequences, since it may allow the use 
of generic tumour-derived cell lines as immunogens, in place o f patient-derived 
tumour cells which are more difficult to obtain and inherently more heterogeneous. 
The HLA of the cell line used as immunogen will in fact be irrelevant, since T cells 
will be primed to antigens presented in the context of the host MHC on host DCs. 
Such T cells will therefore be syngeneic to the primary host tumor, and therefore 
should be able to recognise the primary tumor directly. In this scenario a cell line 
would simply need to share tumour antigens with the primary tumour (e.g. MUCl or
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HER-2/neu positive tumours for SK-OV-3 priming). The use of such “ standardised” 
cell lines would have major benefits in terms of practical application, since it obviates 
the need for patient specific tumor tissue collection and preparation. Studies to test 
this hypothesis, using primary autologous patient-derived tumour cells as targets 
following in vitro priming with SK-OV-3 cells are in progress.
The third important observation in this study was the tumour specificity of the 
responses. A persistent concern in the development of tumour immunotherapy is that 
the immune system will recognise and kill cells other than the tumour and hence 
cause autoimmune disease. This problem is particularly acute with the use of whole 
cell immunogens, since all cells share an enormous number of “ common” proteins 
involved in housekeeping cellular metabolic functions, as well as expressing smaller 
numbers of “ tissue specific” proteins. It is, therefore, o f importance that in this 
model the response showed specificity in relation to at least two quite distinct tumour 
cell types. SK-OV-3 specific T cells did not respond to the melanoma line MEL-11, 
while conversely, T cells immunised to M EL-11 melanoma cells did not respond to 
SK-OV-3 cells. Further studies are in progress to identify the breadth of the response 
to SK-OV-3 cells, in terms of tissue specificity, tumour specificity, and its ability to 
recognise “ normal”  tissue.
The ability of innate immunity to drive enhanced adaptive immunity is now a central 
tenet of immunology. In this study, we seek to manipulate tumour immunity using 
HOCl, a known microbicidal product of myeloperoxidase activity in neutrophils. 
Although myeloperoxidase is well-established as playing a role in the effector 
microbicidal function of neutrophils, its role in linking innate and adaptive immunity
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has only been recognised more recently (Marcinkiewicz, 1997). As discussed above, 
in vivo vaccination o f patients with DCs preloaded with oxidised SK-OV-3 may 
induce therapeutic tumour-specific T cells responses to autologous tumor cells. 
Cytolysis of tumour cells by tumour-specific T cells will release further tumour 
antigen, and also release cytokines that drive localised inflammation. A virtuous cycle 
of further rounds o f oxidation and immunological stimulation is thus established.
3.5. Conclusions
• HOCl in HBSS induced rapid primary necrosis of SK-OV-3 cells in a dose- 
dependent manner. Oxidised, but not live, SK-OV-3 cells were rapidly taken up 
by monocyte-derived DCs and induced partial DC maturation.
• DCs cultured from HLA-A2^ healthy volunteers pulsed with oxidised SK-OV-3 
(HLA-A2') stimulated autologous T cells that produced IFN-y in response to the 
immunising cellular antigen and to peptides coding for MUCl and HER-2/neu 
HLA-A2 restricted epitopes, demonstrating efficient cross-presentation of cell- 
associated antigens. In contrast, no response was seen after priming with heat- 
killed or HCl-killed SK-OV-3, indicating that HOCl oxidation and not cell death 
or necrosis per se enhanced the immunogenicity of SK-OV-3.
• Finally, T cells stimulated with oxidised SK-OV-3 showed no cross-reaction to 
oxidised melanoma cells, nor vice versa, demonstrating that the response was 
tumour-type specific.
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Therefore, immunisation with oxidised ovarian tumour cell lines may represent an 
improved therapeutic strategy to stimulate a polyclonal anti-tumour cellular 
immune response and hence extend remission in ovarian cancer.
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4.1. Introduction
In chapter 3, it was demonstrated that allogeneic SK-OV-3 ovarian tumour cells 
oxidised by HOCl were potent immunogens for DCs in priming autologous tumour- 
specific T cell responses. As the studies were done using the peripheral blood of 
healthy volunteers, this model was tested further in the ovarian cancer setting. 
Ovarian cancer patients in remission are attractive candidates for immunotherapy as 
they have minimal tumour burden and their immune system appears to have returned 
to normal (Colombo et al., 2006). In addition, autologous tumour cells can be 
obtained frequently direct from ascitic fluid as a single cell suspension, thus 
minimising the need for tissue disruption and manipulation, and facilitating in vitro 
restimulation assays. Furthermore, studies of the immune microenvironment in 
ovarian tumours showed convincing evidence for a “natural” immunoprotective 
response, which may be capable of enhancement by appropriate vaccination strategies 
(Zhang et al., 2003). In this chapter, two critical questions were being addressed. 
First, whether T cells from patients that are exposed to high levels of ovarian cancer 
antigens over prolonged periods and yet are apparently tolerant to them, still respond 
effectively to the oxidised antigens. Second, whether the T cells stimulated in 
response to SK-OV-3 cross-priming actually respond to autologous tumour, which is 
an obvious requirement for any potential immunotherapeutic approach. It is being 
proposed that these studies suggest a generic method to stimulate an anti-tumour T 
ceil response which will be capable of targeting autologous tumour in patients with 
ovarian cancer.
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4.2. Objectives
• Using IFN-y ELISPOT assay determine whether T cells derived from patients 
with ovarian cancer would recognise ovarian TAAs and produce IFN-y in 
response to priming with autologous DCs preloaded with oxidised SK-OV-3.
• To demonstrate the presence of HER-2/neu specific T cells after priming with 
patients’ autologous DCs pulsed with oxidised SK-OV-3.
• To assess the ability o f cancer patients’ DCs to mature in the presence of two 
maturation stimuli, i.e. agonistic CD40 mAh and MPL, and to compare the T cell 
stimulatory capacity of such mature DCs to immature DCs preloaded with HOCl- 
oxidised SK-OV-3 cells in cross-priming T cells in vitro.
• To evaluate the ability o f patients’ T cells primed with mature DCs (treated with 
agonistic CD40 mAh or MPL) preloaded with oxidised SK-OV-3 in recognising 
autologous ascites in the absence of APCs in IFN-y ELISPOT assay.
• To investigate whether patients’ T cells stimulated with mature DCs loaded with 
oxidised tumour cells were immunogen and tissue-specific.
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4.3. Results
4.3.1. T cells from patients with ovarian cancer are not tolerant to autologous 
dendritic cells pulsed with oxidised SK-OV-3 tumour cells
Previously it was showed that DCs, derived from HLA-A2^ healthy volunteers and 
preloaded with oxidised SK-OV-3, stimulated T cells that recognised the immunising 
antigen (i.e. oxidised SK-OV-3) and unmodified (i.e. not oxidised) peptides derived 
from HER-2/neu and M UCl, two TAAs expressed by the SK-OV-3 cell line (Chiang 
et a l,  2006). In this present study, the responses o f seven healthy volunteers was 
compared to the responses from a group o f ten patients with ovarian cancer using DCs 
loaded with oxidised SK-OV-3 and autologous T cells (Fig. 4.1 A). All ten patients 
responded to the oxidised cells (>500 spots per million). The average number o f spots 
was lower than in the volunteer cohort {P< 0.01, Mann Witney test), which might 
reflect differences in age distribution and general health. Indeed the mean background 
(media alone. Fig. 4 .IB) response o f the healthy volunteers was also slightly higher 
than that of the patients, although this difference was not statistically significant. A 
typical dose response to the oxidised SK-OV-3 in a representative patient is shown in 
Fig. 4.1C.
Four HLA-A2^ individuals from this group were also tested using HLA-A2 restricted 
HER-2/neu and MUCl peptides, and a control peptide derived from the melanoma 
antigen MART-1 (Fig. 4 .ID). Strong responses were seen to all four HER-2/neu and 
MUCl peptides tested but there was no response to the MART-1 peptide. Since the 
SK-OV-3 line is HLA-A2', these experiments demonstrated that oxidised SK-OV-3 
cells were cross-presented by the DCs, and that the T cells recognised non-oxidised 
TAAs. All four patients expressed high levels of tumour MUCl as assessed by
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immunocytochemistry, and one (patient 27) was also positive for HER-2/neu (Table 
4.1). No responses were seen to either oxidised SK-OV-3 cells or peptides when 
PBMCs were tested directly from patients, without DC presentation/expansion, thus 
confirming that exposure to the tumour in vivo had not primed a significant response. 
It was noted that an important control that was absent was to determine the precursor 
frequency of ovarian-specific T cells in naïve unprimed T cell population in IFN-y 
ELISPOT. This data would be useful for determining whether in vitro priming o f T 
cells with oxidised SK-OV-3 would indeed increase the number of such tumour- 
specific T cells. This was not done due to the limitation of the number of patients’ T 
cells obtained and thus all the T cells were used for in vitro priming experiment.
As an additional measure o f antigen specificity, pentamer staining was performed 
using a HER-2/neu peptide (E75; KIFGSLAFL)/HLA-A2 pentamer (Fig. 4.2). After 3 
weeks of in vitro stimulation (i.e. priming with oxidised SK-OV-3 loaded DCs, and 
expansion with HER-2/neu peptide), between 2 and 4% of the CD8^ T cells were 
specific for the HER-2/neu pentamer. These results were very similar to those 
obtained previously from healthy volunteers (Chiang et al., 2006). Less than 0.2% 
pentamer specific cells were detected on T cells expanded on a MUCl peptide (data 
not shown). All three patients’ tumours were M UCl positive, and one patient’s 
tumour was also positive for HER-2/neu expression. An important control which was 
lacking was the HER-2/neu pentamer staining o f naïve unprimed T cells to determine 
the precursor frequency of ovarian-specific T cells, and for comparison after antigen 
stimulation. This was not done due to the limitation o f the number of patients’ T cells 
that was available for this assay and the IFN-y ELISPOT that was set up in parallel.
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4.3.2. Ovarian cancer patients’ dendritic cells matured normally when 
stimulated with CD40 agonistic antibody or monophosphoryl lipid A 
Our previous study showed that oxidised SK-OV-3 cells induced only a partial 
maturation of DCs. Thus in this study DCs were matured further by addition o f anti- 
CD40 antibody, or the TLR4 agonist MPL. The optimum concentration was first 
determined by monitoring DC maturation by flow cytometry. As shown in Fig. 4.3 
(left panels), upregulation of DC maturation markers and costimulatory molecules -  
CD83, CD86, HLA-DR and CD40 -  was observed with increasing doses of CD40 
antibody or MPL. The relatively low expression o f CD40 observed on CD40- 
activated cells may reflect competitive interference between the antibody used to 
activate the cells and the antibody used to monitor expression, although two different 
mAb antibodies were used. The viability of DCs was reduced by 10% at 1000 ng/ml 
CD40 agonistic antibody treatment (data not shown). Representative fluorescence 
histograms and median fluorescence values are shown in the right panels o f Fig. 4.3 
for DCs that had been loaded with oxidised tumour cells in the absence o f further 
stimulus, in the presence of MPL (100 ng/ml) or in the presence of CD40 antibody 
(500 ng/ml), the concentrations that were used for further experiments.
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Table 4.1 Details of patients used in the study
Patient no. HLA-A2 status Age Tumoui" histology Tumourgi'ade
MUC-1 staining
HER-2/neu staining
Pattern Intensit}^
1 Positive 70 Serous 3 Cyto. mem 3- 0
6 Positive 58 Serous 3 NA NA NA
7 Positive 70 Serous 2 Cyto, mem 3+ 3 + '
8 Negative 64 Serous 2 Cyto, mem 3^ 1^
9 Positive 52 Clear cell NA NA NA NA
12 Positive 62 Serous 2 Cyto, mem 3- 0
13 Negative 77 Endometnoid 2 Cyto. mem 3-v 34-"
14 Negative 52 Endometrioid 2 Cyto. mem 3+"
15 Negative 63 Serous 3 Cyto, mem 3- 0
16 Not done 68 Endometnoid 3 NA NA NA
17 Negative 63 Serous 2 Cvio.mem 3-
18 Negative 67 Serous 3 Cyto, mem 3+"
19 Negative 67 Endometnoid 2 Cyto 3^ 0
20 Negative 60 Serous 2 Cyto, mem 3^ 1+
21 Not done 58 Eiidometiioid Cyto. mem 3- 1-
22 Not done 48 Serous 3 Cyto, mem 3^ 0
23* Negative 70 Serous 3 Cyto, mem 3+ 0
24 Not done 46 Serous 3 NA NA NA
26* Positive 72 Eiidometiioid 2 Cyto, mem 3 - 1+
27 Positive 60 Serous 3 Cyto, mem 3+ 2+
K)O
Note\ C\io- cytoplasm: mem -  membmue; Eiidometiioid -  endometrioid carcinoma: Serous -  serous carcinoma; Clear cell -  clear cell 
carcinoma: Inv due Breast -  invasive ductal breast carcinoma
NA: no tissue sample available for these patients: * ascites also available and tested: ■ HER-2/neu 3+ inteipreted as a clear positive 
Note": Patient 3, 4, 5, 6 and 10 were not shown in the table as they were used for another study, while Patient 2. 11 and 25 gave insufficient 
number of cells for experiments.
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Figure 4.1 T cells from patients with ovarian cancer respond to autologous dendritic 
cells loaded with oxidised SK-OV-3 cells. IFN-y T cells responses using T cells and 
DCs isolated from ten patients and seven healthy volunteers, DCs were cocultured 
with A) oxidised SK-OV-3 or B) complete AIM-V media and then with autologous T 
cells. After a two week expansion period, T cells were collected and restimulated with 
oxidised SK-OV-3 cells (ratio o f  I T cell; I tumour cell) and PBMCs in ELISPOT 
assays. Each point represents the average o f triplicate cultures from a different 
individual. The line shows the m edian response. The two groups were compared using 
Mann Whitney. The difference between the responses of patients’ and volunteers’ T 
cells to oxidised SK-OV-3 was statistically significant (**, P < 0.01; Mann-Whitney), 
and both these responses were significantly greater than to media (**, P < 0.01; 
Mann-Whitney). C) T cells from a HLA-A2' patient were expanded with oxidised 
SK-OV-3 loaded DCs as in A, and restimulated with PBMC and different ratios of 
oxidised SK-OV-3 cells as shown. The figure shows the average and standard error of 
triplicate cultures from one representative individual out of ten. D) T cells from HLA- 
A2^ patients were expanded with oxidised SK-OV-3 loaded DCs as in A, and 
restimulated with PBMC and HER-2/neu (E75 and GP2), M UCl (M l.l  and M l.2), 
MART-1 or media control in ELISPOT assays. The last 2 columns show the response 
o f T cells in the absence o f  antigen or PBMCs. The figure shows mean and standard 
error o f responses from four individuals. The mean differences between the responses 
o f T cells to the peptides (i.e. E75, GP2, M l . l ,  M l.2) compared to media were 
statistically significant (**, P  < 0.01 ; Anova with Dunnetts post-hoc modification).
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I
I
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Patient 1 Patient 7 Patient 12
3.2% 2.2% 4.1%
CDS FITC
Figure 4.2 Patients’ dendritic cells preloaded with oxidised SK-OV-3 stimulated 
HER-2/neu specific T cells. DCs were cocultured with oxidised SK-OV-3 and then 
with autologous T cells as described in Materials and Methods, After a three week 
expansion period, T cells were collected, and stained with HER-2/neu (HLA-A2/ 
KIFGSLAFL epitope) pentamers and CD8-FITC. The number in the upper left panel 
indicates the percentage pentam er positive cells as a proportion of total CD8+ cells. 
The figure shows results obtained from three individuals (patient numbers refer to 
Table 4.1).
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Figure 4.3 Activating anti-CD40 and MPL induce further maturation in patients’ 
dendritic cells loaded with oxidised SK-OV-3 cells. DC were prepared from patient 
PBM Cs and cultured in the presence o f  different concentrations o f MPL (50-200 
ng/ml) or CD40 agonistic antibody (100-1000 ng/ml) for 24 h. Expression o f each 
m arker was m easured independently by flow cytometry using PE-conjugated 
antibodies as described in M aterials and Methods. The left panel shows the average 
mean fluorescent intensity (M PI) ± standard error bars from three independent 
experiments, expressed relative to the MPI in the absence o f stimulus (defined as 
100%). The right panel shows one representative frequency histogram o f fluorescence 
(PL2 channel) in the absence o f stimulus, or in the presence o f 100 ng/ml MPL or 500 
ng/ml CD40 agonistic antibody. The num ber in the right hand top corner o f each 
histogram shows the MPI (channel number). The empty profile shows negative 
control staining with control PE-conjugated IgG.
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4.3.3. Mature dendritic cells loaded with oxidised SK-OV-3 induced strong 
CD4^ and CD8^ tum our-specific responses
Two experimental approaches were used to demonstrate a CD4^ T cell response. In 
Fig. 4.4, unfractionated T cells were tested against a range o f ovarian antigens in the 
ELISPOT, including two HER-2/neu peptides that had previously been shown to 
represent promiscuous M HC class II epitopes that bound to a wide variety (though not 
all) o f HLA-DR haplotypes (Baxevanis et al., 2006). Immature DCs were compared 
to DCs matured by CD40 agonistic antibody (as detailed above) for these 
experiments. Unfractionated T cells stimulated by immature DCs gave good 
responses to oxidised SK-OV-3 cells (as above), and these responses were further 
boosted (about two fold) by using mature DCs (Fig. 4.4A). In contrast, T cells failed 
to respond {P > 0.5, response not significantly above background) to either o f the 
MHC class II peptides when primed by immature DCs (Fig. 4.4C, D). However, 
priming with mature DCs loaded with oxidised SK-OV-3 stimulated responses against 
both the class II HER-2/neu peptides tested, H360 and H776 [both P < 0.01 when 
compared to priming with immature DCs] (Fig. 4.4C, D).
In a second approach (Fig. 4.5), T cells were depleted o f CD8^ T cells before 
coculturing with DCs. After depletion, the CD4^ T cell population which contained 
about 5% contaminating CD8^ T cells was tested in the assay. The total CD4^ T cell 
population gave a smaller, but significant response to oxidised SK-OV-3 cells, which 
was enhanced about 2-3 times by using mature DCs [in these experiments matured 
with MPL] (Fig. 4.5A). Neither immature nor mature DCs primed responses to 
peptide H369 (Fig. 4.5C), while mature DC primed a small response to H776 (Fig. 
4.5D).
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4.3.4. Dendritic cells pulsed with oxidised SK-OV-3 primed IFN-y producing 
V cells that efficiently recognise autologous ovarian tumour cells isolated from ascites 
1 he key test for the strategy o f  using oxidised SK-OV-3 cells as a generic cell based 
antigen is whether 1 cells primed in this way will recognise autologous tumour. For 
these experiments PBMC were taken from two patients in remission, from whom 
ascitic tumour cells had been collected and stored in advance in -80°C. The 
expression o f H FR-2/neu and M U Cl in the tumour sample itself was analysed by 
immunoblotting (Fig. 4.6A and B). Tum our M UCl glycoproteins were detected as 
multiple glycosylated variants o f approximately 250 kOa in the SK-OV-3 ovarian cell 
line and in both patients’ ascites samples. HER-2/neu (molecular weight 
approximately 185 kDa) was detected as a single band in the SK-OV-3 line but was 
absent in both ascites samples. Both antigens were absent from the melanoma tumour 
line MEL-11. It was noted that dilution controls for both HER-2/neu and M UCl 
proteins (i.e. loading fewer tum our cells or less tumour proteins per lane) were not 
performed. The data would be useful to show clearer and more defined bands, 
especially for the M UCl protein, in the western blot.
For functional studies, on the basis o f  the data shown in Figs. 3 and 4, we used DCs 
loaded with oxidised SK-OV-3 and then cultured with either CD40 agonistic antibody 
or MPL. The first patient (patient 23 in Table 1) was HLA-A2', and therefore was 
tested with the promiscuous class II MHC restricted peptides, but not the HLA-A2 
restricted peptides (Fig. 4.7A). The T cells responded to both MHC class II peptides 
tested (Fig. 4.7A), as well as to the oxidised SK-OV-3 used for priming (Fig. 4.7B). 
Critically, the T cells primed with oxidised SK-OV-3 also showed responses to the 
autologous unmodified tum our cells over a range o f tumour to T cell ratios, and in the
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F igure  4.4 Dendritic cells m atured with agonistic CD40 antibody induce CD4^ as 
well as CD8^ tum our-specific T cell responses. Unfractionated T cells isolated from 
patient PBMCs were cocultured with autologous DCs that were preloaded with 
oxidised SK-OV-3, and then either m atured with 500 ng/ml CD40 agonistic antibody 
or cultured in complete AIM -V m edia alone. After a 2-week expansion period, T cells 
were isolated and tested in IFN-y ELISPOT assays with PBM Cs (1 x 10"^ ) and 
oxidised SK-OV-3 cells (ratio o f 1 T cell : 1 tumour cell), or HER-2/neu class II 
MHC peptides H369 and H776 (all at a final concentration o f IpM ), or complete 
AIM-V media only. The results show mean num ber o f  spots per million T cells from 
four independent experiments (i.e. different patient PBM Cs in each experiment). The 
T cell responses to all antigens tested (i.e. oxidized SK-OV-3, H369 and H776) using 
anti-CD40 matured DCs were statistically greater (**, ?  < 0.01, Student’s paired t- 
test) than those using dendritic cells w ithout anti-CD40, and also significantly greater 
{P < 0 .05 ; Anova with Dunnetts post-hoc modification) than those to responses in the 
absence o f antigen.
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Figure 4.5 Dendritic cells matured with MPL enhance CD4^ tumour-specific T cell 
responses. T cells isolated from patient PBMCs were depleted o f CD8^ T cells by 
immunomagnetic bead selection as described in Materials and Methods. The residual 
T cells contained about 5% CD8^ T cells. The purified CD4^ cells were cocultured 
with autologous DCs that were preloaded with oxidised SK-OV-3, and then either 
matured with 100 ng/ml M PL or cultured in complete AIM-V media alone. After a 2- 
week expansion period, viable CD4^ T cells were isolated and assessed in IFN-y 
ELISPOT assays with PBM Cs (1 x lO"^ ) and oxidised SK-OV-3 cells (ratio o f  1 T cell 
: 1 tum our cell), or HER-2/neu class II MHC peptides H369 and H776 (all used at a 
final concentration o f 1 pM ), or complete AIM-V media only. The results show mean 
number o f spots per million T cells from three independent experiments (i.e. different 
patient PBM Cs in each experiment). T cell responses from the MPL treatm ent were 
statistically significant compared to that o f no MPL treatment in the oxidised SK-OV- 
3 group (*, P < 0.05; S tudent’s paired /-test) but not for H369 and H776 groups (NS, 
not significant). The response to oxidised SK-OV-3 and H776 with MPL treatment 
was statistically significant (P < 0.05; Anova with Dunnetts post-hoc modification) 
compared to no MPL treatment and no antigen.
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Figure 4.6 Expression o f  M UCl and HER-2/neu tumour antigens on ovarian cancer 
patients’ ascites. 1 x 10^ ascite tumour cells, SK-OV-3 cells or MEL-11 cells were 
lysed in sample buffer, resolved on 7.5% SDS-PAGE electrophoresis, and transferred 
to nitrocellulose membranes as described in Materials and Methods. MUCl and HER- 
2/neu expressions were detected by anti-MUCl and anti-HER-2/neu monoclonal 
antibodies, respectively. In A) M UCl glycoproteins were detected as multiple 
glycosylated variants o f approximately 250 kDa in the ascite tumour cells o f Patient 
23 and 26, and in SK-OV-3. In B) HER-2/neu appeared as a single band of 185 kDa 
in the SK-OV-3 but absent in the patients’ ascites. M EL-11 was negative for both 
M UCl and HER-2/neu.
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absence o f any exogenous antigen presenting cells in the ELISPOT assays (Fig. 
4.7C). An important control that was not performed was to determine the precursor 
frequency of ovarian-specific 1 cells in naïve unprimed T cell population in IFN-y 
I’LlSPO f. 1 his data would be useful for determining whether in vitro priming o f T 
cells with oxidised SK-OV-3 had increased the number o f such tumour-specific T 
cells. 1 his was not done due to the limitation o f the number o f patients’ T cells 
obtained and thus all the T cells were used for in vitro priming experiment.
Since more cells were available from the second patient (patient 26 in Table 1), an 
additional specificity control was added. H alf the DCs were loaded as above with 
oxidised SK-OV-3 cells, while half were loaded with an oxidised melanoma line, 
M EL-11 (also HLA-A2 ). Since the individual was HLA-A2^, the T cells responded 
to the class 1 HER-2/neu peptide E75, as well as the class II MHC HER-2/neu 
peptides tested (Fig. 4 .8A). There was no response to the melanoma HLA-A2 
restricted peptide MART-1. The T cells stimulated with the oxidised SK-OV-3 cells 
also responded to oxidised SK-OV-3 cells, but showed no response to oxidised MEL- 
11 cells (Fig. 4 .SB). As with patient 23, the T cells also reacted to unmodified 
autologous tumour in the absence o f exogenous APCs (Fig. 4.8C), demonstrating 
directly that they were not tolerant to the tumour cells. In contrast, the T cells 
stimulated in vitro with the oxidised M EL-11 cells showed little response to the 
autologous ovarian tum our cells (Fig. 4.9A). The cells did respond strongly to the 
oxidised M EL-11 cells, and showed a significant response to the MART-1 peptide, 
but no response to any HER-2/neu peptide tested (Fig. 4.9B). Thus the T cells 
stimulated by oxidised antigen remain tolerant to common self antigens shared
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Figure 4.7 Patient’s T cells stimulated with mature dendritic cells pulsed with 
oxidised SK-OV-3 efficiently recognise autologous ascites derived tumour cells and 
ovarian tumour-associated antigens. T cells from a HLA-A2 negative patient (Patient 
23) were cocultured with autologous DCs that were loaded with oxidised SK-OV-3, 
and then matured with CD40 agonistic antibody (500 ng/ml) or MPL (100 ng/ml). 
After a 2-week expansion period, T cells were isolated and tested in IFN-y ELISPOT 
assays. In A) T cells were cocultured with PBMCs (I x 10"^ ) and HER-2/neu class II 
MHC peptides H369 and H776 , or control peptide MART-1 (all at a final 
concentration o f 1 pM ), or complete AIM-V media only. In B) T cells were 
cocultured with PBMCs (1 X 10^) and oxidised SK-OV-3 cells (ratios o f SK-OV-3; T 
cells were 2:1 or 1:1 as shown). In C) T cells were cocultured in the absence o f 
PBM Cs with autologous ascites-derived tumour cells at various ratios as shown. The 
results show mean num ber o f spots per million T cells, from triplicate cultures. P  
value is significant if  < 0.05 (*) or < 0.01 (**) when comparing the test groups to the 
m edia control using Anova with Dunnetts post-hoc modification. In panel C asterisks 
are not shown but all colum ns are significantly different from media control {p <0.01 
or p  <0.05).
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F igure 4.8 Patients’ T cells stimulated with mature dendritic cells pulsed with 
oxidised SK-OV-3 cells demonstrate tumour-specificity. T cells from a HLA-A2^ 
patient (Patient 26) were co-cultured with autologous DCs preloaded with oxidised 
SK-OV-3 and matured with CD40 agonistic antibody (500 ng/ml) or MPL (100 
ng/ml). After a 2-week expansion, T cells were isolated and evaluated in IFN-y 
ELISPOT assays. In A) T cells were cocultured with PBMCs (1 x 10^) and HER- 
2/neu class 1 MHC (HLA-A2, E75) and HER-2/neu class II MHC peptides H369 and 
H776, or control peptide MART-1 (all at a final concentration o f IpM ), or complete 
AIM-V media only. In B) T cells were cocultured with PBMCs (1 x 10"*) and oxidised 
SK-OV-3 cells or oxidised MEL-11 (ratio o f 1 tumour cell: 1 T cells). In C) T cells 
were cocultured in the absence o f PBMCs with autologous ascites-derived tumour 
cells at various ratios as shown. P  value is significant if  < 0.05 (*) or < 0.01 (**) 
when comparing the test groups to the media control using Anova with Dunnetts post- 
hoc modification.
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Figure 4.9 Patients’ T cells stimulated with mature dendritic cells loaded with 
oxidised M EL-11 cells were immunogen-specific and did not recognise autologous 
ascites. T cells from a HLA-A2^ patient (Patient 26) were cocultured with autologous 
DCs that were loaded with oxidised melanoma cell and then matured with CD40 
agonistic antibody (500 ng/ml). After 2 weeks o f stimulation, T cells were isolated 
and assessed in IFN-y ELISPOT assays. In A) T cells were cocultured in the absence 
o f PBMCs with autologous ascites-derived tumour cells at various ratios as shown. In 
B) T cells were cocultured with PBMCs (1 x 10"^ ) and oxidised M EL-11 or oxidised 
SK-OV-3 cells (ratio o f 1 tum our cell: 1 T cell), or various peptides as detailed above. 
The results show mean number o f spots per million T cells, from triplicate cultures. P 
value is significant if  < 0.05 (*) or < 0.01 (**) when comparing the test groups to the 
media control using Anova with Dunnetts post-hoc modification.
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between cells o f different tissue origin, but can respond to tissue specific antigens 
expanded in vitro by DCs loaded with SK-OV-3 or MEL-11, respectively.
4.4. Discussion
In this study we have shown that the oxidised tumour line SK-OV-3 can induce DC- 
mediated stimulation o f antigen specific T cells isolated from ovarian cancer patients. 
I his priming, similar albeit lower to that seen previously in healthy controls, was a 
very consistent feature in all patients examined. The studies presented in chapter 3 
have already demonstrated that non-oxidised tumour cells either live or killed by non- 
oxidative means have very poor stimulatory activity in this system (Chiang et al., 
2006), and these antigens were therefore not explored further here.
The responses seen included both M UCl and HER-2/neu epitopes (even though the 
intrinsic tumours overexpressed one or both these antigens) and were elicited from 
both CD8^ and CD4^ T cells. T cell priming resulted from cross-presentation, since 
although SK-OV-3 is H LA -A 2’, HLA-A2^ DCs presenting oxidised SK-OV-3 cells 
stimulated T cell responses to HLA-A2 restricted peptides. Furthermore the T cells 
stimulated by cross-presentation o f  oxidised SK-OV-3 cells recognised autologous 
tum our cells isolated from ascites. Thus we propose that oxidised tumour cell lines 
may be very useful tools as potent generic immunogens for DC immunotherapy 
protocols that aim to generate T cells which can target autologous tumour.
The model sheds light on some key questions regarding the tolerance/effector balance, 
which are fundamental both to our understanding o f tumour immunology and to 
advancing realistic prospects for successful DC driven adoptive immunotherapy. An
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important objective o f the study was to demonstrate that presentation o f oxidised SK- 
OV-3 cells could breach in vivo tolerance to tumour i.e. that at least a proportion o f 
the T cells stimulated by DCs loaded with oxidised SK-OV-3 were in fact directed at 
bona fide “s e lf ’ tumour antigens to which the immune system had previously been 
exposed in vivo. Oxidised SK-OV-3 cells contain a variety o f non-self antigens, 
including both SK-OV-3 specific alloantigens (since this line is not syngeneic to the 
volunteers or the patients used in this study) and neo-epitopes formed by the oxidation 
process. Responses against bona fide tumour antigens were therefore documented in 
two ways.
Firstly, ovarian cancers often overexpress a variety o f TAAs, including the well 
characterised HER-2/neu (Hellstrom  et al., 2001) and M UCl (McGuckin et al., 1995) 
proteins, as confirmed in the responding individuals for this study (see Table 4.1). A 
panel o f peptides encoding known MHC class I and MHC class II peptides from these 
antigens were recognised by the oxidised SK-OV-3 in vitro stimulated T cells. This 
implies cross-presentation o f  SK-OV-3 proteins by the DCs via both class I and class 
II MHC, and establishes clearly that any prior exposure did not prevent the ability o f 
the SK-OV-3 loaded DCs to stimulate T cell responses to defined tumour antigen 
epitopes. Secondly, T cells stimulated by the oxidised SK-OV-3 cells recognised and 
responded strongly to autologous unmodified tumour cells, in the absence o f any DCs 
(Figs 4.7C and 4.8C). A lthough we have so far been able to collect matched PBMCs 
and ascites from only two individuals, these results suggested that at least in a 
proportion o f individuals, the oxidised SK-OV-3 share sufficient antigens with 
primary ovarian tumours to act as a generic antigen for DC immunotherapy.
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Furthermore, presentation o f  the oxidised cells by DCs is sufficient to break any 
existing tolerance to these prim ary ovarian cancer-related antigens at least in vitro.
Since the immune system is exposed to tumour antigens in large amounts in vivo 
(especially in the case o f  developm ent o f a large bulk of coelomic cavity metastatic 
tumour, associated with ascites), but this does not prevent growth o f tumour, it is clear 
that an efficient effector response does not occur in these patients. Many mechanisms 
may contribute to tum our escape, including failure to prime an effector response, 
active tolerance induction, and tumour evasion of effector mechanisms. We were 
unable to detect any cx vivo responses to tumour cells in patient PBMCs without prior 
in vitro stimulation (data not shown). Furthermore, the in vitro response stimulated by 
DCs loaded with oxidised SK-OV-3 cells was not amplified in patients versus 
volunteers. Both these observations suggest that if there is any effector T cell immune 
response stimulated in vivo, at least to M UCl and HER-2/neu then it is very limited.
A second important observation concerned the ability o f oxidised cellular antigen to 
activate tumour antigen specific T cells in a class II as well as a class I MHC 
restricted fashion. There is considerable evidence which suggests that CD8^ T cell 
responses primed in the absence o f  cognate help are impaired functionally in a variety 
o f  ways (Chamoto et al., 2006; Nishimura et al., 1999; Xiang et al., 2005; Zhang et 
al., 2007). Our findings indicate that the in vitro protocol adopted here can overcome 
these limitations. Both by using two peptide epitopes known to bind a broad range o f 
class II MHC molecules, and by direct depletion o f CD8^ T cells, we showed that 
class II MHC restricted CD4^ T cell responses are activated in these cultures. The 
response to the peptides is variable, and may reflect differential binding o f these
135
____________________________ C hapter 4: Oxidised SK-OV-3 as Cancer Vaccine to Break Tolerance
peptides to different HLA alleles (note that we did not HLA type the individual 
patients, other than to determ ine if they were HLA-A2 positive or negative). The 
overall magnitude o f the response is much smaller (at least in terms o f IFN-y 
producing cells per million T cells) than the class I response, a difference which is 
common for immune responses to many viral antigens (Maini et al., 2000). 
Furthermore, the response was more dependent on full maturation o f the DCs, perhaps 
reflecting the greater dependency o f the CD4^ T cell response on costimulatory 
activity by the APCs.
The third important observation in this study was the tumour specificity o f the 
response. Given that the effectiveness o f tumour therapy must depend on partial 
breaking o f self tolerance, a persistent concern has been that the immune system will 
recognise and kill cells other than the tumour and hence cause autoimmune disease. 
This concern is not simply hypothetical -  a recent immunotherapy trial demonstrated 
a close relationship between tum our response, and the development o f autoimmune 
pathology (Gogas et a l ,  2006). This problem is particularly acute with the use o f 
whole cell immunogens, since all cells share a large number of “common” proteins 
involved in housekeeping cellular metabolic functions, as well as expressing smaller 
numbers o f “tissue specific” proteins. A striking result from our study was that these 
“com m on” proteins do not appear to break tolerance in these experiments, since 
priming with oxidised ovarian-derived SK-OV-3 and with oxidised melanoma- 
derived M EL -11 cells generated T cells with minimum cross-reactivity with each 
others priming antigen. O f course the risk remains of some cross reactivity with 
normal (untransform ed) epithelial tissue, such as breast epithelium, which shares 
several TAAs, or normal peritoneum. Further studies will be required to define the
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exact repertoire o f the response, and the potential danger o f excess autoimmune 
reactions.
This study leaves some important questions for future study. The molecular 
mechanism by which oxidation enhances immunity, and why this can lead to a break 
in tolerance remains unknown and is the subject o f detailed examination in our 
laboratory. Preliminary results, however, indicate that alterations in Treg activation do 
not play the major role. Furthermore, it is very likely that the responses generated 
could be amplified further, for example by blocking negative regulatory interactions 
between DCs and T cells, such as those mediated by CTLA-4 (Hodi et al., 2003; 
Ribas et al., 2005) or PD -Ll (Iwai et al., 2002; Nomi et al., 2007). Nevertheless, the 
results presented here suggest that oxidised tumour cells will provide an excellent and 
novel starting option as a source o f  generic antigens for use in DC-based 
immunotherapy protocols. We are now further optimising antigen loading and DC 
maturation in ovarian cancer patients with recurrent disease, as the combination o f 
oxidised tumour and DCs could provide a successful adjuvant therapeutic strategy for 
these patients.
4.5. Conclusions
• DCs derived from ovarian cancer patients that were preloaded with HOCl- 
oxidised SK-OV-3 were as capable as DCs from healthy volunteers in stimulating 
ovarian tumour-specific T cell responses.
• DCs derived from ovarian cancer patients were capable o f maturation in the 
presence o f agonistic CD40 antibody and MPL. These mature DCs were superior
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to immature DCs, and prim ed stronger CD4^ and CD8^ tumour-specific T cell 
responses.
Ovarian cancer patients T cells were not tolerant to autologous DCs pulsed with 
HOCl-oxidised SK-OV-3, and demonstrated tumour-specificity. These T cells 
efficiently recognised the immunogens (i.e. SK-OV-3) and also the tumour 
antigens, HER-2/neu and M U Cl which were overexpressed by SK-OV-3 cells.
Most importantly, T cells stimulated with DCs loaded with oxidised SK-OV-3 
directly recognised autologous ascites (i.e. in the absence o f APCs).
These T cells were tissue and tumour-specific. T cells primed with DCs pulsed 
with oxidised MEL-11 cells only recognised oxidised MEL-11 and the MART-1 
melanoma im m unodom inant peptide and not the autologous ascites. Similarly, T 
cells primed with oxidised SK-OV-3 cells recognised oxidised SK-OV-3 but not 
oxidised M EL-11 cells.
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5.1. Introduction
In chapter 3, a robust human in vitro cell-culture system was developed to examine 
the use o f HOCl-oxidised allogenic ovarian carcicnoma cell line, SK-OV-3, as a 
potent source o f immunogens for monocyte-derived DCs to prime autologous tumour- 
specific T cells. T cells recognising specific epitopes of HER-2/neu and M UCl (both 
being overexpressed on SK-OV-3 cell line and ovarian carcinomas), and to oxidised 
SK-OV-3 were generated. In chapter 4, the study was further extended in the context 
o f ovarian cancer patients in remission to determine whether these patients’ T cells 
were tolerant to stimulation with autologous DCs preloaded with oxidised SK-OV-3. 
Strong T cell responses were elicited to HER-2/neu and M U C l, and they were further 
enhanced with the use o f  m ature DCs. The T cells were also efficient in the direct 
recognition o f autologous ascites, suggesting that oxidised whole cell antigens could 
be used as potential cancer vaccines. However, this approach could only realistically 
be tested in vitro.
In this chapter, a well-characterised mouse B16.F10 melanoma model was selected 
for preliminary studies o f the immunogenicity o f DC pulsed with oxidised tumour 
cells as cancer vaccines in vivo. There are several advantages o f this tumour model. 
First, the B16.F10 m elanom a alone are poorly immunogenic due to their low basal 
expression o f MHC Class I, B7-1 and ICAM-1 important for CTL recognition 
(Casorati et al., 1995; Dezfouli et al., 2003; Itoh et a l ,  1994; Nishio et a l ,  1996), and 
this characteristic makes them ideal for studying HOCl-oxidation and enhancement o f 
tumour immunogenicity. Second, the B16.F10 melanoma overexpresses several 
defined TAAs, including TRP-1 and 2, gp-100 and M ART-1. MHC class I 
immunodominant epitopes o f these TAAs, in particular the TRP-2 (Bloom et a l .
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1997) have been cloned and well-characterised by several groups, and can be used for 
evaluating tumour-specific responses after cancer vaccine administration. Third, this 
tumour model is a good model to explore peripheral tolerance and overcoming such 
tolerance with DC-based vaccines. The differentiation antigen TRP-2, which is 
expressed by both normal melanocytes and melanoma for melanin synthesis, is poorly 
immunogenic (Tang et al., 2007), most probably because o f the involvement of 
peripheral tolerance. Thus a demonstration o f the induction o f anti-TRP-2 responses 
by the DC-based vaccine would suggest that peripheral tolerance has been overcome. 
The results o f  this autologous tum our mouse model described would provide insights 
into the parameters that govern successful DC vaccines and would facilitate the 
optimisation o f these vaccines in tum our immunotherapy.
5.2. Objectives
• To determine the TRP-2 expression on B16.F10 melanoma and their sensitivity to 
HOCl-oxidation and killing.
• To compare and evaluate the different routes of vaccination (i.e. intravenous, 
intraperitoneal and subcutaneous) with DCs preloaded with oxidised B16.F10 
m elanoma cells.
•  To determine whether HOCl-oxidised B16.F10 cells are superior immunogens for 
DCs to prime specific T cells than heat-killed or HCl-killed B16.F10 cells.
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• To compare and evaluate the immunogenicity of direct immunisation o f mice with 
oxidised B16.F10 melanom a cells in the absence o f DCs to immunisation with 
DCs preloaded with oxidised B16.F10 cells.
5.3. Results
5.3.1. B16.F10 m elanom a overexpress tyrosinase-related protein 2 
Fhe expression o f TRP-2 was previously reported (Bloom et al., 1997; Tsukamoto et 
al., 1992) and confirmed by western blot. Antibodies to TRP-2 identified a single 
band with molecular w eight o f approximately 75 kDa (Fig. 5.1). Its expression was 
absent in the CHO cell line.
5.3.2. HOCl induces necrosis in B16.F10 melanoma 
The susceptibility o f  B16.F10 cells to HOCl-oxidation killing was measured by PI 
staining and shown in Fig. 5.2. Treatment o f B16.F10 cells with increasing 
concentrations o f HOCl resulted in a dose dependent increase in the % of 
unpermeabilised cells which took up PI (gate M l, Fig. 5.2A, quantified in Fig. 5.2B). 
Viable cells are impermeable to PI, and the % PI positive cells gave a measure o f 
dead cells. More than 99% o f  cell death was consistently observed at 60 pM  HOCl 
and above, and this concentration was selected for use in all further experiments. 
Cellular necrosis was also determined by measuring the DNA content with PI 
staining. It clearly showed the presence o f the Gi and G2 peaks and no sub-Go staining 
which corresponded to fragmented DNA from cells undergoing apoptosis.
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Figure 5.1 Expression o f  TRP-2 tumour antigens on B16.F10 melanoma. 1 x 10 
B16.F10 melanoma or CHO cells were lysed in sample buffer, resolved on 12.5% 
SDS-PAGE electrophoresis, and transferred to nitrocellulose membranes as described 
in Materials and M ethods. TRP-2 expression was detected by the polyclonal anti- 
PEP8 antibody that specifically recognises TRP-2 in melanocytes. It was detected as a 
single band o f approximately 75 kDa. CHO cells were negative for TRP-2 expression. 
Data are representative o f  3 independent experiments.
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Figure 5.2 Dose dependent necrosis o f B16.F10 melanoma treated with HOCl. A and
B) B16.F10 melanom a cells were incubated with different concentrations o f HOCl as 
indicated for 1 h at 37°C. Cells were washed twice and stained with PI as described in 
Materials and M ethods either without (non-perm, A top row) or after permeabilisation 
with 70% ethanol (perm, A bottom row). The percentage o f highly PI positive cells 
(M l gate) corresponded to percentage of dead cells was plotted against HOCl 
concentration in B. D ata are representative of 5 independent experiments.
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5.3.3. Phenotypic profile o f mouse bone marrow-derived dendritic cells 
To evaluate the CD80, CD86 and MHC Class II expression on immature bone 
marrow-derived DCs, and to determine whether they could respond and mature in the 
presence o f LPS and MPL, the DCs were treated with low dose (100 ng/ml) or high 
dose (1000 ng/ml) o f the maturation stimuli. IFN-y is a strong stimulator of 
marcophages and DCs, and has been shown to induce upregulation o f maturation 
markers on DCs (He et al., 2007). IFN signaling is controlled via the promoters of 
IFN-inducible genes (Pestka et al., 2004), and it has been demonstrated recently that 
the interferon-regulatory factor (IRF)-8/lFN consensus sequence-binding protein is 
involved in TLR signaling and contributes to the cross-talk between TLR and IFN-y 
signaling pathways (Scharton-Kersten et al., 1997). Hence DC maturation could be 
augmented in the presence o f TLR agonist(s) stimulation. For this purpose, rat 
recombinant IFN-y (100 U/ml) was added at the same time as the stimuli and 
incubated for 24 h at 37°C, 5% CO 2 . Fig. 5.3A showed the typical dot-plot profiles o f 
isotype control, PE -labelled-C D lIc DCs, and FITC-labelled MHC Class II DCs. In 
Fig. 5.3B, representative fluorescence histograms showed upregulation o f DC 
maturation markers and costimulatory molecules -  CD80, ICAM and MHC Class II -  
in both low and high doses o f LPS or MPL plus IFN-y. The median fluorescence 
values and the % o f DCs in the M l gate are shown in the top right com er o f the 
histograms. DCs treated with IFN-y showed a small upregulation o f these maturation 
markers, while the expression o f these markers was low on untreated DCs. The CD80 
and ICAM expression were further enhanced, although slightly, when treated with 
LPS or MPL (both low and high doses) in addition to IFN-y. Higher percentage of 
these DCs compared to that o f untreated DCs also appeared in the M l gate as showed 
in the figure. For MHC Class II expression, it was upregulated in the presence o f LPS
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or MPL plus IFN-y when compared to that o f untreated DCs. However, the use of 
IFN-y in addition to LPS or MPL did not cause further upregulations on the DCs 
compared to IFN-y treatm ent alone. Surprisingly, the level of CD80, ICAM and MHC 
Class II expression on these LPS/ MPL and IFN-y treated DCs were low compared to 
those reported in the literature (Escors et al., 2008; Veeraswamy et al., 2003; W inzler 
et al., 1997). One highly possible reason was that the LPS and MPL that were used in 
this experiment had lost their usual potency. Another possible reason might be that a 
longer LPS, MPL and IFN-y treatment time (e.g. 48 h instead o f 24 h used here) 
and/or a high dose o f  the stimulus was required. Hence further optimistion o f this 
maturation protocol is necessary. The CD86 expression on these treated DCs was not 
shown here because its level o f upregulation was very small even after treatment with 
LPS or MPL plus IFN-y, in comparison to untreated DCs and also to markers such as 
CD80, ICAM and M HC Class II. This effect has also been demonstrated by other 
groups (M. Collins, personal communications).
5.3.4. In vivo adm inistration o f DCs loaded with HOCl-oxidised B16.F10 
tum our cells prim ed anti-tum our responses in C57BL/6 mice
To evaluate the im m unogenicity o f  bone marrow-derived DCs loaded with oxidised 
B I6.F10 cells as cancer vaccines, 6-8 weeks old C57BL/6 mice were immunised via 
the tail vein with day 6 DCs loaded with the oxidised tumour cells (each mouse 
received 50 pi o f HBSS containing 1 x 1 0 ^  DCs that had been preloaded with 1 x 10  ^
oxidised B I6 .F I0). 60 pM  HOCl was selected for treating the tumour cells because it 
consistently induced cellular necrosis in more than 99% o f the B16.F10 cells. Also in 
chapters 3 and 4, this concentration had been used in the human in vitro studies and 
found to induce robust anti-tum our responses. Two sets o f negative controls were set
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cultured in complete IM DM  m edia but no tumour cells. In preliminary studies, we 
isolated the spleen cells from the mice after two weeks o f in vivo priming (i.e. 
vaccination) and assessed their responses directly in an IFN-y ELISPOT assay. 
However, high background responses were seen with the spleen cells that were taken 
from the mice im m unised with DCs loaded with oxidised B16.FI0 cells or TRP-2 
peptides, and subsequently cultured with complete RPMI media only in the 
ELISPOT. A possible reason for this high background could be due to the presence of 
residual oxidised B16.F10 cells on the APCs. Such APCs in the spleen cell population 
could present the residual antigens to specific T cells, leading to high IFN-y 
production without the need o f adding exogenous antigens in the assay. No such high 
background responses were seen in the ELISPOT with spleen cells taken from mice 
immunised with DCs and no tum our cells or with HBSS alone. To increase 
specificity, the spleen cells were cultured in vitro for a further week, either in the 
presence o f additional oxidised B I6 .F I0  or with complete RPMI media only. Viable 
cells were then collected, and tested in the IFN-y ELISPOT for their responses to 
oxidised B I6 .F I0  cells, TRP-2 H-2K^ restricted peptide, or complete RPMI. The 
general protocol is showed in Fig. 5.4.
In Fig. 5.5A (black bars), spleen cells from mice immunised with DCs pulsed with 
oxidised B16.F10 exhibited strong responses to the oxidised B16.FI0 (>180 spots per 
million spleen cells) and TRP-2 peptides (> I50  spots per million spleen cells) in the 
ELISpot assay after I week o f  in vitro antigen restimulation and expansion. This 
suggested that antigen-specific T cells prim ing by the DC-oxidised B16.FI0 priming 
had occurred in vivo. Furtherm ore the high background IFN-y secretion by these 
spleen cells as previously m entioned was not seen when they were restimulated and
147
_________ Chapter 5: O ptim isation o f Anti-Tum our Responses in an Autologous M elanoma Model
expanded for a further week with RPMI media alone (white bars; <50 spots per 
million spleen cells). This suggested that antigen-specific T cells in the spleen 
population died due to the lack o f appropriate stimulation by presenting APCs. In this 
same population o f antigen-stim ulated T cells, high IFN-y secretion was seen in the 
media alone group in ELISPOT. This high IFN-y secretion observed in the former 
could be explained by the presence o f APCs that were being kept alive by the 1 week 
antigen stimulation and presenting residual oxidised B16.F10 cells on their cell 
surface to antigen-specific T cells, leading to high IFN-y production in the assay.
It was noted that the tumour-specific responses in the ELISPOT for this mouse 
melanoma model were considerably lower (about 10-fold lower) to those obtained in 
the studies involving healthy volunteers and ovarian cancer patients. Though oxidised 
tumour cells were used in these two studies, they were different cell lines obtained 
from two different species and thus difficult to directly compare. However, the anti­
tumour responses might be improved by increasing the ratio o f tumour cells to DCs 
(e.g. four tumour cells to one DC) to maximise the chance o f antigen uptake by the 
DCs. Very low responses were observed from the spleen cells o f mice immunised 
with either DC pulsed w ith complete IMDM media (Fig. 5.SB, black bars) or with 
HBSS only (Fig. 5.5C, black bars). Similar poor results were obtained when the 
spleen cells were restim ulated with RPM I media alone in all the groups (Fig. 5.SB, C; 
white bars). To determine the precursor frequency o f melanoma-specific T cells in the 
naïve spleen o f CS7BL/6 mice, spleen cells were isolated and directly tested in the 
ELISPOT for their IFN-y production (Fig. S.6). No IFN-y responses were detected to 
oxidised B16.F10, TRP-2 peptides or to the media.
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Figure 5.3 Bone marrow-derived DCs matured in the presence of LPS, MPL and 
IFN-y. Day 6 bone marrow-derived DCs were treated for 24 h with IFN-y (100 lU/ml) 
together with a low dose LPS/MPL (lOOng/ml), or high dose LPS/MPL (1000 ng/ml). 
For negative control, DCs were treated with complete IMDM media alone (i.e. 
untreated DCs). DC cultures were also set up to evaluate the effect of IFN-y alone. 
After treatment, DCs were double-stained with PE-conjugated C Dl l c  and FITC- 
conjugated antibodies to CD80, ICAM or MHC Class II as described in Materials and 
Methods. A) Representative dot-plots of CDl l c ,  MHC Class II DCs and FITC- 
isotype control antibodies staining. B) One representative frequency histogram of 
fluorescence (FLl channel) in the absence of stimulus, or in the presence LPS or MPL 
plus IFN-y, or IFN-y alone. The number in the right hand top comer of each histogram 
shows the MFI o f the total population (channel number), while the figures in brackets 
showed the % o f cells in the M l gate. The black filled profile shows negative control 
staining with control FITC-conjugated IgG, the black line profile shows different 
treatement, while the grey line profile shows untreated DCs for comparison.
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Figure 5.4 A schematic diagram showing the experimental approach o f in vivo 
administration o f bone marrow-derived DCs pulsed with oxidised B16.F10 to 
C57BL/6 mice and evaluation o f their IFN-y production in ELISPOT following 1 
week o f restimulation in the presence or absence o f oxidised B16.F10. Mice were 
immunised via the intravenous, intraperitoneal or subcutaneous route in the tail vein 
with 1 x 1 0 *  DCs pulsed with equal number o f oxidised B16.F10 (ratio o f DCs to 
tumour cells was 1:1) per mouse. Two weeks later, the spleens were isolated and 
divided into 2 cultures; one was restimulated with oxidised B16.F10 (ratio o f 1 
tumour cell to 10 spleen cells) and the other restimulated with complete RPMI 
without antigen. IFN-y production was measured by testing the primed spleen cells (1 
X 10* cells/well) responses to fresh APCs (1 x 10  ^ cells/well) with oxidised B16.F10 
(1 X 10  ^ cells/well), TRP-2 peptides (final o f 1 pM) or in complete RMPI only in the 
ELISPOT.
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Figure 5.5 In vivo administration o f bone marrow-derived DCs pulsed with oxidised 
B16.F10 primed a potent anti-tumour response in C57BL/6 mice. Mice were 
immunised in the tail vein with A and B) 1x10^ DCs pulsed with equal number of 
oxidised B16.F 10 (ratio =1: 1)  per mouse, C) 1x10^ DCs pulsed with complete IMDM 
media, or D) HBSS only. After 2 weeks, the spleens were isolated and divided into 2 
cultures: restimulated with antigens (i.e, oxidised B16.F10 or TRP-2 peptides) or with 
complete RPMI only. IFN-y production was measured by ELISPOT. The results are 
the means ± standard error o f the mean of at least six independent experiments (i.e. 
spleen cells from at least 6 different mice) per group. The asterisk indicates those 
columns differing significantly (**, P<0.001, paired Student t test) from the RPMI 
media control. The background secretion of IFN-y by spleen cells was low in all the 
groups when they were restimulated with RPMI media alone (white bars).
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Figure 5.6 Naïve spleen cells from C57BL/6 mice did not response to oxidised 
B16.F10 or to TRP-2 peptides. Naïve spleen cells were isolated from C57BL/6 mice 
(i.e. without prior adm inistration with DCs pulsed with oxidised B16.F10 cells or with 
TRP-2 peptides), and directly tested in the ELISPOT for their IFN-y production. The 
results are the means ± standard error o f the mean o f three independent experiments 
(i.e. spleen cells from 3 different mice).
152
_________ Chapter 5: Optimisation of Anti-Tumour Responses in an Autologous Melanoma Model
5.3.5. Intravenous route o f administration o f DC preloaded with oxidised B16 
is superior to intraperitoneal and subcubtaneous routes for the induction of tumour- 
specific responses
DC presumably must home to secondary lymphoid organs to prime T cell responses, 
and the route o f administration of such antigen-loaded DCs in vivo might significantly 
affect the overall success o f the vaccines. Several studies showed that differential 
immune responses are induced using different routes o f immunisation in both mice 
and humans (Eggert et al., 1999; Fong et al., 2001). In the case o f mice, subcutaneous 
and intraperitoneal immunisations but not intravenous immunisation had primed 
potent anti-tumour responses that led to B16 tumour rejection in vivo (Eggert et al., 
1999). To determine the best route o f immunisation o f mice with DCs preloaded with 
oxidised B16.F10, we immunised the mice with antigen-loaded DCs via three 
different routes, intravenous (IV), subcutaneous (SC) or intraperitoneal (IP) and 
evaluated spleen cells anti-tumour responses in the IFN-y ELISPOT after 2 weeks of 
vaccination as detailed in Materials and Methods.
As shown in Fig. 5.7, the IV route o f DC vaccination was the most potent in inducing 
tumour-specific T cells that recognised the oxidised B16.F10 and TRP-2 derived 
peptides (Figs. 5.7A and B first columns, • )  as compared to SC or IP routes after a 
further week of restimulation and expansion with oxidised B16.F10. An average of 
175 spots and 150 spots per million spleen cells responding to the oxidised B16.F10 
and TRP-2 peptides, respectively, were observed with the IV route. Contrary to the 
findings by other groups, the SC route o f vaccination gave the poorest anti-tumour 
responses (an average o f 50 spots per million spleen cells observed for oxidised 
B16.F10, and 75 spots per million per spleen cells recognising TRP-2 peptides) [Figs.
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5.7A and B third columns, •] . It was noted that results obtained from the SC route of 
vaccination were difficult to replicate and inconsistent. Although the IP route induced 
responses to oxidised 816 and TRP-2 peptides (Figs. 5.7A and B middle columns, •), 
the magnitude o f the responses was smaller compared to that o f I.V route. Very low 
responses (approximately 35 spots per million spleen cells) were seen from spleen 
cells restimulated with media only across all vaccination routes (Fig. 5.7, ■).
5.3.6. Oxidised B16.F10 and not heat-killed or hydrochloric acid killed 
B16.F10 are potent immunogens for priming anti-melanoma responses 
In previous study, it was showed that HOCl-oxidised tumour cells had enhanced 
immunogenicity and were more potent as a source o f antigen for human DCs to prime 
anti-tumour T cells. It was found that the enhanced immune response seen was due 
specifically to oxidation by HOCl and not simply a result o f cell necrosis (Fig. 3.4). In 
this current study, necrosis in B16.F10 cells was induced via HOCl oxidation, a brief 
exposure to acid (1 M HCl, 60 sec) or with heat treatment (56°C, 30 min). Under 
these conditions, the B16.F10 cells retained cellular integrity but were >99% dead by 
necrosis (confirmed by trypan blue and PI staining, data not shown). Then we loaded 
the DCs with one o f these necrotic B16.F10 cells and immunised the mice via the IV 
route (it was selected as it gave the best anti-tumour responses compared to SC and IP 
routes as determined previously). The results confirmed our previous findings; the 
spleen cells that were primed using DC loaded with oxidised B16.F10 gave strong 
tumour-specific responses (Fig. 5.8A) whilst DC loaded with either acid-killed (Fig. 
5.SB) or heat-killed (Fig. 5.SC) tumour cells in vivo failed to prime a significant 
immune response to any antigen tested in the IFN-y ELISPOT. It was again noted that 
the population o f antigen-stimulated T cells exhibited high IFN-y secretion in the
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Figure 5.7 Intravenous adm inistration o f DCs loaded with oxidised B16.F10 primed a 
more potent tumour-specific response than immunisation via the intraperitoneal or 
subcutaneous route. M ice were immunised intraveously (IV) in the tail vein, 
intraperitoneally (IP) in the right peritoneum, or subcutaneously (SC) at the right 
flank with 1 x 1 0 ^  DCs pulsed with equal number o f oxidised B16.F10 (ratio =1 : 1)  
per mouse. After 2 weeks, spleen cells were isolated and divided into 2 cultures; one 
was restimulated with oxidised BI 6 . FI 0  and the other with complete RPMI. IFN-y 
production was measured by ELISPOT. Each point represents the average o f triplicate 
cultures o f a different mouse. The line shows the median response. The responses of 
spleen cells restimulated with oxidised B16.F10 ( • )  is significantly greater than the 
RPMI media control (■) in the same IV group (**, P < 0.01; Mann-Whitney). The 
responses o f the spleen cells restim ulated with oxidised B16.F10 ( • ,  first columns) in 
the IV group were also significantly greater than that o f spleen cells restimulated with 
oxidised B16.F10 in the IP ( • ,  second columns) and SC groups (#, first columns) [**, 
P < 0.01; M ann-Whitney]. Background IFN-y secretion o f spleen cells restimulated 
with RPMI media alone was low (■).
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Figure 5.8 DCs loaded with HOCl-oxidised B16.F10 cells, but not heat-killed or 
HCl-killed B16.F10, or IMDM media stimulated T cells specific to both B16.F10 
melanoma cells and epitope o f TRP-2. Mice were immunised via the IV route in the 
tail vein with DCs pulsed with B16.F10 killed with A) HOCl-oxidation, B) heat, or C) 
HCl (ratio o f DC to tumour cell = 1:1). The spleens were isolated 2 weeks later and 
divided into 2 cultures; one was restimulated with HOCl-oxidised B16.F10 and the 
other restimulated with complete RPMI without antigen. IFN-y production was 
measured by ELISPOT. The results are the means ± standard error o f the mean for at 
least three independent experiments (i.e. spleen cells from three different mice). The 
asterisk indicates those columns differing significantly (**, P<0.001) from the RPMI 
media control (paired Student t test). The background secretion o f IFN-y by spleen 
cells was low in all the groups when they were restimulated with RPMI media alone 
(white bars).
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F igure 5.9 DCs loaded with oxidised BI6.F10, but not oxidised B16.F10 in the 
absence o f DCs or DC alone stimulated T cells specific to both B16.F10 cells and 
epitope o f TRP-2. Mice were immunised via the IV route in the tail vein with A) DCs 
pulsed with oxidised B16.F 10, B) oxidised B16.FI0 alone, or C) DC pulsed with 
IMDM media. The spleens were isolated 2 weeks later and divided into 2 cultures; 
one was restimulated with oxidised B16.F10 and the other with complete RPMI 
without antigen. IFN-y production o f the spleen cells was measured by ELISPOT. The 
results are the means ± standard error o f  the mean for at least four independent 
experiments (i.e. spleen cells from four different mice). The asterisk indicates those 
columns differing significantly (**, P<0.001) from the RPMI media controls (paired 
Student t test). The background secretion o f IFN-y by spleen cells was low in all the 
groups when they were restim ulated with RPMI media alone (white bars).
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media alone group in ELISPOT. This could again be explained by the presence o f 
APCs that were being kept alive by the 1 week antigen stimulation and presenting 
residual oxidised B16.F10 cells on their cell surface to antigen-specific T cells, 
casuing high IFN-y production in the ELISPOT.
5.3.7. DC is required for the in vivo processing and presentation o f B16 
oxidised tumour cells in vivo
A further analysis was carried out to investigate whether DCs were required for the 
processing and presentation o f oxidised B16.F10 in vivo, or the oxidised B16.F10 
could be taken up by the migrating APCs in the blood stream and be processed and 
presented to T cells, or accumulated in the lymphoid organs as a source o f antigens 
for APCs. As it had been determined previously that IV route o f immunisation gave 
the best anti-tumour responses, it was selected as the route o f immunisation in this set 
o f experiments. The mice were immunised via the IV route with DCs preloaded with 
oxidised B16.F10 or with oxidised B16.F10 only (i.e. no DCs) for 2 weeks, then their 
spleen cells were isolated and restimulated with oxidised B16.F10 or with RPMI 
media only. As a negative control, some mice were immunised with DCs that were 
pulsed with IMDM media only. Strong anti-tumour responses were observed in mice 
immunised with DCs preloaded with oxidised B16.F10 (Fig. 5.9A, black bars) and not 
with oxidised B16.F10 alone (Fig. 5.9B, black bars) or with DCs plused with 
complete IMDM media (Fig. 5.9C, black bars). Low background responses were 
seemed across all groups when the spleen cells were re stimulated with RPMI media 
only (Fig. 5.9, white bars). This confirmed that DCs were required for the processing 
and presentation o f oxidised B16.F10 in vivo. The absence o f anti-tumour immunity 
observed with oxidised B16.F10 only immunisation might be that the oxidised tumour
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cells were rapidly cleared from bloodstream after IV injection before reaching the 
lymphoid organs or other APCs.
5.4. Discussion
Results presented in chapters 3 and 4 strongly suggested that oxidised SK-OV-3 
ovarian tumour cells were potent immunogens for DCs in priming anti-tumour T cell 
responses, and could be used as a therapeutic approach in treating ovarian cancer 
patients in remission. The well-characterised B16.F10 melanoma C57BL/6 mouse 
model was being selected for the preliminary study o f the immunogenicity o f this DC- 
based immunotherapy in vivo. This tumour mouse model has been widely studied by 
several groups. The B16.F10 melanoma overexpresses the TRP-2 tumour antigen of 
which a MHC Class I epitope has been identified, and could help to facilitate the 
analysis o f anti-tumour responses following in vivo priming.
To establish the potential o f B16.F10 killed with HOCl-oxidation as immunogens for 
DCs, C57BL/6 mice were each immunised via the tail vein with 1x10^  bone-marrow 
derived DCs previously loaded with 1 x 1 0 ^  HOCl-oxidised B16.F10 cells. It was 
observed that the DC vaccines were well-tolerated and no toxicity was observed in the 
mice immediately or 2 weeks after vaccination. It was also noted that no obvious 
abnormality was seen in the immunised animals, as dissection o f the animals 2 weeks 
after vaccination to isolate the spleen cells for restimulation revealed perfectly normal 
spleen and other internal organs. There was also no change or depigmentation o f their 
coat-color, which is a sign o f autoimmunity. However a detailed analysis o f 
autoimmunity, such as measuring auto-antibodies, would be required to rule out this 
possibility. In initial IFN-y ELISPOT assays, the spleen cells from the immnunised
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mice were evaluated without a further week o f restimulation with antigens (i.e. 
oxidised B16.F10 or TRP-2) or complete RPMI media only. High background 
responses were seen in the spleen cells in the absence o f antigens (i.e. media only) in 
the ELISPOT. This might be due to APCs presenting residual oxidised B16.F10 cells 
to antigen-specific T cells in the spleen cell population. To increase the assay 
specificity, the spleen cells were divided into 2 cultures with one being restimulated 
with oxidised B16.F10 cells or TRP-2, and the other with complete RPMI media 
without antigen. After 1 week o f in vitro restimulation and expansion, the spleen cells 
from mice immunised with DCs preloaded with oxidised B16.F10 developed immune 
responses to the TRP-2 derived peptides and to the oxidised B16.F10 (Fig. 5.5A). No 
responses were seen in the spleen cells o f the same animal when they were 
restimulated with complete RPMI media alone as the antigen-specific T cells died in 
culture without receiving appropriate antigen stimulation.
To further confirm that the responses were indeed specific to B16.F10 and to TRP-2 
which was highly expressed on these cells, parallel experiments were set up to 
immunise mice with the DC vaccines. After 2 weeks, the spleen cells were isolated 
and restimulated with TRP-2 peptide or with complete RPMI media only (Fig. 5.5B). 
Anti-tumour responses were seen in spleen cells restimulated with TRP-2 peptide and 
not with media alone. These results were being further supported when no IFN-y 
production was seen in mice immunised with HBSS only or DC pulsed with IMDM 
media (Fig. 5.5C, D). In addition, naïve spleen cells from C57BL/6 mice were 
isolated and tested in IFN-y ELISPOT and found not to response to either oxidised 
B16.F10 or TRP-2 peptides (Fig. 5.6).
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In line with the results first shown in chapter 3, the TRP-2 epitope was being cross­
presented by the DCs to T cells. It was observed that the tumour-specific responses in 
the ELISPOT in the C57BL/6 melanoma model were considerably lower (about 10- 
fold lower) to those obtained in the studies involving healthy volunteers and ovarian 
cancer patients. The results from these studies were difficult for direct comparison as 
two very different tumour cell lines derived from two different species were used. 
However, the anti-tumour responses in this mouse melanoma model might be 
improved by increasing the ratio o f tumour cells to DCs (e.g. four tumour cells to one 
DC) to maximise the chance o f antigen uptake by the DCs and enhancing their 
antigen presentation capacity by stimulation with DC maturation stimuli such as MPL 
or CpG. Other B16.F10 derived TAA peptides such as TRP-1 and M AGE would be 
useful in the IFN-y ELISPOT analysis to define the breadth o f the anti-tumour 
responses. The results nevertheless established the potential use o f oxidised B16.F10 
in DC-based immunotherapy o f  melanoma in C57BL/6 mice.
It has been shown that the route o f administration o f antigen-loaded DCs in vivo 
might significantly affect the overall success of the vaccines, and differential immune 
responses were being induced via different routes of immunisation in both mice and 
humans (Eggert et al., 1999; Fong et a l ,  2001). One study clearly demonstrated that 
immunisation via the subcutaneous and intraperitoneal routes and not intravenous 
route primed potent anti-tumour responses that led to B16 tumour rejection in vivo 
(Eggert et al., 1999). It showed that the TRP-2 peptide-loaded DCs injected 
subcutaneously accumulated preferentially in the lymph nodes and to lesser extend in 
the spleen. In the same study, similar observation was observed with intraperitoneal 
immunisation. However, this study demonstrated that the intravenous route o f
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immunisation was superior to that o f subcutaneous and intraperitoneal. One reason 
could be that the different antigen used (i.e. whole oxidised B16.F10 versus TRP-2 
peptide in the other study) might influence the DCs processing and presentation o f the 
antigen, and the subsequent activation o f the T cells. The dose o f the antigens and 
variation o f the vaccination protocols, which are both very difficult to compare, could 
also affect the outcome o f the immune response. In chapter 3, HOCl-oxidised tumour 
cells and not tumour cells made necrotic by heat or HCl were able to prime 
therapeutic anti-tumour responses in vitro. This was further validated in vivo. 
C57BL/6 mice were immunised with DC pulsed with one o f the following: oxidised 
B16.F10, heat-killed B16.F10 or HCl-killed B16.F10. Spleen cells were isolated after 
2 weeks o f in vivo prim ing and restimulated in culture with the relevant antigen (i.e. 
oxidised, heat-killed or HCl-killed B16.F10) or with complete RPMI media only. 
Strong immune responses were observed in the spleen cells o f mice receiving DCs 
pulsed with oxidised B16.F10 (Fig. 5.8). This therefore confirmed that oxidised 
B16.F10 cells, and not heat-killed or HCl-killed B16.F10 cells, were potent 
immunogens for DCs. The mechanism of HOCl enhancement was not pursued in this 
study. However, it was showed that oxidised but not live SK-OV-3 ovarian carcinoma 
cells were readily taken up by human monocyte-derived DCs (Fig. 3.3). It could be 
hypothesised that HOCl-treatment o f tumour cells led to enhanced processing and 
presentation o f the immunogenic peptides by DCs (Carrasco-Marin et al., 1998). Hsp 
70 might act as a chaperone for the unfolded polypeptides to help them regain a 
functional structure or to direct them to a degradation pathway (Feder and Hofmann, 
1999). The scavenger receptors on DCs (e.g. LOX-1 and CD36) that take up oxidised 
antigens might also be involved in the uptake o f the oxidised tumour cells (Delneste et 
al., 2002; Marsche et al., 2001; Marsche et a l ,  2003). The precise nature o f the
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chemical reactions that are responsible is the subject o f intensive investigation in this 
laboratory.
An attractive alternative to immunisation with antigen preloaded DC was to directly 
inject the antigen (in the absence of DC) into the host. This would eliminate the need 
for in vitro culture o f the DC before administration. It was showed in Fig. 5.9 that 
oxidised B16.F10 cells alone were only able to elicit poor anti-tumour responses, and 
strong responses were seen when DCs were used. One possible reason for the poor 
tumour-immunity observed was that the oxidised B16.F10 were rapidly cleared from 
the blood stream after IV vaccination and this did not allow the accumulation of the 
oxidised antigens in the spleen cells and/or lymph nodes to be taken up by the resident 
DCs. On the other hand, DCs loaded with oxidised antigens would migrate and 
efficiently present the oxidised B16.F10 cells to the T cells in spleen and lymph 
nodes. Oxidised BI6.F10 cells given alone via the subcutaneous route also induced a 
very poor anti-tumour response (data not shown). It would be interesting to determine 
whether multiple doses o f the oxidised B16.F10 cells given alone at different time 
points in the vaccination regime would give a better immune response.
In this study, it was demonstrated that oxidised B16.FI0 melanoma were potent 
immunogens for DCs to induce anti-tumour T cell responses. The results presented 
here and in chapters 3 and 4 strongly suggested that such DC vaccines could be useful 
in the treatment o f cancer. Due to time constraint, this preliminary study is far from 
completed. Further optimisation o f the vaccination protocol in vivo is needed -  e.g. 
the dose and frequency o f the administration o f the DC vaccines, the breadth and 
duration o f the elicited immune responses, and whether the primed T cells could
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directly recognise and lyse non-oxidised autologous tumour cells. Results in chapter 4 
strongly suggested that mature DCs were superior to immature DCs in priming an 
anti-tumour response. Therefore it would be o f great interest to compare the 
immunogenicity o f mature to immature mouse bone marrow-derived DCs in this 
C57BL/6 mouse melanoma model. As seen in Fig. 5.3, the level o f DC maturation 
with LPS, MPL and IFN-y was low compared to untreated DCs. This might be 
because the LPS and MPL used had lost their usual potency, or a longer treatment 
time with LPS and MPL (e.g. 48 h instead o f 24 h used here) or a high dose was 
needed. The ultimate goal o f any immunotherapy is the ability to generate CTL that 
will directly recognise and lyse tumour cells. Thus it is essential to set up a tumour 
protection assay to determine whether immunisation with autologous DCs loaded with 
oxidised tumour cells (i.e. oxidised B16.F10 in the C57BL/6 mice) will provide the 
immunised subjects protection against tumour growth and result in prolongation of 
their survival. Other methods to boost the anti-tumour responses, e.g. maturing DCs 
with clinical approved MPL or CD40 ligand before in vivo administration, or 
preventing Tregs activation with CTLA-4 antibodies or PD-IL, could be incorporated 
in the vaccination regime. Nevertheless, the results from this mouse melanoma model 
supported the use o f oxidised allogenic tumour cell line as immunogens for DC-based 
immunotherapy o f cancer. This might present a novel and straight forward method as 
such “ standardised”  cell lines would eliminate the need to obtain patient-derived 
tumour cells that are more difficult to obtain and inherently more heterogeneous.
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5.5. Conclusions
• B16.F10 m elanoma cells highly expressed TRP-2 and were sensitivity to HOCl- 
oxidation killing in vitro.
• Immunisation o f mice with bone-marrow derived DCs preloaded with oxidised 
B16.F10 cells via the intravenous, and not intraperitoneal or subcutaneous routes 
o f immunisation induced potent anti-TRP-2 and anti-B16.F10 responses.
• HOCl-oxidised B16.F10 cells were superior immunogens for DCs to prime 
specific T cells in vivo compared to heat-killed or HCl-killed B16.F10 cells.
• DCs were required for the processing and presentation o f oxdised B16.F10 in vivo 
to prime tumour-specific T cells.
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6.1. Introduction
Due to the importance o f DCs in regulating the outcome of an immune response, 
considerable attention has been given in a clinical context to their potential use in 
cancer treatments. The research performed in this thesis addresses issues surrounding 
DC-based tumour immunotherapy on two different levels. Firstly, the development of 
a robust in vitro human cell culture system serves as a mean to investigate the 
important parameters that govern successful DC priming o f potent anti-tumour T cell 
responses. Comparative studies done between the healthy volunteers and ovarian 
cancer patients in rem ission not only help to highlight the similarities but also the 
differences in the immune functions o f these two different groups. Such information 
would be invaluable in the future design o f DC vaccines. Secondly, using the 
information generated from the in vitro studies, an in vivo mouse model o f melanoma 
is used to investigate the immunogenicity o f such DCs vaccines. Factors that could 
influence the anti-tum our responses in vivo are being assessed. Finally, the impact of 
this work on the future developm ent o f DC-based tumour immunotherapy is 
discussed.
6.2. Defining the in vitro and in vivo parameters for DC-based immunotherapy
6.2.1. Choice o f tum our antigen for loading dendritic cells 
DC-based immunotherapy is a promising adjuvant therapy for treating cancers which 
are refractory to conventional chemotherapeutic approaches, and this technology is 
further assisted by the identification o f  shared and unique TA As expressed by a 
variety o f histologically different tumours. One major question is the choice of 
antigen for loading DCs. Examples o f antigens used include peptides encoding HLA- 
restricted immunodominant epitopes recognised by either CD8^ or CD4^ T cells.
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whole tumour cell lysates, tum our DNA or RNA, and tumour exosomes. The most 
popular and straight forward method is to load DCs with one or more HLA-restricted 
peptides. It is relatively easy to synthesize large quantities o f clinical grade peptides, 
however only patients possessing the required HLA expression(s) are eligible. 
Moreover, the resulting immune responses are often limited to the epitope(s) used for 
immunisation, and the longevity o f M HC-peptide complexes in vivo is unknown. In 
addition, the affinity o f peptides for their various HLA molecules varies and this 
could affect their immunogenicity in vivo should competition occur between/amongst 
the peptides. Lastly, the phenomenon o f epitope spreading is only observed in a very 
small number o f patients after single or multiple peptide immunisation (Brossart et 
al., 2000; Disis et al., 2004). Some research groups have incorporated peptides 
encoding epitopes recognised by CD4^ T helper cells to elicit a stronger overall 
immune response through providing cognate help to CD8^ T cells. However, few 
authentic tumour antigen CD4 epitopes have been defined to date. Peptide-based trials 
have met with limited success and the issues previously mentioned still need to be 
addressed.
A promising alternative to peptides is whole tumour cells. Tumour cells express a 
whole array o f TAAs that are characterised and uncharacterised, and this rich source 
o f antigens contains epitopes o f both CD8^ CTLs and CD4^ T helper cells. This is 
important as the parallel presentation o f both MHC Class I and II restricted antigens 
would help to generate a stronger overall anti-tumour response and long term CD8^ T 
cell memory via CD4^ T cell help (Toes et al., 1999; Zajac et al., 1998). Also, it 
would greatly diminish the chance o f tum our escape compared to using single epitope 
vaccines. In addition, the use o f whole tum our cells eliminates the need to define, test
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and select for immunodominant epitopes. The tumour cells could be autologous, i.e. 
obtained from the patients, or allogeneic. The major drawback for using autologous 
tumour cells is that they are only useful in single patient-tailored anti-tumour 
immunotherapies, and they pose problems o f collection, processing, reproducibility 
and inter-patient variability. On the other hand, allogeneic cell lines that share one or 
even several o f the TAAs as autologous tumour cells provide a simpler method of 
delivering antigens to DCs.
The SK-OV-3 ovarian carcinom a cell line used in this study highly expresses the two 
important ovarian TAAs, i.e. HER-2/neu and M UCl (Fig. 3.1), found in a significant 
number o f prim ary and metastatic ovarian cancers. The results in this thesis showed 
that priming T cells derived from both healthy volunteers and ovarian cancer patients 
with autologus DCs pulsed with oxidised SK-OV-3 generated CD8^ and CD4^ T cell 
responses directed against specific epitopes o f HER-2/neu and M U C l. These results 
strongly suggested that it is unnecessary to match the HLA of the cell line (HLA-A3^ 
and A2') to the patients/volunteers (most were HLA-A2^) as the T cells will be 
primed to antigens presented in the context o f the host MHC on host DCs. Another 
advantage is that it is relatively easy to propagate SK-OV-3 tumour cells to sufficient 
quantities for the purpose o f  DC-based immunotherapy. Moreover, the quality o f the 
SK-OV-3 cells can be easily controlled through stringent laboratory procedures. 
However, a potential problem  with using allogeneic SK-OV-3 cell line is that they 
might not share enough common TAAs to induce anti-tumour responses that could 
cross-react and reject all ovarian cancers. This question could only be answered 
properly in controlled clinical trials involving a large number o f ovarian cancer 
patients, perhaps in different stages o f the disease including patients who are already
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in remission. Nevertheless, allogeneic cell lines have been used in clinical trials for 
treating patients with melanoma and other cancers (Holtl et al., 2002; Palucka et al., 
2006; Salcedo et al., 2006; Stift et al., 2003; Vilella et al., 2004). This highlights the 
potential o f SK-OV-3 cell line as a source o f antigens for DC-based immunotherapy 
o f  ovarian cancer. This idea is further supported by the in vivo melanoma study in 
C57BL/6 mice. Specific anti-tumour responses were elicited when the mice were 
immunised with bone marrow-derived mouse DCs preloaded oxidised B16.F10 
m elanom a (Fig. 5.4), highlighting the effectiveness o f cell lines as a source o f 
antigens for DC.
6.2.2. M ethods for killing and enhancing the immunogenicity o f antigens 
Live tumour cells are poorly immunogenic and can possess an array o f mechanisms, 
such as loss o f FILA class I expression or deficiencies in antigen processing and 
presentation pathways, to evade the immune system. Moreover, live tumour cells can 
secrete soluble factors, such as VEGF, soluble FasL, IL-10 and TGF-P to suppress 
DC and T cell functions (see chapter 1). In this thesis, a strong oxidising agent -  
HOCl, has been used to induce rapid necrotic tumour cell death and at the same time 
enhancing their immunogenicity. In a physiological context, HOCl is one o f the first 
lines o f  defense o f the human immune system against microbial pathogens. It also 
enhances the immunogenicity o f  protein antigens by several folds in vivo and ex vivo.
In this thesis, it has been shown that treatment o f SK-OV-3 tumour cells with 60 pM  
HOCl or more induced greater than 99% necrotic cell death (Fig. 3.2). The HOCl- 
oxidised and not live SK-OV-3 cells are efficiently taken up by DCs (Fig. 3.3) and 
showed enhanced immunogenicity and primed potent anti-tumour T cell responses
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when compared to priming with SK-OV-3 cells made necrotic by non-oxidative 
means (i.e. heat-killed, HCl-killed, freeze-thawed, or x-ray irradiated) [see chapter 3 
results and Fig. 3.4]. This effect is also demonstrated in vivo with the B16.F10 model 
(Fig. 5.8). Although the exact mechanism is outside the scope o f this thesis, the 
improvement in antigen immunogenicity might be explained by three possible 
reasons. First, HOCl can quantitatively deaminate serine and convert its side chain 
into an aldehyde, and some studies have shown that tagging protein antigens with 
such aldehydes led to significant improvement in the responses directed against the 
antigens (Anderson et al., 1997; Anderson et al., 1999; Hazen et al., 1996b). Second, 
oxidation o f protein antigens might allow protein unfolding (e.g. by the reduction of 
disulphide bonds in the protein) and therefore enhance both processing by DCs and 
exposure o f immunogenic peptides to specific T cells (Carrasco-Marin et al., 1998). 
The heat-shock protein, such as Hsp 70, might also play a role in chaperoning 
polypeptides that unfolded during oxidative stress to help them regain a functional 
structure or by directing them to a degradation pathway (Feder and Hofmann, 1999). 
Third, scavenger receptor such as the lectin-like oxidised low-density lipoprotein 
receptor-1 (LOX-1) might be involved in the uptake o f HOCl-oxidised SK-OV-3 
tumour cells. LOX-1 is a type D scavenger receptor expressed on the surface of 
dendritic cells, macrophages, smooth muscle cells and platelets (Chen et al., 2002). It 
binds to a broad range o f ligands that include oxidised low-density lipids (OxLDL), 
hyphochlorite-modified HDL, advanced glycation end products (AGE), 
aged/apoptotic cells, activated platelets and bacteria (Jono et al., 2002; Kakutani et 
al., 2000; Marsche et a l ,  2001; Moriwaki et a l ,  1998; Oka et al., 1998; Shimaoka et 
a l ,  2001). LOX-1 has been implicated in antigen cross-presentation in DCs (Delneste 
et a l ,  2002), therefore it is reasonable to postulate that it is involved in the uptake of
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oxidised SK-OV-3 by DCs and facilitate cross-presentation of ovarian TAAs to CD8^ 
T cells. CD36, a class B scavenger receptor expressed by macrophages and DCs for 
endocytic take up o f OxLDL (Marsche et al., 2003) and AGE-proteins (Ohgami et a l ,  
2001), might also play a role in the uptake o f oxidised SK-OV-3. Preliminary studies 
with other forms o f oxidation (e.g. by H2 O2) can also improve protein 
immunogenicity, and it would be interesting to determine if there are any differences 
in the type o f immune response obtained from priming with SK-OV-3 cells treated 
with HOCl and H2O 2 .
6.2.3. Improving the stimulatory capacity o f dendritic cells via maturation 
Some o f the advantages o f  in vitro manipulation o f DCs include the ability to control 
the quality o f the DCs (i.e. maturation status) and their expression level o f desired 
antigens and/or costimulatory molecules, the selection of specific DC subset(s), and 
the in vivo administration o f the prepared DCs at anatomical sites o f interest (e.g. 
lymph nodes or tumours). In chapter 5, it is demonstrated in the B16.F10 melanoma 
model that DCs are required in the immunisation protocol as oxidised B16.F10 cells 
alone could not prime any anti-tumour response (Fig. 5.9). This might be due to the 
rapid clearance o f oxidised B16.F10 cells from the blood stream after IV vaccination 
and hence did not allow for their accumulation and uptake by the residential DCs in 
the spleen cells and/or lymph nodes. In contrast, DCs preloaded with oxidised 
B16.F10 could migrate and efficiently present the oxidised antigens to the T cells in 
spleen and lymph nodes.
The use o f mature DCs is preferred to immature DCs as the latter have been shown to 
induce T cell tolerance and deletion, and leads to the development of Tregs (Brocker,
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1999; Dhodapkar et a/., 2001; Jonuleit et al., 2000; Steinman et al., 2003). In chapter 
3, it is demonstrated that oxidised SK-OV-3 tumour cells induced a partial activation 
of DCs by upregulating the maturation associated markers -  CD83, CD86 and CD40 
(Table 3.1) However, this DC maturation is sub-optimal compared to the TLR agonist 
LPS, and additional stimulation o f DC might further enhance the response. Priming 
with these partially activated, oxidised SK-OV-3 loaded DCs stimulated a 
predominantly CD8^ response via cross-presentation. In chapter 4, two DC maturation 
stimuli, i.e. agonistic CD40 antibody and MPL that have already been approved for 
use in clinics, are being assessed. Using DCs derived from ovarian cancer patients in 
remission, it is demonstrated that both agonistic CD40 antibody and MPL induced the 
upregulation o f CD83, CD86, CD40 and DR expression on the DCs. When the T cells 
are primed with oxidised SK-OV-3 loaded DCs that are matured with either agonistic 
antibody or MPL, a significant improvement in the overall anti-tumour response is 
observed (Fig. 4.4). In addition, the magnitude o f CD4^ T cell responses is increased 
by at least 2-fold when such matured DCs are used (Fig. 4.5). Improved CD4^ 
response is more dependent on full maturation o f the DCs, and it might reflect the 
greater dependency o f  the CD4^ T cell response on costimulatory activity by the 
APCs. The ability to elicit CD4 T cell response in this priming culture system is 
important as increasing evidence suggests that CD8^ T cell responses primed in the 
absence of cognate help are impaired functionally in a variety o f ways (Chamoto et 
al., 2006; Nishimura et al., 1999; Xiang et al., 2005; Zhang et al., 2007). Critically, 
CD4^ T cell help is required for developing long term CD8^ T cell memory and CTL 
function (Toes et a l ,  1999; Zajac et a l ,  1998). Hence using mature DCs to stimulate 
both potent CD8^ and CD4^ T cell responses is desirable.
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Other maturation stimuli that have already been used in DC clinical trials and could 
also be evaluated in this priming culture system includes the cytokine cocktail 
containing TN F-a, IL -lp , Poly I:C, IFN-a, and IFN-y (Mailliard et al., 2004), which 
has been shown to induce potent CTL responses. This is preferred to the monocyte- 
conditioned media mimic that contains TNF-a, IL-ip, IL-6, and PGE2 (Jonuleit et a l, 
1997) as there are concerns about PGE2 mediating Th 2 polarisation and promoting 
IL-10 secretion by DCs (Morelli and Thomson, 2003). Such cytokine cocktail- 
matured DCs are also more effective than immature DCs in expanding Tregs 
(Banerjee et a l ,  2006). Another area o f concern is the induction o f IL-17 producing 
Thl7 CD4^ T cells that are found to be involved in host defense against pathogens as 
well as in autoimmunity (Weaver et a l ,  2006). IL-6 together with TGF-p (that is 
frequently present at high level in the tumour microenvironment) that have been 
found to be necessary for T h l7  cell differentiation (Mangan et a l ,  2006). Other 
potential DC maturation stimuli such as the TLR agonists (e.g. CpG ODN, R848 and 
imiquimod) could be used on their own or in combinations to stimulate a more potent 
DC maturation and production o f pro-inflammatory cytokines. The ligation o f CD40 
with recombinant CD40 ligand (French et a l ,  2007; Rew et a l ,  2005; Watanabe et 
a l, 2003) or with a drug-inducible CD40 expression system (Hanks et a l ,  2005) is 
also a promising method o f inducing DC maturation and enhancing their production 
of IL-12, and CTL priming capacity.
6.2.4. Avoiding autoimmunity and generating tumour-specific responses 
A persistent concern in tumour immunotherapy is that the immune system will be 
activated to recognise and kill cells other than the tumour, hence causing autoimmune 
disease. This is particularly important with the use o f whole cell immunogens as all
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cells share large amounts o f “ common”  housekeeping proteins, as well as expressing 
smaller numbers o f “ tissue-specific” proteins. It is essential that priming with 
oxidised SK-OV-3 only generated anti-tumour responses directed against TA As on 
ovarian tumour cells, and not predominantly to self proteins that are expressed on 
normal cells for normal cellular metabolic functions. In this thesis, it is demonstrated 
that the T cells that responded to SK-OV-3 and its TAAs but did not respond to the 
melanoma line M E L -11 or to melanoma TAAs expressed on the M EL-11 cell line. 
Conversely, T cells immunised to MEL-11 melanoma cells did not respond to SK- 
OV-3 cells or to its TAAs. These observations applied to both healthy volunteers and 
ovarian cancer patients (chapters 3 and 4). Moreover, T cells specific to M EL-11 
showed no recognition for ovarian tumour cells from autologous ascites (Fig. 4.9). 
Thus in this model, it is important that both tissue-type specific and TAA-specific 
responses have been generated in relation to at least two quite distinct tumour cell 
types. The risk o f  autoim m unity still needs to be further addressed as there remain 
some risks o f cross-reactivity with normal (untransformed) epithelial tissues that share 
some TAAs, such as breast and normal peritoneum. In the B16.F10 melanoma study, 
the DC vaccines were well-tolerated and did not induce any anti-organ or tissue 
reactions in the animals immediately or up to 23 days. More detailed studies looking 
for immunopathological responses are needed but the potential o f such DC-oxidised 
tumour cell vaccines inducing autoimmunity seems low.
Though it is o f param ount importance to avoid generalised non-tumour specific auto­
immunity, effective tum our therapy is also dependent on the partial breaking o f self 
tolerance. This close relationship between tumour response and the development of 
autoimmune pathology has been demonstrated in a recent trial (Gogas et al., 2006).
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Two questions relating to ovarian cancer are being addressed in this study. First, it is 
important to determine whether the T cells o f ovarian cancer patients that have been 
exposed to high levels o f  ovarian TAAs antigens in vivo over prolonged periods and 
yet are apparently tolerant to them, could still respond effectively to the oxidised SK- 
OV-3 antigen priming. Second, whether these patients’ T cells stimulated in response 
to SK-OV-3 cross-prim ing actually respond to autologous tumour, which is an 
obvious requirement for any potential immunotherapeutic approach. In chapter 4, it 
has been demonstrated that priming with DCs preloaded with oxidised SK-OV-3 
stimulated autologous T cells derived from ovarian cancer patients that could 
efficiently recognise and respond to specific epitopes o f HER-2/neu and M UCl on 
SK-OV-3. This observation is especially important as T cells from patients whose 
tumours overexpressed M UCl and/or HER-2/neu also exhibited anti-M UCl and 
HER-2/neu responses. In addition, two patients (patient 23 and 26) with T cells that 
were primed with autologous DCs preloaded with oxidised SK-OV-3 efficiently 
recognised autologous tum our cells from ascites without the need o f APCs (Figs. 4.7 
and 4.8). These results showed that despite exposure to high levels o f ovarian TAAs 
in vivo, ovarian cancer patients’ T cells are not tolerant to ovarian TAAs and can be 
primed with oxidised SK-OV-3 to recognise autologous ovarian tumour cells. These 
results therefore suggested a generic method to stimulate an anti-tumour T cell 
response which will be capable o f  targeting autologous tumour in patients with 
ovarian cancer.
6.3. Limitations of in vitro and animal studies
The in vitro studies on human cell cultures have helped to identify the important 
parameters, such as antigens for DCs and maturation state o f DCs, needed for
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generating potent anti-tumour responses. The breath o f the responses could be 
broadened to test other ovarian TAAs such as NY-ESO-1 which is expressed on many 
ovarian carcinomas. However, there are some limitations with these in vitro studies. 
First, it is not possible to predict the toxicity or the potential o f autoimmunity 
induction by these DC vaccines in vivo. Second, it is not possible to model the tumour 
microenvironment in vivo, which is extremely complex and involves the interplay o f 
many different cell types (including fibroblast, B cells and macrophages). Therefore 
vaccines have to be tested in vivo to evaluate their efficacy. Preliminary studies done 
in a mouse B16.F10 melanom a model confirmed some o f the findings o f the in vitro 
studies. Though not totally representative o f human cancers, the results in the 
melanoma mouse model suggested the potential use o f oxidised whole cell line as a 
source o f immunogens for DCs, and the DC vaccines were well-tolerated and did not 
seem to induce autoim m unity such as depigmentation o f the coat-colour. Certain 
parameters are species-specific, and might work well in one but not in the other. 
These could only be realistically tested in human clinical trials. One example is the 
route o f administration o f  DC vaccines and it might significantly influence the 
outcome o f the immunotherapy. Another example is the doses and duration o f 
effectiveness o f the DC vaccines. Mice and humans would require different dose of 
the DC vaccines when taking the body mass into considerations. This is also true 
when administrating a prim e-boost regime and the number o f boosts given would also 
be different. The general health o f the patients at the beginning o f the DC vaccination 
could also influence the outcome o f the treatment.
• k - k - k - k
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6.4. Future work
To increase the potency o f DC vaccines, it is envisaged that it be used in combination 
with chemotherapy, radiotherapy or with other immunointerventions. For example in 
this study, the use o f mature DC preloaded with oxidised allogeneic tumour cells is a 
promising method o f  inducing T cells that can recognise both ovarian TAAs and 
ovarian tum our cells in ascites. There are several methods to induce DC maturation 
and two stimuli evaluated in this study, i.e. agonistic CD40 antibody and MPL, 
significantly enhanced both CD4^ and CD8^ T cell responses. Other promising DC 
maturation stimuli that are already in use in clinics and can be assessed in future 
studies include the cytokine cocktail mixture containing Poly I:C, CD40 ligand, and 
TLR agonists such as CpG ODN, R848 and imiquimod. The TLR agonists can be 
used in combinations to further improve DC activation.
To block negative regulatory interactions between DCs and T cells, 
immunointerventions such as depletion o f Tregs, administration of anti-CTLA4 
and/or anti-PDl are being pursued in human clinical trials. Such interventions could 
be administrated in vivo together with the DC vaccines to enhance the latter’s 
efficacy. It might also be helpful to genetically modify DCs to produce cytokines, 
such as GM-CSF or IL-2, or to express increased levels o f costimulatory molecules so 
to enhance T cell priming. Also o f great interest is the use of other oxidising agents, 
such as H2 O 2 in killing and enhancing the immunogenecity o f tumour cells. It might 
be important to determine if  there are any differences in the immune responses 
elicited by these different oxidising agents.
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The ultimate goal o f tumour immunotherapy is the direct lysis o f autologous tumour 
cells by CTLs. Thus it would be imperative to test such ability in the primed T cells 
obtained from ovarian cancer patients using chromium release assay or other non­
radioactive CTL assays. A multi-colour flow cytometry assay could also be performed 
to assess the cytokine profiles o f the primed T cells. A major limitation o f this study is 
the small num ber o f ovarian cancer patients being recruited (n-27), and amongst them 
only two had autologous ascites available. A larger patient sample size will give a 
clearer picture o f the overall efficacy o f priming T cells with autologous DCs loaded 
with oxidised SK-OV-3 cells. In addition to evaluating the responses in cancer 
patients in remission, patients with other stages o f ovarian cancer (in particular Stage I 
patients with small tumour burdens) could also be studied.
In the B16.F10 m elanoma study, it would be essential to conduct a tumour protection 
assay to further determine the crucial parameters governing effective anti-tumour 
response. In this assay, the tumour growth and survival o f the mice would be 
monitored following DC vaccine administration. It is also of great interest to assess 
the immunogenicity o f mature DCs preloaded with oxidised B16.F10 in the C57BL/6 
melanoma model. In addition, a prime-boost protocol could be developed to 
determine the optimal amount o f DC vaccines and time for administration. As a 
mouse ovarian tumour model is now available, it would be especially useful to test the 
DC-oxidised SK-OV-3 vaccines in the transgenic HLA-A2 expressing mouse ovarian 
tumour model. The responses to oxidised SK-OV-3 and to HLA-A2 restricted 
epitopes o f M U C l, HER-2/neu and other ovarian TAAs (such as NY-ESO-1) could 
be tracked in this model. CTL and tumour protection assays could also be performed.
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